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1. Introduction       
1.1 Cancer and mammary tumorigenesis 
Breast cancer is the most common type of cancer found in women, with about 70.000 
new cases diagnosed per year. In addition, it is the leading cause of cancer death 
among women in Germany with 17.4% patients succumbing to the disease (Cancer 
in Germany 2009/2010). However, breast cancer mortality is declining because of 
novel and more effective treatment regimens, and improvements in cancer screening 
and prevention programs (Jemal et al. 2009).  
In routine clinical laboratory testing, pathological markers are used to classify tumors 
and to stratify patients for outcome predictions and treatment selection. In addition to 
patient age, node status, tumor size and histological grade, expression of estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) are all used for the classification of tumors (Holliday and Speirs 
2011, The Cancer Genome Atlas Network 2012, Tab. 1.1). Molecular taxonomy of 
breast cancers based on variations in gene expression derived from cDNA 
microarrays classifies six intrinsic subtypes of breast cancer, namely luminal A, 
luminal B, HER2-enriched, claudin-low, basal-like and normal breast-like (Perou et al. 
2000, Sorlie et al. 2001, Prat and Perou 2011). 
 
Tab. 1.1: Molecular classification of breast carcinomas 
classification  immunoprofile    proliferation 
luminal A    ER+, PR+/-, HER2-    low proliferation 
luminal B   ER+, PR+/-, HER2+    high proliferation 
basal-like   ER-, PR-, HER2-, CK5/6+ &/or EGFR+ high proliferation 
claudin-low   ER-, PR-, HER2-    low proliferation 
HER2    ER-, PR-, HER2+    high proliferation 
normal breast-like  ER-, PR-, HER2-, CK5/6-, EGFR-
  
low proliferation 
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The majority of all breast cancers (up to 80%) are hormone-receptor-positive  (Hart et 
al. 2015), thus underlining the importance of molecular tumor classification to define 
therapy options, such as treatments with Tamoxifen as an antagonist for estrogen- 
positive receptor, or Trastuzumab (Herceptin®) to block the HER2 receptor in HER2-
positive tumors (Bezwoda et al. 1982, Vogel et al. 2002).  
Tumorigenesis is a multistep process based on several genetic alterations which 
causes progressive transformation of healthy normal cells to malignant cancer cells. 
Hanahan and Weinberg (2000) postulated that malignant cell growth is characterized 
by several alterations in cell physiology, such as evading apoptosis, self-sufficiency in 
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potential and sustained angiogenesis. More recently (Hanahan 
and Weinberg 2011), the authors extended the list to include two further hallmarks: 
reprogramming of energy metabolism and evading immune cell surveillance. Genes 
that are involved in the multistep process of tumorigenesis are widely divided into 
proto-oncogenes and tumor suppressor genes. Gene products of proto-oncogenes 
promote normal cell proliferation, but a mutation at a single allele can result in cell 
transformation. Tumor suppressor genes (recessive oncogenes) on the other hand, 
counteract excessive proliferation. This results presented in this thesis originated 
from observations made while investigating one member of the epidermal growth 
factor receptor (EGFR) family belonging to the group of proto-oncogenes - the 
EGFR -, where it is well characterized that overexpression or mutations within the 
gene result in dysregulation of cell growth leading to tumorigenesis.  
 
1.2 Lipid metabolism in cancer cells 
 
Several diseases, including cancer, are accompanied by changes in the lipid 
composition of cellular membranes and alterations in lipid metabolism. It is well 
known that cancer cells have increased requirement for energy and adjust their 
metabolism to meet their demands, a process termed “metabolic reprogramming” 
(Santos and Schulze 2012). The Warburg effect, defined as elevated glycolytic 
activity and impaired oxidative phosphorylation even in the presence of sufficient 
oxygen, is the best known and characterized feature of this metabolic reprogramming 
(Hanahan and Weinberg 2011). Tumor metabolism may therefore support recycling 
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and remodeling of damaged cellular components, such as organelles or membranes, 
as well as their high proliferating capacity (Muńoz-Pinedo et al. 2012).  
Besides being the essential structural components of all biological membranes, lipids 
are involved in the regulation of proliferation, inflammation, apoptosis, differentiation, 
autophagy, motility, and can function as second messengers and hormones. 
Consequently, to ensure proper homeostasis, their biosynthesis must be strictly 
controlled (Baumann et al. 2013). Figure 1.1 illustrates several features of lipids that 
could contribute to the development of cancer (Santos and Schulze 2012). For 
instance, based on their high proliferation rate, cancer cells require increased lipid 
amounts for membrane synthesis in general. In addition, cancer cells tend to have 
increased amounts of lipids with saturated (no double bonds) acyl chains in their 
membrane, as both saturated and monounsaturated acyl chains are less susceptible 
to peroxidation, compared to carbon atoms between double bonds in acyl chains that 
are morelikely damaged by oxidative attack and chemotherapeutics (Hulbert 2006, 
Rysman et al. 2010). Accumulated lipids stored in lipid droplets facilitate survival in 
phases of starvation. Perilipins contribute to this survival by enabling the mobilization 
of lipid droplets to provide energy by β-oxidation in mitochondria (Wang et al. 2011). 
A further adaptation is that nicotinamide adenine dinucleotide phosphate (NADPH) 
can be used as an electron donor when oxygen is not available in hypoxia- tolerant 
cancer cells (Hochachka et al. 2002). Finally, cholesterol and fatty acids represent 
precursors for hormones which stimulate proliferation and invasion-related pathways, 
both of which are critical for tumorigenesis and cancer progression. 
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Fig. 1.1: Lipids support several aspects of cancer development. Fatty acids taken up from 
exogenous sources or generated via endogenous de novo fatty acid synthesis support multiple cellular 
processes: They represent building blocks for membrane synthesis in case of proliferation and 
membrane saturation; and they become stored in lipid droplets to ensure lipid survival under stress 
conditions. Nicotinamide adenine dinucleotide phosphate (NADPH) is used from hypoxia-tolerant 
cancer cells when oxygen is not available. Cholesterol lipid hormones influence proliferation- and 
invasion-related pathways (source: Santos and Schulze 2012; the figure is modified) 
 
 
Fatty acids can be taken up exogenously from the environment, transported for 
example, by lipoproteins or mobilized from adipose tissue, and can be as well 
endogenously produced by de novo synthesis. 
 
 
1.2.1 Lipids can influence immune cell behavior 
Otto Warburg described in 1924 that tumor cells exhibit increased glycolysis despite 
the presence of oxygen (Hanahan and Weinberg 2011). This metabolic shift 
represents only one aspect of tumor cell metabolism. Tumor cells accumulate 
specific metabolic determinants (for example cytokines, chemokines and growth 
factors) in their environment to create a favorable milieu supporting tumor growth, 
progression and metastasis (Gottfried et al. 2012). These secreted metabolites 
protect cancer cells from tumor infiltrating immune cells, or help increase their 
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immunity. The immune system distinguishes the innate from the adaptive immune 
system. The former initiates an immediate but non-specific response, like 
inflammation, and comprises leukocytes, such as macrophages, neutrophils and 
dendritic cells, in addition to natural killer cells. The adaptive immune system, on the 
other hand offers a pathogen or antigen-specific response mediated by lymphocytes, 
including B- and T-cells.  
As mentioned, cancer cells produce and secrete numerous tumor-specific 
metabolites, such as amino acids, lipids and chemical compounds into their 
environment to escape immune cells and increase immunosuppression. For 
example, an altered fatty acid supply in the tumor environment can change the 
immune response by inducing perturbations in the composition of membrane 
phospholipids of immune cells, which can ultimately influence signal transduction 
(Calder et al. 2011). Herber et al. (2010) reported that dendritic cells phagocytize 
lipids and cholesterol in their tumor-bearing hosts. The resulting lipid-laden dendritic 
cells have a reduced capacity to process and present antigens, such as MHC class I 
and II, leading to reduced antigen presentation and diminished T-cell stimulation. 
Lysophosphatidic acid blocks the cytotoxic activity of natural killer cells by inhibiting 
their release of the cytolytic protein, perforin which enables tumor cell escape from 
the immune cell attack (Lagadari et al. 2009). Furthermore, in vitro incubation of 
Jurkat T-cells with increased free fatty acids or albumin-bound fatty acids inhibited T- 
cell signaling (Stulnig et al. 2000). On the other hand, lysophosphatidylcholine has 
been shown to stimulate the maturation of dendritic cells (Jin et al. 2005). In 
summary, lipids can positively as well as negatively affect immune cell behavior.  
 
1.2.2 Lipid classification and cellular lipid uptake 
Lipids are involved in several essential physiological pathways as mentioned before. 
They are defined as hydrophobic or amphipathic small molecules and divided into 
eight categories in ‘the Comprehensive Classification System for Lipids’ by the 
International Lipid Classification and Nomenclature Committee (ILCNC). These eight 
categories comprise fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, 
sterol lipids, prenol lipids, saccharolipids and polyketides (Fahy et al. 2009). Each 
category contains distinct classes and subclasses of molecules. Fatty acids (FA) are 
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major building blocks of complex lipids and are distinguished by the number of 
carbon atoms and double bonds. A saturated fatty acid carries no double bond 
compared to unsaturated ones, which may contain different numbers of double 
bonds. Glycerolipids include mono-, di-, and tri- substituted glycerol, with fatty acid 
triesters of glycerol, such as triacylglycerides (TAG). Most prominent are 
triacylglycerides (TAG), which function as energy storage in lipid droplets.  
Phospholipids or glycerophospholipids are key components of the lipid bilayer of 
cellular membranes and are also involved in metabolism and cell signaling pathways 
(Fahy et al. 2005).  
As described above, fatty acids are the basic building blocks for more complex lipids. 
Cells are able to produce fatty acids either via endogenous synthesis or by 
extracellular uptake. Two types of free fatty acid uptake exist across the membrane 
passive diffusion or protein-facilitated transfer. The aqueous solubility of fatty acids is 
in the range of 1-10nM; therefore, fatty acids in blood serum or in the extracellular 
environment are bound to the protein albumin in a ratio of 1:6 (albumin:fatty acid) 
(Vorum et al. 1992). The physical transport of fatty acids includes seven kinetic steps: 
1) dissociation of fatty acid from albumin into the aqueous phase; 2) diffusion through 
the outer aqueous phase; 3) insertion into the outer leaflet of the cell bilayer 
membrane by receptors like CD36; 4) flip-flop from the external to the internal 
membrane face; 5) dissociation from the inner leaflet; 6) diffusion through the inner 
aqueous phase and 7) binding to fatty acid binding proteins (Glatz et al. 2010, Hajri 
and Abumrad 2002, Potter et al. 1989, Mashek and Coleman 2006). Several lipids 
are enclosed by lipoproteins to emulsify the lipid molecules and enable their transport 
through the blood. 
 
1.2.3 Lipoproteins and the lipase superfamily 
Lipoproteins are complexes of lipids and proteins which transport lipids (mostly TAG, 
cholesteryl esters and fat-soluble vitamins) through body fluids to and from organs. 
They are mainly spherical complexes classified into five major classes based on their 
relative density (determined by the amount of lipid and protein per particle) as shown 
in Tab. 1.2: chylomicrons, very low density lipoproteins (VLDL), intermediate density 
lipoprotein (IDL), low density lipoproteins (LDL) and high density lipoproteins (HDL, 
Fig. 1.2). Each lipoprotein class differs in density, size and migration during 
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electrophoresis, and protein composition. Apo-lipoproteins are required for the 
structure and assembly of lipoproteins, and can mediate and determine the binding of 
the lipoproteins to cell-surface receptors (Eren et al. 2012). 
Tab. 1.2: Major lipoprotein classes sorted by density 
lipoprotein diameter [nm] major apo-lipoproteins 
 chylomicrons 75-1200              apoB-48 
           VLDL                30-80 apoB-100 
           IDL                25-35 apoB-100 
           LDL                18-25 apoB-100 
           HDL                  5-12              apoA-1 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2: Schematic illustration of a high-density lipoprotein molecule. The HDL envelope 
consists of a phospholipid monolayer, unesterified cholesterol and apo-lipoprotein. The core 
contains cholesteryl ester and fatty acids, including triacylglycerides 
 
Many lipases are involved in the binding and processing of extracellular lipoproteins 
(holoparticle uptake or cleavage). Lipases are enzymes which catalyze the hydrolysis 
of lipids. They can be classified into different protein families, with the majority 
belonging to the subclass of esterases (Staege et al. 2010). Lipases support cellular 
metabolism via digestion, transport and processing of lipids. Tab 1.3 contains a 
selection of some lipases and their functional role.  
envelope 
unesterified 
cholesterol 
apo-lipoprotein 
phospholipid 
core 
cholesteryl ester 
triacylglyceride 
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Tab. 1.3: Overview of some lipases and their functions 
gene name description references 
LIPC 
(HL) 
hepatic lipase hydrolysis of phospholipids, 
MAG, DAG, TAG, and acyl-
CoA thioesters 
Wang et al. 2013 
LIPD 
(LPL) 
lipoprotein lipase  hydrolysis of TAG of 
circulating chylomicrons and 
VLDL 
Kersten 2014 
LIPE 
(HSL) 
 
hormone 
sensitive lipase 
regulatory role in initiating 
the degradation of TAG 
Watt and Spriet 2004 
LIPG 
(EL) 
endothelial lipase phospholipase A1 activity Riederer et al. 2012 
LIPH lipase H hydrolysis of TAG Cui et al. 2014 
MAGL monoacylglycerol 
lipase 
hydrolysis of MAG Nomura et al. 2010 
 
Our initial findings of LIPG induction by NeuT expression in MCF7/NeuT cells 
(Cadenas et al. 2012) were the first report linking LIPG expression to breast cancer. 
However, the mechanism underlying LIPG’s function in oncogene-induced 
senescence in breast cancer remained unexplored. 
 
1.3 Structure of the endothelial lipase 
In the year of 1999, two working groups reported simultaneously the discovery of the 
endothelial lipase (LIPG; EL; EDL) (Jaye et al. 1999, Hirata et al. 1999). Lipase G 
expression was observed in cultured endothelial cells and on the wall of blood 
vessels, providing a mechanism for local regulation of lipolytic activity and processes 
related to atherosclerosis and other vascular diseases (Hirata et al. 1999). LIPG, 
located on chromosome 18q21.1, encodes a protein of 500 amino acids and belongs 
to the triglyceride lipase gene family with 46% identity to lipase member H (LIPH), 
45% to lipoprotein lipase (LPL), 40% to hepatic lipase (HL, HTGL or LIPC) and 31% 
to pancreatic lipase (PNLIP) (Choi et al. 2002, Cui et al. 2014, Wu et al. 2010). Ishida 
et al. (2004) described three LIPG mRNA isoforms, EDL1a, EDL2a and EDL2b, 
expressed by endothelial cells. EDL1a represents the previously characterized full- 
length isoform; whereas, EDL2a and EDL2b appear to result from alternative splicing. 
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Both splicing isoforms lack the first 80 amino acids residues (containing a signal 
peptide) at the N-terminal, with EDL2b lacking an additional 74 amino acid region, 
which encodes a portion of the lid domain (part of the catalytic triad) (Fig. 1.3). As a 
result, both isoforms display no catalytic activity and are localized in the cytosol 
compared to the enzymatic active EDL1a isoform, which has catalytic activity and 
can be secreted into the cell supernatant.  
 
Fig. 1.3: Human amino acid sequences of human EDL2a and EDL2b compared with EDL1a (full-
length). Boxes mark identical amino acids. Dashed lines indicate the GXSXG lipase motif. Vertical 
arrow shows EDL1a signal peptide cleavage site. Asterisks illustrate the catalytic triads, and dots the 
conserved cysteines. Dashed boxes mark heparin binding positions. Solid bars indicate hydrophobic 
sequences. Horizontal bars show the lid region with 19 residues whereas horizontal bars with arrows 
indicate the peptide sequences which were chosen to generate antibodies in this publication (Ishida et 
al. 2004_Genbank Accesssion No. NM_006033) 
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In Figure 1.3, asterisks illustrate the three catalytic residues, including the cysteine 
residues that form intramolecular disulfide bonds, the lid that covers the catalytic 
pocket, as well as lipid and heparin binding regions (addition of heparin increases 
EDL/LIPG release into environment). These features are conserved in all members of 
the triglyceride lipase gene family (Miller et al. 2004). 
 
1.3.1 Enzymatic and non-enzymatic function of LIPG protein 
Adenoviral-based overexpression of full length LIPG cDNA in mice resulted in a 
decrease in plasma HDL-cholesterol and apo-A1-lipoprotein, and to a lesser extent 
VLDL- and LDL-cholesterol levels (Jaye et al. 1999), showing that indeed HDL is the 
preferred substrate of LIPG. LIPG-overexpressing COS-7 kidney cells incubated with 
phosphatidylcholine labeled at the sn-1 position accumulated increased levels of 
labeled free fatty acids (Hirata et al. 1999), indicating cellular uptake of hydrolyzed 
sn-1 fatty acids. Also, McCoy et al. (2002) confirmed this observation by incubating 
conditioned media from LIPG-overexpressing COS-7 cells with radioactive labeled-
phosphatidylcholine containing glycerol-tri-oleate in order to detect increased free 
fatty acid amounts in the aqueous phase. These results support the phospholipase 
A1 and triacylglycerol lipase activity of LIPG, as well as the preference of LIPG for 
HDL as its main substrate. However, other studies involving LIPG overexpression in 
HepG2 cells incubated with HDL in presence or absence of tetrahydrolipstatin, an 
inhibitor of the enzymatic activity, demonstrated that LIPG mediates HDL binding and 
holoparticle uptake together with selective HDL-cholesterol ester uptake independent 
of its enzymatic activity (Strauss et al. 2002). 
The analysis of cellular lipids released by LIPG-overexpressing cells incubated with 
HDL-phosphatidylcholine 14C-HDL-PC revealed increased levels of intracellular 14C-
lipids which were mainly incorporated into phospholipids and TAGs. Furthermore, 
LIPG is able to cleave HDL-PC into free fatty acids (FFA) and 
lysophosphatidylcholine (LPC). These liberated saturated and unsaturated FFA serve 
as substrates for the biosynthesis of intracellular synthesized lipids (Strauss et al. 
2003, Gauster et al. 2005).  
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Mass spectrometric-based analysis of LIPG-overexpressing human aortic endothelial 
HAEC cells in the presence of HDL resulted in the generation of LPC and 
lysophosphatidylethanolamine (LPE) species in cell culture supernatant, together 
with  increased intracellular phosphatidylcholine, TAG, LPC and FFA content 
(Riederer et al. 2012). Razzaghi et al. (2013) postulated that LIPG does not lead to 
complete HDL catabolism but instead remodels HDL into  smaller pieces with higher 
preferences to release certain fatty acids like palmitic acid (C16:0), stearic acid 
(C18:0), oleic acid (C18:1), linoleic acid (C18:2), arachidonic acid (C20:4) and 
docosahexaenoic acid (C22:6).  
Altogether, the results of these studies elucidate that LIPG has both enzymatic as 
well as a non-enzymatic activity (Fig. 1.4), and influences both the intracellular and 
the extracellular lipid composition (Fig. 1.5). 
 
Fig. 1.4: Illustration of LIPG-enzymatic and non-enzymatic activities. Left: By virtue of its 
phospholipase activity and also triacylglycerol lipase activity LIPG is able to bind and cleave HDL into 
free fatty acids (FFA) and lysophosphatidylcholine (LPC). Right: Blocking the enzymatic activity of 
LIPG does not inhibit the HDL-binding, holoparticle uptake and selective HDL-cholesterol ester uptake 
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Fig. 1.5: LIPG alters by HDL bridging intracellular and extracellular lipid composition. LIPG- 
related cell surface binds HDL and enables the cellular uptake of lipids (1) and cleavage of HDL 
resulting in lipid release into cell media (2). Internalized lipid can be secreted by cells (3) 
 
Analysis of LIPG-overexpressing cells incubated with heparin or the inhibition of 
proteoglycans sulfation revealed decreased HDL-bridging on the cell surface by 
LIPG. Heparan sulfate proteoglycans- (HSPG) deficient Chinese hamster ovary 
CHO-677 cells also showed decreased lipoprotein binding compared to control cells. 
LIPG-expressing kidney COS cells were incubated with HDL at 4°C to minimize the 
enzymatic activity of LIPG, which resulted in a significantly higher HDL- binding 
compared to control cells. The same was measured with a catalytically inactive LIPG 
mutant, and the results showed that binding of lipoproteins by LIPG is independent of 
its enzymatic activity, but requires active HSPGs (syndecans, glypicans and 
perlecans) on the cell surface (Fuki et al. 2003). 
 
1.3.2 N-linked glycosylated maturation and cleavage processes of LIPG 
Western blotting analyses have been crucial to elucidate the maturation steps of the 
translated LIPG product, and cleavage processes of the secreted LIPG protein. LIPG 
contains five potential N-linked glycosylation sites. The full-length 68kDa LIPG form 
was reduced to 55kDa using glycosidase F, the predicted size of unglycosylated 
LIPG. Cellular lysates, cell membranes and conditioned media from LIPG- 
overexpressing cells with or without tunicamycin (glycosylation inhibitor) were 
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isolated and analyzed for protein sizes and lipase activity. All three compartments 
showed the presence of a 68kDa and 40kDa protein fragment in untreated LIPG- 
overexpressing cells. However, tunicamycin-treated cells only displayed a 55kDa 
LIPG protein band in the intracellular and in the membrane-bound fraction. Retention 
of an inactive 55kDa protein in tunicamycin-treated cells revealed a lack of secretion 
and abolished triglyceride lipase and phospholipase activities. The importance of four 
out of five putative N-linked glycosylation sites for LIPG secretion and activation was 
demonstrated by site-directed mutagenesis experiments (Miller et al. 2004, Skropeta 
et al. 2007). 
Gauster et al. published in 2005 that in addition to the 68kDa mature LIPG proteins 
found in cell lysates and media, two additional LIPG fragments with 40kDa and 
28kDa could be identified in the supernatant. These are the products of extracellular 
proteolytic cleavage of the mature catalytic active 68kDa LIPG protein by pro- protein 
convertases (Fig. 1.6). Although the N-terminal 40kDa fragment of LIPG harbors the 
catalytic site, a phospholipase activity assay could demonstrate that this LIPG 
fragment it is unable to bridge and hydrolyze HDL. Therefore, the proteolytic 
cleavage of LIPG results in its inactivation. 
 
Fig. 1.6: Illustration of LIPG protein maturation and cleavage. LIPG is synthesized as an inactive 
55kDa protein. It is then glycosylated intracellularly to a mature catalytic active 68kDa LIPG protein 
and transported to the cell membrane. The secreted enzymatically active 68kDa LIPG protein is 
cleaved by pro-protein convertases (pPC) into inactive LIPG fragments with 40kDa and 28kDa 
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1.3.3 LIPG expression in human cell lines and tissues 
Angiogenesis, the formation of new blood vessels, occurs in numerous physiological 
and pathophysiological processes, like wound healing, placental development, as 
well as tumor growth. Rapidly dividing and growing cancer cells or tumors need an 
enormous supply of oxygen and nutrients, and the generation of new blood vessels is 
required to ensure sufficient supply. Tumor-induced angiogenesis offers potential for 
treatment. Therefore, understanding the molecular angiogenesis pathways which 
regulate endothelial cell differentiation and growth is of fundamental interest. 
Endothelial cells cover the interior surface of blood vessels and are in direct contact 
with circulating blood. LIPG (endothelial lipase) was initially identified in an analysis 
of genes involved in vascular formation (Hirata et al. 1999). LIPG RNA expression 
measurements in different human cell lines performed by the Human Protein Atlas 
show high RNA expression in endometrial AN3-CA cancer cells, colon CACO2 
cancer cells, ovarian Efo21 cancer cells, keratinocytes HACAT cells, and endothelial 
time cells (Fig. 1.7) (http://www.proteinatlas.org). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7: LIPG RNA levels in different human cell lines. LIPG show a high RNA expression in 
endometrial AN3-CA cancer cells, colon CACO2 cancer cells, ovarian Efo21 cancer cells, 
keratinocytes HACAT cells and endothelial time cells (source: Human Protein Atlas_ 
ENSG00000101670) 
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Figure 1.8, based on Human Protein Atlas data, illustrates the LIPG mRNA 
expression level in different human tissues which shows an enormous amount in 
placenta and thyroid gland. 
 
Fig. 1.8: LIPG RNA expression in human tissues. LIPG shows enormous expression in the thyroid      
gland and placenta. A moderate expression is detectable in the appendix, gallbladder and liver 
(source: Human Protein Atlas_ ENSG00000101670) 
 
1.3.4 Functional role and stimulation factors of LIPG 
Analysis of the functional role of LIPG on endothelial cell surfaces revealed 
enhanced binding of monocytes (THP-1 or U-937 cells) to COS7 cells 
overexpressing LIPG, which normally do not express endogenous LIPG. Heparin 
treatment, which detaches cell-surface associated LIPG, disrupted this binding. 
Furthermore, incubation of LIPG-overexpressing COS7 or THP-1 cells together or 
separately with heparinase I (degradation of HSPGs) abolished monocyte binding. 
These results suggest that LIPG-mediated monocyte binding depends on functional 
HSPGs both on the monocyte surface and on the surface of LIPG-expressing cells 
(Kojma et al. 2004). Accumulation of monocytes/macrophages on the inner layers of 
the artery walls is a common feature of inflammation and the earliest event in 
atherosclerosis (chronic inflammatory disease). Atherosclerosis is referred to an 
accumulation of fatty materials, like cholesterol, on the vessel walls, and since 
overexpression of LIPG is accompanied by decreased HDL-cholesterol levels, it has 
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been suggested that, increased LIPG expression is associated with the development 
of atherosclerosis (Dalan et al. 2013). 
Injection of lipopolysaccharide (LPS; a mediator of inflammation) into C57BL/6 mice 
has been shown to increase LIPG expression at both the RNA and protein level 
(Kojma et al. 2004). Incubation of three different endothelial cell types with 
inflammatory cytokines - including IL-1β (produced mainly by monocytes) and TNF-α 
(mainly produced by macrophages) - resulted in increased LIPG protein expression, 
secretion, and phospholipase as well as triglyceride lipase activity in the media. 
Conversely, lipoprotein lipase (LPL) and hepatic lipase (HL) were downregulated by 
inflammatory cytokines. Accordingly, LIPG-upregulation during inflammatory 
processes could offer an alternative way of generating fatty acid support derived from 
HDL (Jin et al. 2003). The study of Nakajima et al. (2013) reporting LIPG induction 
and concomitant decrease in LPL expression upon heart failure (HF; the heart 
muscle being unable to pump sufficiently to maintain the blood flow through the body) 
supports this hypothesis. Interestingly, patients with early phase exhibited enhanced 
inflammatory cytokine levels in heart tissue and circulation. In conclusion, LIPG may 
represent an alternative way by which cells are supported with fatty acids under 
inflammatory conditions. 
Besides the induction of LIPG expression in cells by inflammatory cytokines, Azumi 
et al. (2003) published that macrophages themselves also express LIPG. 
Suppression of LIPG expression in THP-1 macrophages resulted in decreased 
concentration of pro-inflammatory cytokines IL-1β, TNF-α, IL-6, IL-8 and MCP-1 
(monocyte chemoattractant protein-1) and reduced levels of total cellular cholesterol, 
triacylglycerides, and lysophosphatidylcholine (lyso-PC) (Qiu et al. 2007). 
Furthermore, Yasuda et al. (2007) postulated that LPS mediates the induction of 
LIPG expression in macrophages via the functional toll-like receptor 4 (TLR4) 
cascade and intracellular H2O2-production (reactive oxygen species, oxidative 
stress). In summary, LIPG-transcription in endothelial cells that line blood vessels in 
numerous organs, as well as in macrophages is induced by inflammatory signals. 
Conversely, LIPG can also control cytokine expression and alter the cellular lipid 
composition. 
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In vivo studies revealed a statistically significant, direct correlation of obesity- 
associated inflammation in humans and upregulated LIPG plasma concentrations 
accompanied by low HDL-cholesterol levels (Badellino et al. 2008). The intravenous 
LPS injection in twenty human healthy volunteers has contributed to a statistically 
significant increase in LIPG plasma concentration and a concomitant statistically 
significant reduction of total plasma phospholipid plus HDL-phospholipid 
concentration. In addition LIPG plasma concentrations in pre- and post-heparin 
plasma showed a statistically significant correlation with obesity (body mass index) 
and atherosclerosis (Badellino et al. 2005, Paradis et al. 2006).  
 
1.3.5 LIPG protein contribution in carcinogenesis  
There is only little known and published about the contribution of LIPG in human 
cancer progression. Our laboratory (Cadenas et al. 2012) reported the expression of 
LIPG after HER2/ErbB2 overexpression in MCF7 breast cancer cells. Mudvari et al. 
(2013) established an isogenic stable cell line representing HER2-positive breast 
cancers by introducing HER2 into the breast cancer cell lines MDA-MB-231 and 
MDA-MB-468 (both triple-negative breast cancer cell lines). Cancer cells showed 
down-regulated LIPG expression pattern compared to HER2-positive clones. 
Nevertheless, nothing is known and published about the functional role of LIPG in 
breast cancer.  
Dong et al. (2013) reported that LIPG is a highly accurate and statistically significant 
urinary biomarker for gastric cancer. LIPG levels in tissue and serum of gastric 
cancer patients compared to healthy donors were not as discriminative as in urine 
samples. Gastric cancer patients exhibited an approximately 9.9-fold average 
decrease in LIPG protein levels compared to healthy urine controls. The glomerular 
filtration system of the kidney filters small positively charged molecules, such as LIPG 
that has a number of positively charged clusters, more easily. Interestingly, this 
finding was not linked to tumor grade or stage. LIPG urinary protein level was also 
investigated in lung, colon and rectum cancer, but was not found to be as significant 
as for gastric cancer.  
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LIPG protein expression was highly expressed in human testicular germ cell tumors 
(Nielsen et al. 2010), which may facilitate nutrient supply in the testis, and may be 
involved in steroidogenesis, providing cholesterol for testosterone production in 
Leydig cells.  
Finally, Füri et al. (2015) reported that tumor tissue-derived DNA-treated HT-29 cells 
exhibited upregulated LIPG RNA expression compared to control cells.  
The above publications are the only studies currently available that discuss a 
possible role for LIPG in cancer. They all reported increased LIPG expression in 
human breast cancer cell lines, human gastric cancer patients, human testicular 
germ cell tumors and human colon cancer cells; however, the contribution of LIPG in 
carcinogenesis or tumor development remains to be elucidated.  
Several oncogenes have been found to be related to tumorigenesis including the 
tyrosine kinase family. As mentioned our initial findings revealed LIPG induction upon 
HER2/ErbB2 expression in MCF7/NeuT cells (Cadenas et al. 2012).  
 
1.4 The ErbB family 
Our initial findings revealed LIPG induction upon HER2/ErbB2 expression in 
MCF7/NeuT cells (Cadenas et al. 2012). The epidermal growth factor receptor 
(EGFR) family comprises four members, all of which are receptor tyrosine kinases 
that play an important role in development and tumorigenesis: EGFR (HER1 or 
ErbB1), HER2 (ErbB2 or Neu), HER3 (ErbB3) and HER4 (ErbB4) (Casalini et al. 
2004). All ErbBs are transmembrane receptors that dimerize in response to the 
binding of their specific ligand(s), but differ regarding their kinase activity, ligand 
specificity, and downstream signaling activation. Ligand-binding results in the 
formation of ErbB- receptor homo- and heterodimers. Activation of intrinsic kinase 
domain induces autophosphorylation as well as phosphorylation of other signaling 
molecules on specific tyrosine residues (Simon 2000). A range of downstream 
effector proteins bind these phosphorylated residues resulting in the activation of 
intracellular signaling pathways (Yarden 2001, Yarden and Sliwkowski 2001) (Fig. 
1.9). Of the four family members, the overexpression of HER2/ErbB2 is well 
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described as associated with malignancy and poor outcome in breast cancer (Rubin 
and Yarden 2001).  
 
 
 
 
 
 
 
 
 
Fig. 1.9: Illustration of the ErbB signaling network. The signaling network comprises an input, a 
signal-processing and an output layer. The input layer illustrates the ten dimeric receptor combinations 
with corresponding ligands. Until now no ErbB2-specific ligand has been identified and ErbB3 
homodimers are catalytically inactive. The signaling-processing layer shows the corresponding 
adaptors and enzymes of only two receptor dimers (ErbB1 homodimer & ErbB3/ ErbB2 heterodimer) 
that lead to initiation of different cascades and induction of several transcription factors. The output 
layer illustrates possible cellular events like apoptosis, migration, cell growth, adhesion and 
differentiation (source: Yarden and Sliwkowski 2001; the figure is modified) 
 
 
1.4.1 The receptor tyrosine kinase HER2/ErbB2 
 
Human ErbB2 gene is localized on chromosome 17q21 and encodes a 
transmembrane protein with a homology of 50% to the EGF-receptor. To date, no 
ErbB2-specific ligand has been identified, but ErbB2 can act as a co-receptor and is 
a preferred heterodimerization partner for the other ErbB family members (Neve et al. 
2000). Rubin and Yardin (2001) described that on the cell surface of normal cells only 
few ErbB2 molecules existing compared to the other ErbB family receptors, meaning 
that only a few heterodimers with ErbB2 are formed and consequently weak growth 
signals are developed. Upon ErbB2 overexpression, the number of ErbB2 
heterodimers increases, resulting in a strong downstream signal. It was shown by 
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Slamon et al. (1987) that 30% of all breast tumors overexpress ErbB2 and this 
correlates with worse prognosis for the patients (Ross and Fletcher 1999). Aberrant 
ErbB2 activation can be a precursor for tumorigenesis and the development of breast 
cancer due to its influence on cell proliferation, angiogenesis, invasive growth therapy 
resistance, and metastatic behavior (Menard et al. 2004, Yu et al. 2000, Eccles 2001, 
Holbro et al. 2003). ErbB2 overexpression has also been reported in other types of 
cancer, including ovarian carcinoma (Zhang et al. 1989), non-small lung cancer 
(Schneider et al. 1989) and other human malignancies (Menard et al. 2001).  
An oncogenic variant of ErbB2, named NeuT, was isolated from rats (Shih et al. 
1981). This activated NeuT carries a point mutation (amino acid exchange from 
valine to glutamine at position 664) in the transmembrane domain of the receptor 
resulting in a constitutively active variant (Bargmann et al. 1986) as a result of ligand- 
independent dimerization. In order to investigate ErbB2/NeuT-mediated oncogenic 
transformation, Trost et al. (2005) generated a MCF7 breast cancer cell system with 
doxycycline-inducible expression of the oncogene, NeuT. Unexpectedly, 
overexpression of NeuT by the addition of tetracycline in MCF7/NeuT cells triggered 
premature senescence (Trost et al. 2005, Cadenas et al. 2012). 
 
 
1.5 Oncogene-induced premature senescence 
 
Cellular senescence represents a state of irreversible cell cycle arrest. It is divided 
into replicative- or oncogene-induced senescence (OIS) and represents, along with 
apoptosis, a tumor-protective failsafe mechanism (Ohtani et al. 2009). OIS is 
considered a defense barrier against tumors, but under certain circumstances 
senescent cells may support tumor progression caused by their secretory phenotype 
that is enriched in proteases, cytokines and growth factors (Rodier and Campisi 
2011). Despite their growth arrest in the G1-phase of the cell cycle (decreased S- 
phase), senescent cells remaining metabolically active, often acquiring resistance 
against apoptosis signals and display an altered gene expression pattern (Campisi 
and d’Abba di Fagagna 2007). Typical senescence markers include the expression of 
the cell-cycle inhibitor, cyclin-dependent kinase inhibitor p21 (CDKI, WAF1/ CIP1), 
and the decreased incorporation of 5-bromodeoxyuridine as a marker for DNA 
replication. 
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Oncogene-induced senescence has been associated with a decline in lipid synthesis, 
significant increase in fatty acid oxidation, and elevated inflammatory cytokine 
production (Quijano et al. 2012). Senescent cells show elevated overall lipid content 
with evidence of impaired mitochondrial function resulting in a high rate of oxidant 
formation (Cadenas et al. 2010). Mitochondrial dysfunction leads to increased 
amounts of reactive oxygen species (ROS), accumulation of depolarized 
mitochondria around the nucleus accompanied by oxidative DNA damage, 
decreased ATP production and 5' AMP-activated protein kinase (AMPK) activation 
(Moiseeva et al. 2009). 
Doxycycline-inducible expression of NeuT (oncogenic variant of HER2) in MCF7 cells 
leads to the expression of the aforementioned senescence-related markers and 
characteristics in approximately 90% of cells (Trost 2005, Dissertation). Therefore, 
MCF7/NeuT cells provide a suitable cell model for studying ErbB2-mediated 
oncogene transformation and subsequent premature senescence.  
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1.6 Abstract 
The association of endothelial lipase LIPG and atherosclerosis is widely accepted but 
there is only little known and published about the contribution of LIPG in human 
carcinogenesis. LIPG shows strong phospholipase A1 and little triacylglycerol lipase 
activity with high-density lipoprotein (HDL) as main substrate. Located on the cell 
surface binds and cleaves LIPG surrounding HDL followed by cellular fatty acid 
uptake. Several diseases, including cancer, are accompanied by changes in lipid 
composition of cellular membranes and alterations in lipid metabolism. The aim of 
this study was to investigate the contribution of LIPG expression in human breast 
cancer cells under cellular stress conditions as well as LIPG expression distribution in 
breast cancer patients and its role in human cancer progression. Affymetrix gene 
array data analysis in breast cancer patients exhibit LIPG expression in some tumors 
associated with poor outcome like short metastatic-free survival. In vitro shows 
oncogene NeuT-induced senescence in MCF7 breast cancer cells a LIPG-
upregulation in a HER2 independent manner. Our experiments showed that LIPG-
overexpression may support tumor cells with exogenous fatty acids in phases of 
energy deprivation. LIPG expression is a mechanism to preserve mitochondrial 
integrity in terms of impaired fatty acid synthesis and may protect against reactive 
oxygen species-induced damage under oxidative stress.  
 
 
1.7 Zielsetzung der Arbeit 
Die Assoziation der endothelialen Lipase LIPG mit Arteriosklerose ist weitgehend 
akzeptiert, allerdings ist bis heute nur wenig bekannt und publiziert über die LIPG- 
Beteiligung in der humanen Krebsprogression. LIPG weist eine starke Phospholipase 
A1, aber nur schwache Triacylglycerid Lipase Aktivität auf mit Lipoproteinen hoher 
Dichte (HDL) als Hauptsubstrat. Zelloberflächen-assoziiertes LIPG bindet und spaltet 
umliegendes HDL und ermöglicht die zelluläre Aufnahme von Fettsäuren. Etliche 
Erkrankungen, Krebs eingeschlossen, sind begleitet durch Umwandelung der Lipid-
Zusammensetzung der Zellmembran, sowie Veränderung des Lipidmetabolismus. 
Ziel dieser Arbeit war es die Beteiligung der LIPG Expression in humanen 
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Brustkrebszellen unter zellulärem Stress, sowie dessen Verteilung und Funktion in 
Brustkrebstumoren zu ermitteln. Affymetrix gene array Datenanalysen von 
Brustkrebspatientinnen zeigen LIPG Expression in nur wenigen Tumoren, welche 
wiederum assoziiert sind mit schlechter Prognose (kürzeres metastasenfreies 
Überleben). In vitro zeigt die onkogene NeuT-induzierte Seneszenz in MCF7 
Brustkrebszellen eine HER2-unabhängig erhöhte LIPG Expression. Unsere 
Experimente zeigten, dass Tumorzellen in Phasen des Energiemangels durch eine 
LIPG Überexpression mit exogenen Fettsäuren versorgt werden. Darüber hinaus 
ermöglicht die LIPG Expression einen Mechanismus zur Aufrechterhaltung der 
mitochondrialen Integrität in Zeiten blockierter Fettsäuresynthese und schützt 
dadurch gegen reaktive Sauerstoffspecies-induzierte Schäden unter oxidativem 
Stress.  
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2. Materials and Methods    
 
2.1 Materials        
2.1.1 Cell lines 
 
MCF7:  MCF7 (Michigan Cancer Foundation-1; Barbara Ann Karmanos 
Cancer Institute; ATCC: HTB-22) is an adherent growing breast 
cancer cell line. It was isolated 1970 from mammary gland of a 
69-year old Caucasian woman suffering from invasive breast 
adenocarcinoma. MCF7 show an epithelial like cell growth with 
capability of forming domes (Soule et al. 1973). 
MCF7/NeuT: MCF7/NeuT cell line was established by Tatjana Trost (Trost et 
al. 2005) in order to study the consequences of NeuT 
overexpression (oncogenic variant of receptor tyrosine kinase 
ErbB2). In this cell lines the NeuT expression is controlled by 
Tet-On-system meaning a tetracyclin-induced (doxycyclin) 
expression of the gene of interest. For this purpose MCF7 cells 
were stably transfected with pcDNA3Neo/rtTA2 plasmid which 
enables the expression of the reverse tetracyclin-dependent 
transactivator (rtTA). The second transfected plasmid was 
pINSpBI-EGFP/NeuT-containing eGFP (enhanced green 
fluorescent protein) reporter as well as NeuT gene under the 
control of a tetracyclin responsive element (TRE) as a 
bidirectional promoter (Fig. 2.1). Through addition of doxycycline 
to cell media binds rtTA on TRE and initiates the target gene 
expression. The bidirectional promoter enables simultaneously 
the expression of the gene of interest and expression of eGFP 
which facilitates an optic control of expression efficiency. The 
NeuT gene is coming from the proto-oncogene of rats and 
carries a point mutation (amino acid change from valine to 
glutamine at position 664; Bargmann et al. 1986) in 
  Material and Methods 
 
 
25 
 
transmembrane domain of NeuT-receptor and results in a 
constitutive active version. 
 
Fig. 2.1: MCF7/NeuT transfection constructs. (A) expression plasmid pcDNA3Neo/rtTA; (B)                   
expression plasmid pINSpBI-EGFP/hNeu 
                                                       
K-562: K-562 cells are a human myelogenous leukemia cell lines derived 
from a 53 year old female chronic myeloid leukemia (CML) 
patient in blast crisis (last stage of CML with fast progression and 
short overall survival) (Drexler 2000, Academic Press). This 
leukemia cell lines grows as suspension and exhibit less 
clumping than other suspension cell lines. They lack the MHC 
molecule complex required to inhibit natural killer (NK) cells 
activity so they are favored target cells for 51Chromium- release 
assay application. 
NK cells: Natural killer cells (NK cells) are a part of the innate immune 
system and belong to lymphocytes. They recognize tumor cells 
or virus-infected cells by missing-self-hypothesis (absence of 
MHC-I molecules on cell surface) results in binding and 
disrupting integrity of target cell membrane. In this thesis NK 
cells were isolated from whole blood samples of voluntary 
healthy donors.  
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2.1.2 Antibodies 
2.1.2.1 Primary antibodies 
antibody   host  company  Catalog No. 
α-tubulin   rabbit  cell signaling  2144 
Akt-antibody   rabbit  cell signaling  9272 
p-Akt (Ser473)  rabbit  cell signaling  9271 
ADFP (Plin2)  rabbit  abcam  ab52356 
β-actin   mouse sigma Aldrich A5316 
Cleaved PARP  rabbit  cell signaling  9541 
ERK5    rabbit  cell signaling  3372 
FLAG    mouse sigma Aldrich F1804 
Lcn2    rabbit  abcam  ab125075 
LIPG (WB)   mouse sigma Aldrich WH0009388M2 
LIPG (IF)   rabbit  abcam  ab24447 
MEK1/2   rabbit  cell signaling  9122 
Neu    rabbit  Santa Cruz  sc-284 
p38 MAPK   rabbit   cell signaling  9212 
p-p38 MAPK   rabbit  cell signaling  9215 
p44/42 MAPK  rabbit  cell signaling  9102 
p-p44/42 MAPK  rabbit  cell signaling  4377 
p-ERK   rabbit   cell signaling  3371 
p-MEK1/2   rabbit  cell signaling  9127 
p-SAPK/ JNK  rabbit  cell signaling  4668 
p21 Waf1/cip   rabbit  cell signaling  2947 
 
2.1.2.2 Secondary antibodies 
antibody     company  Catalog No. 
anti-mouse IgG, HRP linked  cell signaling  7076 
anti-rabbit IgG, HRP linked  cell signaling  7074 
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anti-mouse AlexaFluor647   Invitrogen  929537 
anti-rabbit AlexaFluor647   Invitrogen  A-31573 
 
Tab. 2.1: Antibody (AB) parameters for western blot 
primary/ secondary AB  incubation   dilution 
α-tubulin / mouse   o.n. 4°C / 1h RT  1:1000 / 1:5000 in BSA 
β-actin / mouse   o.n. 4°C / 1h RT  1:5000 / 1:5000 in BSA 
ERK5 / rabbit   o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
LIPG / mouse   o.n. 4°C / 1h RT  1:2500 / 1:5000 in BSA 
MEK1/2 / rabbit   o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
Neu / rabbit    o.n. 4°C / 1h RT  1:500 / 1:1000 in BSA 
phospho Akt / rabbit  o.n. 4°C / 1h RT  1:1000 / 1:5000 in BSA 
p38 MAPK / rabbit   o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
phospho MAPK / rabbit  o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
p44/42 MAPK / rabbit  o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
phospho p44/42 MAPK / rabbit o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
phospho JNK / rabbit  o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
p-ERK5 / rabbit   o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
p21 Waf1/cip / rabbit  o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
phospho MEK1/2 / rabbit  o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
total Akt / rabbit   o.n. 4°C / 1h RT  1:1000 / 1:1000 in BSA 
 
 
Tab. 2.2: Antibody (AB) parameters for immunofluorescence (IF) 
primary/ secondary AB  incubation   dilution 
ADFP (Plin2) / rabbit  o.n. 4°C /2h RT  1:500/ 1:300 in BSA 
Bodipy    30min RT   50µg/mL in 1x PBS  
DAPI     5min RT   1:20000 in dH2O 
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FLAG-Tag/ mouse   o.n. 4°C / 2h RT  1:2000 / 1:500 in BSA 
LIPG / rabbit    o.n. 4°C / 2h RT  1:500 / 1:100 in BSA 
Rhodamin-Phalloidin   2h RT    1:500 in BSA  
 
2.1.3 Primer and probes  
primer    company   Catalog No. 
ACSL3   life technologies  Hs00244853_m1 
β-actin   Qiagen   QT01680476 
CDH1    life technologies  Hs01023894_m1 
CDKN1   life technologies  Hs00355782_m1 
CHPT1   life technologies  Hs00220348_m1 
GAPDH   life technologies  Hs02758991_g1 
LDLR    life technologies  Hs00181992_m1 
LIPG    life technologies  Hs00195812_m1  
MGLL    life technologies  Hs00200752_m1 
Nedd9   life technologies  Hs00610590_m1 
NeuT    Qiagen   QT00193466 
NPC1    life technologies  Hs00181192_m1 
PLD1    life technologies  Hs00160118_m1 
Plin2    life technologies  Hs00605340_m1 
Snai1    life technologies  Hs00195591_m1 
TBP    Qiagen   QT00000721 
Twist1   life technologies  Hs01675818_s1 
TXN     life technologies  Hs01555214_g1 
TXNIP   life technologies  Hs01006900_g1 
TXNRD1   life technologies  Hs00917067_m1 
UBC    life technologies  Hs00824723_m1 
Vim    life technologies  Hs00958111_m1 
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2.1.4 Small interfering RNA (siRNA) 
siRNA   company    Catalog No. 
β-actin  Ambion (life technologies)  12935-141 
GAPDH  Thermo Scientific Dharmacon D-001830-01-05 
LIPG    Invitrogen    HSS190264 
LIPG    Invitrogen    HSS113931 
LIPG    Invitrogen    HSS113929 
Non-sense siRNA Invitrogen    VHS40202 
LIPG    Ambion (life technologies)  s17961 
LIPG    Ambion (life technologies)  s17962 
LIPG    Ambion (life technologies)  s17963 
LIPG   Thermo Scientific Dharmacon J-009601-05 
LIPG   Thermo Scientific Dharmacon J-009601-06 
LIPG   Thermo Scientific Dharmacon  J-009601-07 
LIPG   Thermo Scientific Dharmacon J-009601-08 
Non-sense siRNA Thermo Scientific Dharmacon D-001810-01-05 
 
 
2.1.5 Cell culture media 
cell lines   media      company 
MCF7   500mL Dulbecco’s modified eagle media  PAN biotech 
(DMEM) 4.5g/L glucose 
5mL sodium pyruvate    sigma Aldrich 
50mL heat-inactivated FCS   PAN biotech 
500µL 100x mem NEAA    Gibco 
500µL insulin      sigma Aldrich 
MCF7/NeuT  500mL Dulbecco’s modified eagle media  PAN biotech 
(DMEM) 4.5g/L glucose 
50mL tetracyclin-free FCS    PAN biotech 
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K-562   500mL Iscove's modified Dulbecco's media Gibco 
(IMDM) 
50mL heat-inactivated FCS   PAN biotech 
NK cells  500mL Iscove's modified Dulbecco's media Gibco 
(IMDM) 
50mL heat-inactivated FCS   PAN biotech 
    
 
experiments   media / reagent     company 
siRNA transfection   
& LIPG overexpression Opti-Mem     Invitrogen 
    lipofectamin 2000    Invitrogen 
    nanofectin     PAA 
    prime kit     PAA 
    interferin     Polyplus 
    JetPrime     Polyplus 
PBMC isolation  LSM 1077 Lymphocytes (Ficoll)  PAA  
starvation experiments 500mL Dulbecco’s modified eagle media PAN biotech 
(DMEM) 0g/L glucose 
 
 
2.1.6  Inhibitors 
inhibitor   company  inhibitor  company   
Cerulenin  sigma Aldrich Oligomycin  sigma aldrich 
PD98059  sigma Aldrich LY294002  sigma Aldrich 
SP600125  sigma Aldrich SB203538  sigma Aldrich 
TOFA   sigma Aldrich Protease inh. sigma Aldrich 
Phosphatase inh. sigma Aldrich 
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2.1.7 Chemical reagents and kits 
reagent / kit (company)     reagent /kit (company) 
2-mercaptoethanol (sigma Aldrich)  acrylamide (Carl Roth) 
albumin fraction V (BSA; Carl Roth)  ammonium chloride (Carl Roth) 
ammonium persulfate (APS; sigma A.)  BCA protein assay kit (Thermo S.) 
BSA (fatty acid free; sigma Aldrich)  bromophenol blue (Carl Roth) 
cDNA kit (applied Biosystems)   CellTiter-Blue cell viability assay  
DEPC treated water (Invitrogen)    (Promega) 
DMSO (Carl Roth)     DTT (Carl Roth) 
EDTA (Carl Roth)     entellan (Merck)  
ethanol (Th. Geyer)     FluorPreserve reagent (calbiochem) 
formaldehyde (Carl Roth)    glycerol (Carl Roth) 
high capacity cDNA RT kit (applied Bios.) human high density lipopr. (BioTrend) 
human low density lipopr. (BioTrend)   glycin (Carl Roth) 
hydrochloride acid (Carl Roth)   innuPREP RNA kit (analytic jena) 
isopropanol (Carl Roth)    methanol (Carl Roth) 
magic marker (Invitrogen)     nonidet P-40 substitute (Roche)  
oleic acid (sigma Aldrich)     oil red O (sigma Aldrich) 
paraformaldehyde 4% (PFA; C. Roth)   PMSF (Carl Roth) 
Rotihistol (Carl Roth)     SDS-pellets (Carl Roth) 
sera plus (PAN biotech)     Sodium chloride (Carl Roth)  
sodium hydroxide (Carl Roth)    TaqMan master mix (applied Bios.) 
TAG quantification kit (abcam)    TEMED (Carl Roth)  
TMRE (molecular probes)    Tris (Carl Roth) 
Triton X-100 (Carl Roth)    Tween 20 (sigma Aldrich) 
western lightning Plus-enhanced chemiluminescence substrate (Perkin-Elmer)  
X-treme gene HP DNA transfection reagent (Roche)   
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2.1.8 Commercial buffers and solutions 
buffer / solution      company    
2x laemmli sample buffer     BioRad 
anode buffer concentrate A    C. Roth 
cathode buffer concentrate    Carl Roth   
Precision plus protein dual color standard BioRad 
Stripping buffer     Thermo Scientific 
Trypsin 0.05% / EDTA    PAN biotech 
   
  
2.1.8.1 Prepared buffers and solutions 
buffer / solution    components     
APS solution    10% (w/v) APS in H2O 
anode buffer    100mL buffer concentrate + 200mL methanol +  
     700mL dH2O 
blocking solution   5% (w/v) BSA in TBS-T 
cathode buffer   100mL buffer concentrate + 200mL methanol +  
     700mL dH2O 
loading buffer (5x)   2.25mL 1M Tris-HCL pH 6.8 + 5mL glycerol +  
0.5g SDS + 5mg bromophenol blue + 2.5mL  
1M DTT    
cDNA synthesis reaction mix 4.2µL H2O + 2µL 10x  RT-buffer +  
2µL random primer + 0.8µL 25x d’NTP +  
1µL reverse transcriptase  
PBS (10x) pH 7.4   2g KCL + 2g KH2PO4 + 9.2g Na2HPO4 + 80g NaCl 
     adjust to a volume of 1L with H2O 
precipitation buffer (proteins) 4M ammonium sulfate in H2O 
RIPA lysis buffer recipe  1% NP-40 (tergitol) + 150mM NaCl +  
20mM Tris pH 7.4 + 1mM EDTA pH 8 + 
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10mM NaF + 1mM MgCl2 + 1mM Na3VO4 pH 10 + 
10% glycerin; adjust with dH2O up to 500Ml 
add directly per mL RIPA: 1mM DTT +  
1mM protease inhibitor cocktail + 1mM PMSF 
running buffer (10x)   30.3g Tris + 144g glycerol + 10g SDS 
  adjust to a volume of 1L with H2O  
pH should be 8.3 
separation buffer   3M Tris in H2O pH 8.8 with HCL 
separation (10%) two gels  16mL H2O + 13.2mL 30% acrylamide +  
10mL separation buffer 0.47M Tris pH 6.8 +   
400µL 10% SDS + 400µL 10% APS + 16µL Temed 
stacking buffer   0.47M Tris in H2O pH 6.8 with HCL 
stacking (4%) two gels  14.5mL H2O + 3mL 30% acrylamide +  
2.5mL stacking buffer 3M Tris pH 8.8 +  
200µL 10% SDS + 300µL 10% APS + 15µL Temed 
TaqMan reaction mix  1.25µL TaqMan probe + 12.5µL PCR master mix + 
6.25µL H2O + 5µL DNA (2ng/µL) 
TBS (10x) pH 7.4   12g Tris + 53h NaCl + 
     adjust to a volume of 1L with H2O 
TBS-T     250mL TBS (10x) + 2.5mL Tween 20  
     adjust to a volume of 2.25L with H2O 
triacylglyceride reaction mix  47.6µL assay buffer + 0.4µL probe +  
2µL enzyme mix 
  
2.1.9 Technical equipment 
equipment        company    
blot imager Vilber Fusion Fx7    Vilber Lourmat 
blot chamber fast blot B44     Biometra  
Casy cell Counter      Innovatis AG/ Roche 
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centrifuge megafuge 10R     Thermo Scientific 
centrifuge MiniSpin plus     Eppendorf   
confocal microscope (LSM) FV1000   Olympus    
electrophoresis chamber     BioRad 
incubator       Binder 
magnetic stirrer IKAMAG RCT    Ikamag 
NanoDrop ND-1000     Thermo Scientific 
optical microscope eclipse TS 100   Nikon 
pH meter       Schott 
plate reader Tecan SpectraFluor Plus   Tecan 
plate reader Tecan infinite 200Pro   Tecan 
power supplies       Biometra 
qRT-PCR system ABI 7500    applied Biosystems 
precision balance EW150-3M    Kern 
sterile hood       Hereaus 
thermo cycler Tgradient     Biometra 
transfer chamber      Biometra 
UV/ Vis spectrometer V-530    Jasco 
Water bath       Labortechnik 
 
2.1.10 Consumables  
consumables (company)    consumables (company) 
6-well plates (Sarstedt)    24-well plates (Sarstedt) 
96-well pl. Black clear bottom (Greiner)  175cm2 cell culture flasks (Sarstedt) 
cell scraper (Sarstedt)    cover slips (Menzel) 
disposal cuvettes (Brand)    microscope slides (Thermo Scientific) 
pipettes sterile (Sarstedt)    PVDF membrane (Perkin Elmer)  
reaction tubes (Eppendorf & Falcon)  Whatman paper 3mm (Schleicher) 
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2.2 Methods                             
     
2.2.1 Cell culture 
All cell lines were routinely cultured under sterile conditions in the corresponding 
culture media (material part) and incubated at constant humidity at 37°C with 5% CO2 
and aqueous vapor saturated atmosphere. Cells were sub-cultured twice a week. For 
this purpose, cells were washed with 1x PBS and detached by trypsin/EDTA. 
Suspended in fresh full media, cells were re-plated with a 1:3 dilution. The CASY®-
Technology (Innovatis AG) was used to determine cell number. 
 
2.2.2 DNA vectors 
Two expression vectors were utilized to analyze the transient overexpression of 
LIPG. The human LIPG Gene cDNA Clone/ORF Clonep/pCMV/hygro-FLAG vector 
encodes for the human LIPG cDNA whereas the pCMV/hygro-negative control vector 
(FLAG-tagged) vector was used as an empty vector control (Hölzl Diagnostika 
Handels GmbH) (Fig. 2.2). 
             
 
 
 
 
 
 
 
Fig. 2.2: Illustration of pCMV/hygro-negative control vector (left) and pCMV-LIPG-FLAG vector 
(right) (source: http://www.sinobiological.com) 
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Both vectors carry a cytomegalovirus promoter (CMV), an antibiotic resistance 
(ampicillin) allowing selection and a FLAG-tag (polypeptide protein tag; Munro and 
Pelham in 1984) to detect transfected cells and cellular localization by using a 
specific anti-flag antibody. In contrast to the control vector the pCMV-LIPG-FLAG 
vector is extended by human LIPG cDNA. 
Delivered 10µg vector cDNA had to be amplified and isolated. Therefore followings 
steps were attached: 1) transformation of bacteria with vectors, 2) culturing and 
multiply vector-containing bacteria and 3) terminated by vector cDNA isolation by 
QIAfilter Plasmid Maxi Kit (Qiagen). 
 
2.2.2.1 Transformation of bacteria 
Transformation of cells is defined as a permanent, heritable alteration resulting from 
the uptake and incorporation of a foreign DNA into the host-cell genome (Lodish et 
al. molecular cell biology, 7th edition). In this thesis DH4α-cells (competent 
Escherichia coli, E. coli) were used for transfection. 50µL E. coli cell suspension was 
defrosted and incubated with 1µL plasmid vector solution for 20min on ice. Following 
heat shock at 45°C for 45sec resulted in membrane holes that free vector DNA can 
pass through. After an incubation of two minutes on ice, cells were mixed with 900µL 
super optimal bouillon (SOC media) for optimal support of stressed cells for one hour 
at 37°C. 200µL of cell suspension was streaked on lysogene bouillon plates (LB agar 
media plates) containing ampicillin. Plates were incubated over night at 37°C. For 
bacteria culturing, a colony was picked from the plate and transferred to 250mL LB 
media with 25mg/mL ampicillin. Suspension was incubated over two days at 37°C 
under shaking conditions. The amplified vector DNA was isolated and purified 
according manufactures instructions of the QIAfilter Plasmid Maxi Kit (Qiagen). 
Bacteria cells were lysed under alkaline conditions and cleared by QIAfilter 
cartridges. After mixing the filtrate with endotoxin removal buffer, whole solution was 
loaded onto anion-exchange tips that selectively bind plasmid DNA under appropriate 
low-salt and pH conditions. Low-molecular-weight impurities as well as RNA, proteins 
and metabolites were washed away. Ultrapure plasmid DNA was eluted in high-salt 
buffer. Using 2-propanol precipitation, DNA that was collected by centrifugation, 
could be concentrated and desalted. 
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2.2.2.2 Transient transfection of MCF7 cells 
MCF7 cells were transient transfected with the pCMV/hygro-negative control or 
pCMV-LIPG-FLAG vector. For transfection, MCF7 cells were plated onto 6-well 
plates (2x105 cells/ well) and incubated for 24 hours. Afterwards, cells were 
incubated with transfection mix (2mL serum containing antibiotic-free full media, 
200µL OPTI-MEM, 1.5µg vector DNA, 6µL X-tremeGENE HP DNA transfection 
reagent per well) for 48 hours.  
 
2.2.3 Feeding LIPG-overexpressing MCF7 cells with substrates 
After transfection, LIPG-overexpressing MCF7 cells were fed with either 800µg high- 
density lipoprotein (HDL, BioTrend) or 800µg 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC or PC-OA; Avanti polar Lipids) and incubated for 48 hours. 
HDL is ready to use whereas DOPC had to be solved. 100mg DOPC powder diluted 
with 10mL DEPC water was incubated for three hours at 45°C in a shaking water 
bath to get large multi-laminar vesicles. To disrupt these vesicles into small uni- 
laminar vesicles lipid solution was sonicated for 30 minutes.  
 
2.2.4 Incubation of MCF7 cells with different inhibitors 
To analyze LIPG expression change as a possible rescue system in case of 
starvation or cellular stress conditions, MCF7 cells were treated with inhibitors of de 
novo fatty acid synthesis. Therefore, inhibitors like 5-(Tetradecyloxy)-2-furoic acid 
(TOFA; sigma Aldrich) and Cerulenin or Oligomycin to block ATP production were 
used (Fig. 2.3).  
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Fig. 2.3: Blockage of de novo fatty acid synthesis. 5-(Tetradecyloxy)-2-furoic acid (TOFA) blocks 
the enzyme acetyl-CoA carboxylase (ACACA) activity, avoids the production of malonyl-CoA and 
consequently blocks the cellular fatty acid production. Inhibition of the fatty acid synthase by Cerulenin 
results in ATP as well as malonyl-CoA accumulation. Oligomycin blocks the membrane-bound 
mitochondrial ATP synthase and proton channels that evokes blockage of oxidative phosphorylation 
and electron transport chain 
 
MCF7 cells were incubated with: 1) 6µM TOFA for 24h or 48h, 2) with 9.98µM and 
31.5µM Cerulenin for 12h, 24h and 48h or 3) with 31.5ng, 99.7ng, 315ng, 995ng and 
3.15µg Oligomycin for 20min and three hours. All reagents were diluted in DMSO 
with serum starved media. After incubation, RNA was extracted and LIPG expression 
was determined by qRT-PCR. 
The impact of LIPG on different pathways is quite unknown. Therefore, diverse 
inhibitors were tested in the MCF7/NeuT cell system to study different pathways 
(Ras/ Raf/ MEK/ ERK; PI3K/ Akt; p38/ MAPK and SAPK/ JNK) that affect LIPG  
expression. MCF7/NeuT cells were incubated with doxycycline in presence or 
absence of specific inhibitors LY294002 (20µM, blocks Akt/ PI3K pathway), 
SB203538 (25µM, blocks p38-pathway), PD98059 (25µM, blocks MEK1/2- pathway) 
and SP600125 (25µM; SAPK/ JNK pathway). Afterwards, cells were incubated over 
seven days. 
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2.2.5 Determination of mitochondrial membrane potential  
Mitochondrial membrane potential-mediated accumulation of tetramethylrhodamine 
ethyl ester perchlorate (TMRE) within inner membrane regions is an indication of 
healthy functioning mitochondria. In case of depolarization (changes in membrane 
potential towards more positive potential) or inactive mitochondria, membrane 
potential is decreased and fails to sequester TMRE (loss of dye at least less 
fluorescence). LIPG-overexpressing MCF7 cells were fed with 800µg PC-OA for 48h 
followed by treatment with 6µM TOFA for 48h. For TMRE-staining, cells were 
washed once with 1x PBS and incubated with 10µM TMRE/DMSO (10mg TMRE 
solved in 500µL DMSO) in media containing serum for 20min at 37°C. After staining 
cells were trypsinated with 200µL Trypsin/EDTA and collected with 800µL media plus 
serum. 200µL of staining cell suspension was transferred onto black 96-well plates 
with clear bottom (Greiner). The TMRE fluorescence was detected by excitation 
545nm and emission 575nm within a plate reader (Tecan SpectraFluor Plus). In 
addition, background fluorescence was measured. 
 
2.2.6 Knock down experiments 
Small interfering RNAs (siRNA) were used cells to knock down the gene of interest 
and to study the function of LIPG. SiRNAs are a class of double-strand RNA (20-
25bp) which can interfere with the expression of a specific gene with complementary 
nucleotide sequence (Fire et al. 1998). In this thesis, ten different siRNAs were tested 
(Invitrogen, Dharmacon and Ambion) using either the transfection reagents 
Lipofectamin 2000 (Invitrogen), Nanofectin (PAA), Prime Kit (PAA), Interferin 
(Polyplus), JetPrime (Polyplus) or electroporation (Lonza). All reagents and 
chemicals were used according to the manufactures instructions.          
 
2.2.7 Gene expression analysis 
Analysis of gene expression in eukaryotic cells based on mRNA abundance was 
performed by qRT-PCR. For this purpose, RNA was isolated and transcribed into 
cDNA.  
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2.2.7.1 Isolation of RNA 
Total RNA was isolated using innuPREP RNA Kit (Analytik Jena) according to 
manufactures instructions. 
Cultured MCF7 cells were washed with 1x PBS after removing media. Afterwards, 
cells were detached by adding 400µL RL lysis buffer to each well. Cell suspension 
was collected by cell scrapers and transferred to tubes. Cells were gently mixed by 
pipetting up and down to insure the complete disruption. The mixture was placed into 
a spin filter D column that is placed in a 2mL receiver tube. Column was centrifuged 
at 10.000x rpm for two minutes to separate genomic DNA and proteins from RNA. 
The filtrate was mixed with 400µL 70% ethanol, transferred into spin filter R that is 
placed in a receiver tube and centrifuged at 10.000xg for two minutes. In this step 
total RNA will bind to the silicon filter. The filter was washed with 500µL HS buffer 
and subsequently with 750µL LS buffer by centrifugation at 10.000xg for one minute. 
To remove any residual ethanol, the column was centrifuged at 10.000xg for three 
minutes. Afterwards the filter was placed into a fresh tube, incubated with 20µL 
RNase-free water and centrifuged for one minute at 8.000xg to elute the total RNA. 
RNA samples were stored at -80°C. 
 
2.2.7.2 RNA quantification 
The NanoDrop-1000 spectrophotometer (Thermo Scientific) enables the 
quantification of isolated RNA. The principal behind is to measure the light which 
passes a liquid sample. A pulsed xenon flash light lamp (source of light) facilitates the 
computer-based analysis. The spectrophotometer is constructed by two optic fiber 
cables (one in the sampling arm and one on the sample receiver place) that are 
connected by closing the sampling arm. The machine is initialized with 1.5µL RNAse-
free water (blank) followed by measurement of isolated RNA samples resulting in 
three values for each sample. The absorbance at 260nm reveals the RNA 
concentration [µg/µL]. Second the purity of RNA based on absorption at 260/280nm 
(values of ~2.0 are accepted as ,,pure’’ for RNA). Third value gives the result of an 
additional measurement of nucleic acid purity based on absorbance 260/230nm 
(values in the range of 1.8-2.2 are accepted as ,,pure’’ for RNA).  
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2.2.7.3 cDNA synthesis 
Transcription of RNA to cDNA permits to work with stable DNA instead of susceptible 
RNA that degrades quickly. Based on reverse transcription reaction, the high 
capacity cDNA reverse transcription kit (Applied Biosystems) was used. The enzyme 
reverse transcriptase (RT) synthesizes cDNA strand by adding complementary 
nucleotide bases on mRNA template. Starting point provides a short DNA sequence 
of oligo-dT primer that binds on the poly-A sequence of all 3’-end mRNAs. The 
secondary strand will be synthesized after degradation and displacement of mRNA 
by RT.  
The reverse transcription was performed using a thermo cycler (Biometra). 
Synthesized cDNA with a concentration of 1µg were diluted with 480µL DEPC water 
to a final concentration of 2ng/µL and stored -20°C. 
 
Tab. 2.3: Thermo cycler program 
     step     temperature              time  
  incubation   25°C     10min 
  reverse transcription 37°C   120min 
  inactivation   85°C       5min 
        4°C       ∞ 
 
 
2.2.7.4 Quantitative real time polymerase chain reaction (qRT-PCR) 
Quantitative real time polymerase chain reaction (qRT-PCR) allows the qualitative 
and quantitative detection of target gene expression. Figure 2.4 illustrates the 
principle of qRT-PCR which includes the polymerization of cDNA strands, strand 
displacement and cleavage of the reporter. Particularly, the TayMan probe is of 
importance for this technique. This oligonucleotide probe carries a quencher (low 
energy molecule) on the 3’-end and a reporter (high energy dye, 6-FAM fluorescence 
labeled) on the 5’-end. Due to the proximity the quencher reduces the intensity of the 
reporter fluorescence by fluorescence resonance energy transfer (FRET). The 
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extension phase, in which the forward primer binds on the 5’-end of DNA, induces the 
degradation and displacement of the TayMan probe. The growing distance between 
quencher and reporter leads to a released reporter fluorescence. Increasing 
fluorescence intensities were detected automatically and results in a Ct-value (cycle 
threshold). This Ct-value describes the point when reporter fluorescence intensity 
exceeds background fluorescence (threshold line). Beginning of the exponential 
amplification of a sample is accepted to set an accurate threshold line. Analysed 
samples are accompanied by a reference gene called endogenous gene or 
housekeeping gene as an internal standard. Reference genes should also be 
expressed in used cell lines and should not show altered expressions over 
experimental variables.  
 
Fig. 2.4: Principle of qRT-PCR (source: www.lifetechnologies.com) 
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For this work, the qRT-PCR assay on 96-well plate formates was performed using 
the ABI 7500 (applied Biosystem). 
Each well contained 20µL reaction mix and 5µL DNA with an end concentration of 
10ng/ well. Covered plates were centrifuged 400xg for 1min and analyzed. 
 
Tab. 2.4: Parameters of standard amplification 
  step   temperature   time  
  heating up   50°C       2min 
  enzyme activation  95°C     10min 
  denaturation   95°C      15sec 
  annealing & elongation 60°C       1min  
    
  repetition of denaturation         40 times 
and annealing & elongation 
 
To quantify the expression of target genes the ∆∆Ct-method was applied. This 
relative quantitative method calculates the correlation between treated against 
untreated samples. All expression levels of target genes were normalized to 
expression level of the reference gene.  
The ∆∆Ct-method includes following calculation steps: 
- Ct = threshold cycle 
Cycle numbers to reach a constant fluorescence niveau (beginning of 
exponential phase) 
- ∆Ct = Ct target gene – Ct reference gene 
Normalization of all observed genes or treatments 
- ∆∆Ct = ∆Ct treated target gene - ∆Ct target gene control sample 
Relationship of ∆Ct treated sample to ∆Ct control (untreated sample) =>  modification 
caused by treatment 
- Calculation of 2-∆∆Ct 
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Relative expression alteration of one sample compared treatment and control, 
normalized to reference relevant to standard sample calculates by arithmetic 
mean. 
 
2.2.8 Protein analysis 
To examine the consequences of treatments on particular proteins in a complex 
sample such as cell, proteins have to be isolated, quantified, separated by gel 
electrophoresis (SDS-page) and transferred to a membrane by western blotting 
(WB). Specific antibodies facilitate the detection of membrane bound proteins. 
 
2.2.8.1 Isolation of proteins from eukaryotic cells 
LIPG is synthetized intracellular with a size of 55kDa. Glycosylated LIPG (68kDa) is 
transported to cell membrane and will be secreted into the media. Afterwards, LIPG 
is cleaved into two fragments of 28kDa and 40kDa by pro-protein convertases. 
Therefore, whole cell protein extraction and preparation of extracellular proteins is 
necessary for a proper protein analysis. 
 
2.2.8.2 Isolation of extracellular proteins 
Collected cell media was incubated with 4M ammonium sulfate ((NH4)2SO4) on an 
orbital shaker for 24h at 4°C. Precipitated samples were centrifuged at 2.000xg for 
30min at 4°C, pellets suspended with RIPA lysis buffer and stored at -80°C.  
 
2.2.8.3 Isolation of membrane-bound LIPG protein 
Heparin are polysaccharides that interrupts heparin sulfate proteoglycans (HSPG) 
protein connections between LIPG protein and cell membrane. HSPGs are part of the 
extracellular matrix located on cell surface. As strongly glycosylated 
glycosaminoglycans, proteoglycans provide stability between two cells as well as the 
bridging of proteins to cell surface. Treatment of cells with 10U/mL heparin cleaves 
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membrane-bound LIPG into media. Cleaved LIPG was collected and handled as 
described for isolation of extracellular proteins (2.2.8.2). 
 
2.2.8.4 Isolation of intracellular whole cell lysate proteins 
Cells were grown to 70% confluence in 6-well plates using specific media. To isolate 
whole cell lysates each PBS-washed well was treated with 200µL RIPA lysis buffer 
for two minutes on ice. Cell suspension was collected in tubes by using cell scraper. 
For digestion, cell membrane suspensions were incubated for 20min on ice followed 
by centrifugation at 13.000xg for 15min at 4°C. Supernatant contained released 
proteins were transferred into fresh tubes. Protein lysates were stored at -80°C.  
 
2.2.8.5 Protein quantification BCA assay 
Bicinchoninic acid (BCA) assay (Thermo Scientific) enables quantification of isolated 
proteins (Smith et al. 1985). This bioanalytical assay is based on colorimetric 
detection of complexed Cu+ that is proportional to the proteinconcentration (Fig. 2.5). 
 
 
 
 
 
 
 
Fig. 2.5: Principle of BCA assay (F. Lottspeich and J.W. Engels) 
 
First step of the BCA assay is the so called Biuret reaction describing the reduction of 
Cu2+ ions to Cu+ in an alkaline environment. This BCA-copper complex is water-
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soluble and detectable with an absorbance at 562nm. The amount of total proteins in 
the samples is proportional to the amount of Cu+. 
Protein samples were defrosted on ice and diluted with water using 5µL sample and 
795µL water. Afterwards, 196µL reagent A (bicinchoninic acid, alkaline solution) plus 
4µL reagent B (4% cupric sulfate) was mixed and incubated at 60°C for 30min on a 
shaker. Subsequent, samples were incubated at room temperature for ten minutes. 
The measurement was performed in cuvettes placed in an UV/VIS 
spectrophotometer (V-530, Jasco). Total protein amount was determined at a 
wavelength of 562nm. The computer software ,spectra manager’ determines protein 
quantity by using a standard curve of serum albumin.  
 
2.2.8.6 SDS polyacrylamide gel electrophoresis and western blot 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) termed a 
commonly used technique for separation followed by detection of proteins using 
western blot. Applying electric current, the gel acts as a sieve that smaller proteins 
can migrate faster than larger proteins. Treatment with SDS (a negatively charged 
detergent) dissociates multimeric proteins and denatures all polypeptide chains. 
Proteins were linearized and their own charge covered by SDS (constant mass/ 
charge ratio). Based on this initial step electrophoretic separation only depends on 
the molecular weight of the proteins. 
 
2.2.8.7 Gel preparation 
Gels were prepared and poured using MiniPROTEAN Tetra electrophoresis system 
(BioRad) following the manufacturer’s instructions. For the LIPG protein with a 
maximal size of 68kDa a gel with 10% SDS was used. The top gel called stacking gel 
is slightly acidic (pH 6.8) with a low acrylamide amount to form a porous gel to collect 
the samples. The lower gel termed separation gel is more basic (pH 8.8) with a 
higher polyacrylamide content. This gel functions as a sieve to separate the proteins 
based on their molecular weight.  
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2.2.8.8 Gel electrophoresis 
SDS gel electrophoresis facilitates the separation of proteins in polyacrylamide gels 
with an applied electric current. For protein preparation 30µg for each protein were 
mixed with 5x loading buffer and heated up for five minutes at 95°C (denaturation of 
proteins). The loading buffer contains dithiothreitol (DTT) to reduce disulphide 
bridges in proteins. Furthermore, the buffer contains glycerin and bromophenol blue 
to increase the density of samples and to visualize samples, respectively. Each well 
was loaded either with one sample or with standards. The precision plus protein 
standard dual color (BioRad) standard and the MagicMark (Invitrogen) were used. 
The gels were placed in chambers. Chambers were filled with 1x running buffer and 
initially run at 25mA until the protein samples passed into the separation gel. 
Afterwards, current was increased to 50mA allowing the samples to run until the dye 
front reached bottom of gel.  
 
2.2.8.9 Western blotting 
Western blotting is a technique to transfer proteins from gel (e.g. SDS gel) on 
polyvinylidene difluorid (PVDF) membranes. Proteins were immobilized on the 
membrane by hydrophobic interactions and hydrogen bonds without impairing their 
immune reactive properties. Utilizing specific antibodies, proteins of interest can be 
detected and visualized on the membrane.  
Trans-blot semi-dry electrophoretic transfer apparatus (BioRad) transfers the 
separated proteins from SDS-PAGE gel to PVDF membrane. In total, 16 blotting 
papers (Whatman, VWR) and one PVDF membrane with the exact size of the SDS-
PAGE gel were used. The PVDF membrane was activated in methanol and 
equilibrated in anode buffer. In addition, twelve blotting papers were placed in anode 
buffer. The gel and four blotting papers were equilibrated in cathode buffer. After 
equilibration, all components were layered from anode to cathode as followed: twelve 
anode blotting papers, PVDF membrane, SDS-PAGE gel and the four cathode 
blotting papers. The transfer was performed for 40min at 315mA per gel (5mA/cm2). 
Afterwards membrane was washed for five minutes with distilled water.  
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2.2.8.10 Protein detection with specific antibodies 
Membranes were incubated with 5% (w/v) bovine serum albumin (BSA) in TBS-T for 
one hour at room temperature to avoid unspecific antibody binding. Membrane was 
exposed to primary antibodies, diluted in blocking buffer, and incubated over night at 
4°C on an orbital shaker. Unbound antibodies were removed by washing with TBS-T 
for 30min at room temperature.  Afterwards, membrane was incubated with 
secondary antibodies that were conjugated to horseradish peroxidase (HRP) and 
diluted in blocking buffer. After incubation for 60min at room temperature, washing 
procedure was repeated. To detect the protein of interest, membranes were 
incubated with Western lightning ECL solution (Perkin Elmer). This ECL chemistry is 
based on a chemiluminescence reaction in which the enzyme HRP catalyses the light 
emission from the oxidation of luminol at a wavelength of 428nm. Detection and 
visualisation was performed using Fusion Fx7 imager (Vilber Lourmat).  
 
2.2.9 Immunofluorescence  
Specific proteins or antigens in tissues or fixed cells can be visualized by 
immunofluorescence (IF) using fluorescent dyes or fluorescently-labeled antibodies. 
These fluorophors absorb light at a specific wavelength and emit light of lower 
energy. Antigen-antibody interactions, visualized by fluorescence detection can be 
examined using fluorescence or confocal microscopy (Fig. 2.6).  
IF methods are separated into two groups. For the direct IF, specific antibodies that 
are conjugated to a fluorophore (e. g. fluorescein or rhodamine) are used. For the 
indirect method, a primary antibody and a fluorophore-conjugated secondary 
antibody are necessary.  
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Fig. 2.6: Schematic illustration of direct vs. indirect immunofluorescence  
 
2.2.9.1 Indirect immunofluorescence staining for target proteins in this thesis 
MCF7 cells were cultured and treated on cover slips that were placed in 24-well 
plates. Cells were washed with 1x PBS and fixed with 4% paraformaldehyde (PFA) 
for 20min at room temperature. After three times of washing with 1x PBS, each for 
five minutes, cells were permeabilized for ten minutes with 0.3% Triton X-100 at room 
temperature and washed again. Unspecific antibody binding was avoided by 
incubation with 3% BSA in PBS for two hours at room temperature. Primary antibody 
was diluted in 0.3% BSA and incubated with MCF7 cells over night at 4°C. After 
washing with 1x PBS, cells were incubated with secondary antibody, diluted in 0.3% 
BSA in PBS, together with phalloidin-eosin (1:500 dilution) to visualize the actin-
cytoskeleton filaments. Cells were washed after incubation for two hours at room 
temperature and subsequently incubated with DAPI (1:20.000 dilution in water; 
4’,6-Diamidin-2-phenylindol) for 5 min at room temperature to stain nuclei. In addition, 
Bodipy 493/503 (50µg/mL; life technologies) was used to visualize lipid droplets. 
After washing with 1xPBS, cover slips were transferred from wells onto glass slips 
mounted and fixed with a drop of FluorPreserve reagent (Calbiochem). The slides 
were dried over night at room temperature and stored at 4°C in the dark until 
confocal microscopic analysis (LSM, light scattered microscope; FluoView TM 
FV1000; Olympus). 
 
 
 
  Material and Methods 
 
 
50 
 
2.2.10 Resolving and complexation of oleic acid (OA) on bovine serum albumin 
MCF7 cells were incubated with OA/BSA to observe a maximum of lipid 
accumulation and resulting effects of increased intracellular fat content. Therefore 
oleic acid (OA) had to be dissolved and complexed on bovine serum albumin (BSA). 
Firstly 3.71g fatty acid-free BSA (FAF-BSA; sigma Aldrich) had to be solved in 
22.5mL dH2O. Oleic acid (sigma Aldrich) was solved in 2.6mL 0.01M NaOH solution 
under stirring for 30min at 75°C in the dark. After OA cooled down, it was mixed with 
three drops 1M NaOH. Complexation of 2.6mL 60mM OA on 10.4mL 2.5mM FAF-
BSA was performed under stirring conditions for one hour at room temperature in the 
dark. OA was completely solved when ,,fat drops’’ were under detection limit. 
Suspensions were sterile filtrated with 0.45µm filter and stored at -20°C. 
 
2.2.10.1 Resolving oleic acid (OA) in DMSO 
To avoid involuntary side effects of bovine serum albumin, cells were incubated with 
OA dissolved in DMSO. Therefore a stock solution of 750mM OA in DMSO was 
prepared and diluted with serum-starved media to a final concentration of 710µM.  
 
2.2.11 Proliferation assay 
Increased fat content is well known as an advantage under starvation conditions. To 
study survival advantages, MCF7 cells were treated with OA/BSA and starved over a 
time of period. Read out was counting the number of living cells.  
50.000 MCF7 cells were seeded onto 24-well plates to let them attach for 24h. After 
washing once with 1x PBS, cells were incubated with 200µg, 400µg and 800µg 
OA/BSA for 48h in serum-free media. As control, cells were cultured in complete full 
media. All cells were washed once with 1x PBS and cultured in starvation media 
without any substrates (w/o serum, w/o glucose, w/o sodium pyruvate, w/o 100x mem 
NEAA and w/o insulin) except a part of control cells that were maintained in complete 
full media. Number of living cells were counted at different time points (0h 
corresponds to time point of media change after 48h incubation with OA/BSA and 
then after 48h, 5d, 7d and 10d). 
  Material and Methods 
 
 
51 
 
2.2.11.1 Cell viability assay 
To analyze survival advantage of LIPG-overexpressing cells, fed with PC-OA, the cell 
viability was measured by CellTiter-Blue® cell viability assay (Promega). Therefore, 
glucose- and serum-starved MCF7 cells were analyzed. MCF7 cells (50.000 
cells/well) were seeded onto 24-well plates and incubated for 24h. Cells were 
transiently transfected with LIPG-DNA for 48h followed by PC-OA incubation in 
serum-starved media for 48h. Cells were washed once with 1x PBS and cultured in 
starvation media without any substrates (w/o serum, w/o glucose, w/o sodium 
pyruvate, w/o 100x mem NEAA, w/o insulin). The number of viable cells was 
estimated using the indicator resazurin to determine metabolic capacity of cells. 
Living cells reduce resazurin (blue and non-fluorescent) to resorufin (pink and highly 
fluorescent) by different enzymes. Resaruzin is able to penetrate cells whereas 
fluorescent resorufin dye is able to diffuse out of cells into supernatant. Each cell-
containing well was incubated over four hours in 100µL media with serum plus 20µL 
resazurin solution in the dark. Fluorescence signal was determined by excitation 
540nm and emission 590nm within a plate reader (Tecan infinite 200Pro) and is 
proportional to the number of viable cells. 
 
2.2.12 Isolation of triglycerides from eukaryotic cells 
LIPG enables fatty acid uptake based on its phospholipase A1 and triglyceride lipase 
activity. Addition of HDL or PC-OA to LIPG-overexpressing or OA/BSA to untreated 
MCF cells resulted in intracellular lipid accumulation. Cellular fatty acid uptake leads 
to formation of triacylglycerides (TAG) stored in lipid droplets. These accumulated 
TAGs can be isolated and quantified (2.2.12.1). HDL-treated cells were incubated 
with 10U/mL heparin for 30min to cleave membrane-bound lipoproteins which were 
not internalized. After washing with 1x PBS, cells were mixed with 200µL 5% NP-40 
in water and heated three times up to 90°C to segregate cytoplasmic membrane. 
Whole insoluble material was removed by centrifugation at 4.000xg for two minutes 
at room temperature. The supernatant-containing mono-, di- & triacylglycerides were 
transferred to fresh tubes and mixed with 20µL DEPC water. Samples were stored at 
-20°C.  
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2.2.12.1 Quantification of triacylglycerides (TAG) 
LIPG-overexpressing cells incorporating fatty acids that were accumulated into TAGs 
and stored in lipid droplets. The Triglyceride Quantification Kit (abcam) enables the 
quantification of TAGs based on enzymatic cleavage of TAGs into their components 
glycerol and free fatty acids (FFA) (Fig. 2.7). Released glycerol will be oxidized and 
reacts with fluorescence labeled probe.  
 
 
 
 
Fig. 2.7: Principle of the Triglyceride Quantification Kit (abcam). The enzyme lipase (Li) cleaves 
TAGs into the components glycerol and free fatty acid. Oxidized glycerol will react with the 
fluorescence labeled probe. Asteriks indicate fluorescence with excitation at 535nm and emission at 
587nm 
 
Black 96-well plates with clear bottom were used to avoid fluorescence spreading 
while measurement. The total protein concentration of isolated TAG samples was 
quantified by BCA assay (2.2.8.5) to apply a defined protein amount. 50µg sample 
adjusted to 50µL with assay buffer was incubated for 20min at room temperature with 
or without 2µL lipase enzyme. Each well was filled up with 50µL TAG reaction mix 
and incubated for one hour at room temperature in the dark. 
Intracellular TAG amount was detected by fluorescence measurement with excitation 
at 535nm and emission at 587nm within a plate reader (Tecan SpectraFluor Plus). To 
correct the influence of background fluorescence, assay buffer plus reaction mix with 
or without lipase enzyme were simultaneously measured.  
Quantification of TAG amount included following calculation steps: 
- sample + lipase = total glycerol; sample alone = glycerol background 
- RFUsample - RFUbackground = RFU only from samples 
- RFUsample + lipase – RFUsample alone => glycerol from TAG (TAG amount) 
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2.2.12.2 Detection of lipid droplets 
Lipid droplets were visualized by staining with oil red O (sigma Aldrich). LIPG-
overexpressing MCF7 cells were treated with HDL or PC-OA or OA/BSA to untreated 
MCF cells. Oil red O powder was solved in 2-propanol and diluted with water (3:2). 
Solution was incubated for 30min at room temperature and sterile filtrated before use. 
After washing with 1x PBS, cells were incubated with oil red O solution for one hour 
at room temperature. Stained cells were washed with 1x PBS and analyzed using 
optical microscopy.  
 
2.2.13 Working with immune cells 
Natural killer cells (NK cells) belong to the group of lymphocytes but are part of the 
innate immunity. NK cells were isolated from whole blood samples coming from 
voluntary healthy donors. 
 
2.2.13.1 Isolation of NK cells from whole blood samples 
Isolation of NK cells from whole blood samples begins with extraction of peripheral 
blood mono-nucleated cells (PBMC). Therefore, 15mL lymphocyte separation 
medium (LSM/Ficoll, density gradient d= 1,077g/mL; Lonza) per tube were carefully 
overlayed with 30mL heparinized (100U/mL) whole blood. Gradient centrifugation at 
2.200rpm for 25min at room temperature (without using brake) separates 
components of whole blood (Fig. 2.9). PBMCs (lymphocytes and monocytes) were 
concentrated in interphase (white layer) between plasma and Ficoll. Plasma was 
aspirated and PBMC-containing white layer was transferred into a fresh tube. PBMC 
suspension was washed two times with 1x PBS and centrifugation at 1.500rpm for 
five minutes at room temperature.  
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Fig. 2.9: Isolation of PBMCs by gradient centrifugation 
 
After centrifugation, supernatant was removed and pellet was suspended in Dynal 
buffer (1x PBS + 0.1% BSA) to a concentration of 1x108 cells/mL. NK cells were 
isolated following manufactures instructions of Dynabeads® Untouched™ Human NK 
Cells protocol (life technologies). Suspended PBMCs (1mL) were mixed with 200µL 
heat inactivated fetal bovine serum (hi-FBS) plus 200µL antibody mix and incubated 
for 20min at 4°C. Antibody mix contained biotinylated mouse IgG antibodies for CD3, 
CD14, CD36, CDw123, HLA class II DR/DP and CD235a (Glycophorin A) to deplete 
contaminating cells as T-cells, B-cells, monocytes, dendritic cells, platelets, 
macrophages, granulocytes and erythrocytes. Cells were washed by adding 4mL 
isolation buffer and centrifuged at 350xg for eight minutes at 4°C. Cell pellet was 
suspended in 1mL Dynal buffer and 1mL of pre-washed Dynabeads (uniform, super 
paramagnetic, polystyrene beads coated with streptavidin) was added. After 
incubation for 15min at 18°C, cells were suspended in 4mL isolation buffer by 
pipetting (avoided foaming) and placed in magnet for two minutes (this step was 
repeated two times). The supernatant contained unbound human NK cells and was 
transferred into a fresh tube. To remove remaining supernatant, cells were 
centrifuged at 300xg for ten minutes at room temperature. Supernatant was 
discarded and cells were suspended with standard media (1x106 cells/mL in IMDM 
media; Gibco). To ensure maximal activity of freshly isolated NK cells, cells were 
stimulated with so called feeder cells (K562mb15-41BBL; 10x 106 NK cells + 5x 106 
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feeder cells) and 200U/mL interleukin-2 (IL-2; cytokine stimulated proliferation, 
differentiation and activation of lymphocytes) for two weeks at 37°C. 
 
 
2.2.13.2 51Cr-release assay (killing assay) 
Using the 51Cr-release assay the cytotoxic activity of NK cells or the resistance of 
target cells of NK cell attacks can be quantified. Treated target cells were incubated 
with radioactive labeled chromium (51Cr) and co-cultured with NK cells. Killer cells 
damaging target cells and released chromium amount gives a value for killing 
resistance. 
200.000 K-562 (leukemia) suspension cells were incubated over 48h with OA/BSA or 
BSA alone to internalize fatty acids and accumulate lipids to form lipid droplets. After 
washing with 1x PBS cells were trypsinated and counted. 5.000 target cells per 
sample were labeled with 100µCi 51Cr (Na251CrO4) for one hour at 37°C under soft 
rotation. Before co-culturing with titrated dilution of NK cell (1:50, 1:25, 1:12.5, 1:6.25) 
amount target cells were washed two times with standard media. Co-culturing step 
took four hours at 37°C (Fig. 2.10). 
 
Fig. 2.10: Schematic illustration of killing assay (51Cr-release assay). K-562 target cells were 
labeled with 51Cr for one hour at 37°C. After washing target cells were co-cultured with NK effector 
cells for four hours at 37°C. NK cells bind and damage target cell membrane which results in 51Cr-
release into media supernatant. 
 
Carried along controls were first labeled K-562 cells alone as negative control 
(spontaneous Cr-release set to 0%) and labeled K-562 cells incubated with 100µL 
2% Triton X-100 as positive control (maximal Cr-release set to 100%). While co-
culturing effector cells (NK) bind and lyse target cells (K-562) hence 51Chromium 
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were released into media supernatant. The complete supernatant were sponged up 
by absorbent cotton and measured by liquid scintillation (gamma counter). Results of 
the killing assay were specific lysis in [%] calculated software-based directly after 
measurement by integrating the spontaneous as well as maximal 51Cr-relase control 
value.  
 
Calculation of specific lysis [%]: 
51Cr-release of target (co-cultured cells) – 51Cr-release of negative control 
Maximum 51Cr-release – 51Cr-release of negative control 
 
 
2.2.14 Statistical methods 
If not mentioned separately were all experiments done with three independent 
biological samples. For statistical comparison of control cell situations against treated 
cells the unpaired T-test was applied. P-values with p<0.05 were accepted as 
significant. All mentioned numeric numbers were mean values and standard error of 
measurement (SEM).  
 
2.2.14.1 Affymetrix gene array data of breast cancer patients 
This study includes four cohorts (Mainz, Rotterdam, Transbig and Yu) which offered 
breast cancer patient data. Application of the Cox model enables the calculation of 
associations between LIPG RNA expression (log2 transformated) and prognosis 
(outcome). The univariate Cox-analysis was applied to evaluate the association 
between LIPG mRNA expression and metastasis-free survival (hazard ratio >1 poor 
prognosis, hazard ratio <1 better prognosis). Metastasis-free survival describes the 
time between diagnosis and appearance of metastasis or patient death. The 
multivariate Cox-analysis was applied to assess the prognostic power of LIPG mRNA 
expression independent of established clinical parameters. To visualize survival 
differences in Kaplan-Meier plots, mRNA expression levels were dichotomized and 
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survival rates were compared with log-rank tests. Cut-off points show the calculated 
limits between low and high LIPG expression. Spearman-correlation test were 
applied to calculate correlations of genes in the different patient subgroups. P-values 
were calculated. The software SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used 
for all analysis. 
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3. Results        
 
3.1 Induced oncogene ErbB2/HER2- (NeuT) overexpression results in 
premature senescence in MCF7/NeuT breast cancer cell 
The receptor tyrosine kinase HER2/ErbB2 plays a central role in breast cancer 
development as well as in other epithelial tumors. HER2-transformation potential is 
based on the transduction of mitogenic and anti-apoptotic signals (Trost et al. 2005). 
The MCF7/NeuT breast cancer cell line, which allows tetracycline-inducible 
expression of an oncogenic variant of Erbb2 (NeuT) in MCF7 cells, was previously 
generated by Trost et al. (2005) in order to study ErbB2-induced tumorigenesis. 
Furthermore, it was characterized by Spangenberg et al. 2006 and Cadenas et al. 
2010.  
Initially surprisingly, instead of enhanced proliferation, overexpression of the 
oncogenic variant of HER2 (NeuT) in MCF7 cells was shown to lead to premature 
senescence. This senescence-associated cell cycle arrest was accompanied by 
morphological alterations and upregulation of p21- (WAF1/ CIP1) expression. In this 
work MCF7/NeuT cells were used to investigate oncogene-induced senescence- 
(OIS) mediated changes in lipid metabolism.  
 
3.1.1 Oncogene HER2- (NeuT) triggered premature senescence is characterized 
by morphological alterations and induction of p21 (WAF1/CIP1) 
The MCF7/NeuT cell line carries a Tet-On-inducible expression of NeuT, an 
oncogenic variant of ErbB2. Addition of the tetracycline derivate doxycycline (dox) 
induces simultaneous overexpression of NeuT- and eGFP via a bidirectional 
promoter. EGFP, as a reporter, enables an indirect control of the efficiency of 
induction (number of green positive cells) by fluorescence microscopy.  
For verification of NeuT expression MCF7/NeuT cells were cultured with or without 
dox for the indicated time periods and RNA as well as protein were isolated. Dox- 
treated MCF7/NeuT cells showed already after six hours increased NeuT mRNA 
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expression which enhanced further in later time points on RNA as well as on protein 
level (Fig. 3.1).  
 
Fig. 3.1: Treatment of MCF7/NeuT cells with doxycycline (dox) triggers ErbB2/NeuT expression. 
MCF7/NeuT cells were incubated during a 14 days period in presence or absence of dox and NeuT 
expression was analyzed in a time-dependent manner. (A) ErbB2/NeuT mRNA was analyzed by 
quantitative real time PCR; as endogenous control TBP (TATA-box binding protein) was used. The 
results represent mean ± SEM (n=3) (B) Immunoblotting of ErbB2/NeuT protein expression in whole 
cell lysates; α-tubulin used as loading control. A representative immunoblotting is shown (n=4) 
 
NeuT overexpression causes premature senescence accompanied by phenotypical 
changes like enlarged and flattened morphology and accumulation of vacuole 
structures within cytoplasm that became obvious 7d after induction of NeuT (Fig. 
3.2). 
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Fig. 3.2: NeuT-mediated senescence is accompanied by morphological changes of MCF7/NeuT 
cells. Doxycyclin-treated cells showed after three days an enlarged but flattened cell shape 
accompanied by a strong cytoplasmic vacuolization. Green fluorescence represents eGFP co-
expression; scale bar 100µm; representative images are shown 
 
For confirmation of the oncogene-driven cell growth arrest expression of the cyclin- 
dependent kinase inhibitor (CDKI) p21 (WAF1/ CIP1), an important mediator of cell 
cycle arrest and premature senescence in breast cancer cells (Okada et al. 2004, 
Sewing et al. 1997), was analyzed by real time qRT-PCR.  
For this purpose MCF7/NeuT cells were cultivated in presence or absence of dox and 
RNA was collected at different time points. P21 expression on RNA level increased 
after dox treatment (Fig. 3.3), therefore confirming previous results (Trost et al., 
2005). 
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Fig. 3.3: Increased p21- (WAF1/ CIP1) expression in senescent MCF7/NeuT cells. MCF7/NeuT 
cells incubated during a 14 days period in presence or absence of doxycycline showed enhanced p21 
(CIP1/ WAF1) mRNA expression as analyzed by quantitative real time PCR; as endogenous control 
UBC (ubiquitin C protein) was used. The results represent mean ± SEM (n=3) 
 
 
3.1.2 ErbB2/NeuT overexpression induces expression changes of genes 
involved in lipid metabolism  
Gene expression alterations triggered by NeuT overexpression in MCF7/NeuT cells 
were analyzed by Affymetrix gene arrays in a time-dependent manner. A number of 
genes involved in several processes of lipid metabolism showed considerable 
alterations in gene expression. Key enzymes were selected for validation by qRT- 
PCR. Selected lipid metabolism associated enzymes whose expression pattern in 
MCF7/NeuT cells was confirmed by qRT-PCR are shown in Figure 3.4. 
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Fig. 3.4: Dox-exposed MCF7/NeuT cells show altered expression of a number of genes involved 
in lipid metabolism. MCF7/NeuT cells were incubated during a 14 days period in presence or 
absence of doxycycline; (A) Affymetrix gene array results of seven selected key enzymes of lipid 
metabolism (B) Confirmation of gene array by qRT-PCR; as endogenous control UBC (ubiquitin C 
protein) was used. The results represent mean ± SD (n=3) 
 
Acyl-CoA synthase long chain 3 (ACSL3) is important for the activation as well as 
degradation of long-chain fatty acids and phospholipid remodeling (Soupene and 
Kuypers 2008). This gene shows an up-regulation of 2.22 ± 0.18 on mRNA level 
seven days after dox exposure. 
Choline phosphotransferase 1 (CHPT1) catalyzes the last step in the de novo 
synthesis of phosphatidylcholine (PC; Kennedy pathway) by transferring 
phosphocholine from CDP-choline to diacylglycerol and releasing CMP (Henneberry 
et al. 2000). This gene shows a down-regulation of 0.35 ± 0.02 on mRNA level seven 
days after dox exposure. 
Phospholipase D1 (PLD1) hydrolyses PC to generate phosphatidic acid (PA) and 
choline (Gomez-Cambronero 2010). This lipase is involved in cell migration, cell 
signaling, intracellular protein trafficking, membrane remodeling and cell proliferation. 
PLD1 shows an up-regulation of 14.17 ± 0.32 on mRNA level seven days after dox 
treatment.  
Monoacylglycerol lipase (MAGL or MGLL) releases free fatty acids from 
monoacylglycerol and generates precursors of pro-tumorigenic signaling molecules 
which facilitate cell migration, survival, and cancer cell growth (Nomura et al. 2010). 
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MGLL level is increased in aggressive cancer cells. This lipase displayed an up- 
regulation of 4.43 ± 0.14 on mRNA level after seven days of dox incubation.  
The low-density lipoprotein receptor (LDLR) enables the uptake of cholesterol- 
carrying lipoproteins by endocytosis (Jeon & Blacklow 2005). This gene shows an up- 
regulation of 3.67 ± 0.35 on mRNA level seven days after dox exposure. 
Niemann-Pick C1 (NPC1) plays a role in intracellular cholesterol trafficking and 
regulation of cholesterol homeostasis (Ory 2004). NPC1 reveals an up-regulation of 
2.91 ± 0.22 on mRNA level seven days after dox exposure. 
Lipoprotein lipase G (LIPG) shows phospholipase activity A1 and a low triglyceride 
lipase activity (Gauster et al. 2005). It binds high density lipoproteins 
phosphatidylcholine (HDL-PC) as main substrate and cleaves it into lyso- 
phosphatidylcholine (LPC) and fatty acids. These released fatty acids can be taken 
up in an autocrine way. LIPG shows an up-regulation of 18.56 ± 0.55 on mRNA level 
seven days after dox exposure. 
Altogether, these expression changes show that a remodeling of lipid metabolism 
takes place in oncogene-induced senescence in MCF7/NeuT cells. On one hand two 
proteins involved in uptake of extracellular lipids - LDLR and LIPG - and enzymes 
known to be involved in phospholipid remodeling - ACSL3 and PLD1 - are 
upregulated. On the other hand enzymes involved in de novo synthesis of 
phospholipids, such as CHPT1, is downregulated. This indicates that MCF7/NeuT 
cells may depend on exogenous lipid supply rather than on endogenous lipid 
synthesis. 
 
3.1.3 NeuT-induced senescence is accompanied by increased LIPG expression 
LIPG was among the genes displaying most prominent mRNA expression alterations. 
LIPG mRNA became immediately induced upon NeuT overexpression and further 
increased as cells entered the senescence state. This gene attracted our attention 
because there was no published connection between ErbB2 and LIPG. Interestingly 
no other member of the triglyceride lipase gene family, such as lipoprotein lipase 
(LPL; LIPD) and hepatic lipase (HL; LIPC) were shown to be significantly up- or 
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down-regulated upon NeuT induction in MCF7/NeuT cells (gene array data, data not 
shown). Therefore, LIPG induction by NeuT seemed to be unique among the 
members of the TAG lipase family members. Analysis of LIPG protein levels in 
MCF7/NeuT cells treated with dox in a timely manner confirmed mRNA data. A band 
of 55kDa corresponding to the full length intracellular LIPG protein could be detected 
by immunoblotting already after three days of dox incubation (Fig. 3.5). 
 
Fig. 3.5: NeuT overexpression in dox-treated MCF7/NeuT cells leads to increased LIPG 
expression. (A) MCF7/NeuT cells were incubated during a 14 days period in presence or absence of 
doxycycline; LIPG expression in RNA extracts analyzed by quantitative real time PCR (LIPG; 
Hs00195812) was increased already after six hours of dox exposure; as endogenous control UBC 
(ubiquitin C protein) was used. The results represent mean ± SEM (n=3) (B) Immunoblotting of LIPG 
protein expression in MCF7/NeuT cells treated or untreated with doxycycline showed increased levels 
of LIPG immunoreactivity (55kDa size) after three days of dox exposure in whole cell protein lysates; 
β-actin used as loading control. A representative immunoblotting is shown (n=2) 
 
Previous results showing induction of LIPG in MCF7/NeuT cells by real time qRT-
PCR (TaqMan primers Hs00195812, spanning exons 8-9) were confirmed by using 
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the additional TaqMan primers Hs00969502 (exons 1-2) and Hs00969505 (exons 4- 
5). The human LIPG locus 18q21.1 contains eleven exons (Ishida et al. 2004).  
All three used primers displayed the same early LIPG gene expression after six hours 
and progressively increased expression at longer times of dox exposure in 
MCF7/NeuT cells (Fig. 3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6: NeuT overexpression in dox-treated MCF7/NeuT cells leads to increased LIPG 
expression. Confirmation of LIPG mRNA induction by real time qRT-PCR with different primers. 
(A) MCF7/NeuT cells were incubated during a 14 days period in presence or absence of doxycycline; 
LIPG expression in RNA extracts was analyzed by quantitative real time PCR using primer (A) 
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Hs00969502 (Exon 1-2) and (B) Hs00969505 (Exon 4-5); as endogenous control UBC (ubiquitin C 
protein) was used. The results represent mean ± SEM (n=2) 
 
To ensure that LIPG expression was specifically induced by NeuT overexpression 
and not by addition of doxycycline we analyzed LIPG on dox-treated MCF7/eGFP 
control cells. MCF7/eGFP cells lack NeuT and therefore only eGFP responds to the 
Tet-On system. As shown in Figure 3.7, no induction of LIPG expression was 
observed in this control cell line. These results indicate a correlation between NeuT- 
overexpression and LIPG expression and exclude the possibility that LIPG becomes 
activated by doxycycline. 
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Fig. 3.7: No induction of LIPG expression in MCF7/eGFP-control cells upon dox treatment. 
MCF7/eGFP cells were incubated during a 14 days period in presence or absence of doxycycline; 
LIPG expression in RNA extracts was analyzed by quantitative real time PCR; as endogenous control 
UBC (ubiquitin C protein) was used. The results represent mean ± SEM (n=2)  
 
3.1.4 Senescent MCF7/NeuT cells display an increased mRNA expression of the 
lipid droplet-coating protein Perilipin 2 (PLIN2) together with elevated cellular 
triacylglyceride levels  
LIPG has been reported to display phospholipase A1 activity and to cleave 
phosphatidylcholine from HDL as main substrate (Gauster et al. 2005). Released 
fatty acids can directly be taken up by cells, and become stored in form of 
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triacylglycerides (TAG) within lipid droplets. To investigate whether induction of LIPG 
in MCF7/NeuT cells is paralleled by lipid droplet accumulation we analyzed both 
expression of lipid droplets-associated proteins and the level of triacylglycerides. 
Among the members of the perilipin family only PLIN2 was shown to be upregulated 
by NeuT overexpression in the Affymetrix gene array data. Therefore, we measured 
PLIN2 mRNA by real time qRT-PCR. The PLIN2 protein coats intracellular lipid 
droplets and is a marker of lipid accumulation. Figure 3.9 illustrates an increase of 
PLIN2 expression in MCF7/NeuT cells upon NeuT overexpression concomitant with 
LIPG upregulation. 
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Fig. 3.8: Overexpression of NeuT in dox-treated MCF7/NeuT cells increases Perilipin2 (PLIN2) 
expression. MCF7/NeuT cells were incubated during a 14 days period in presence or absence of 
doxycycline; PLIN2 expression in RNA extracts was analyzed by quantitative real time PCR; as 
endogenous control UBC (ubiquitin C protein) was used. The results represent mean ± SEM (n=3) 
 
Quantification of triacylglycerol (TAG) was performed to confirm lipid accumulation as 
suggested by the measured PLIN2 expression levels in senescent cells. MCF7/NeuT 
cells were treated for six days with doxycycline and after lipid extraction the 
intracellular TAG content was quantified. Senescent MCF7/NeuT cells exhibited a 
four-fold increase of TAG compared to untreated control cells (Fig. 3.9). 
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Fig. 3.9: Senescent MCF/NeuT cells show increased amounts of intracellular triglycerides 
(TAG). After six days of dox exposure senescent cells revealed a four-fold increased triacylglycerol 
amount compared to untreated cells. Quantification of triacylglycerols was performed with the 
Triglyceride Quantification Kit (ab65336) from abcam. The results represent mean ± SEM (n=2)  
 
3.1.5 Elevated oxidative stress in senescent cells does not lead to increased 
LCN2 gene expression 
Lipocalin2 (LCN2) displays a variety of functions. It can transport hydrophobic 
molecules (Grzyb et al. 2006), promote remodeling of intracellular phospholipids 
(Yang et al. 2012), regulate lipid droplet formation in liver (Asimakopoulou et al. 
2014) and is a well-known marker of inflammation (Jha et al.2014). Moreover, 
oxidative stress has been shown to increase Lipocalin2 (LCN2) levels in H2O2- 
treated HepG2 cells (Roudkenat et al. 2007). Klaunig and Kemanedulis (2004) 
described that oncogene overexpression can lead to production of reactive oxygen 
species (ROS). Quantification of ROS by a TBARS (Thiobarbituric acid reactive 
substances) assay together with upregulation of enzymes that are known to combate 
ROS, such as TXNRD1 (Cadenas et al. 2010), showed increased oxidative stress in 
senescent MCF7/NeuT cells induced by ErbB2/NeuT expression. Therefore, the 
LCN2 RNA level in dox-exposed MCF7/NeuT cells was studied. As shown in Figure 
3.10, no LCN2 expression alteration was observed at any time point. 
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Fig. 3.10: NeuT overexpression in dox treated MCF7/NeuT cells does not result in changes in 
Lipocalin2 (LCN2) expression. MCF7/NeuT cells were incubated for 14 days in presence or absence 
of doxycycline; LCN2 expression in RNA extracts was analyzed by quantitative real time PCR; as 
endogenous control UBC (ubiquitin C protein) was used. The results represent mean ± SEM (n=2) 
 
3.1.6 NeuT oncogene-induced activation of signaling pathways mediating LIPG 
induction 
After onset of NeuT expression in MCF7/NeuT cells several signaling pathways 
become activated, including the AKT/PI3K-, p38-, MEK1/2- and SAPK/JNK- 
pathways (Trost et al. 2005, Cadenas et al. 2010) that may lead to changes in gene 
expression patterns. To study the influence of these pathways on LIPG expression 
different inhibitors LY294002 (targeting PI3K), SB203538 (p38 MAPK inhibitor), 
PD98059 (inhibitor of MEK1/2) and SP600125 (JNK inhibitor) (Fig 3.11) were used. 
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Fig. 3.11: Summary of most important ErbB2-mediated signaling pathways. The aim of the study 
was to investigate the influence of different inhibitors on LIPG transcription  
 
 
Up-regulation of LIPG mRNA upon NeuT oncogene overexpression was reduced by 
the small molecule inhibitors of p38 MAPK (SB203538) (Fig. 3.13) and AKT/PI3K 
(LY294002) (Fig. 3.12) but not by the PD98059 (Fig. 3.14) nor SP600125 inhibitors 
(Fig. 3.15). 
Already after 24h of dox exposure MCF7/NeuT cells displayed increased LIPG 
expression on RNA level. Blocking the PI3K/AKT-pathway by the LY294002-inhibitor 
reduced LIPG gene expression at all investigated time points and more than 14-fold 
in senescent cells after seven days (Fig. 3.12). 
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Fig. 3.12: Blocking the AKT/PI3K-pathway by adding the LY294002  inhibitor to MCF7/NeuT 
cells ± doxycycline affects the induction of LIPG expression. MCF7/NeuT cells were incubated 
with or without doxycycline in the presence or absence of AKT/ PI3K-pathway inhibitor LY294002 
(20µM) up to seven days; LIPG expression in RNA extracts analyzed by quantitative real time PCR; as 
endogenous control UBC (ubiquitin C protein) was used. The numbers represent mean ± SEM (n=3) 
 
Similarly, addition of p38-pathway inhibitor SB203538 dampened upregulation of 
LIPG by NeuT at all studied time points (Fig. 3.13). 
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Fig. 3.13: Blocking the p38-pathway by adding SB203538 inhibitor to MCF7/NeuT cells treated 
with doxycycline prevents the induction of LIPG expression. MCF7/NeuT cells were incubated 
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with or without doxycycline in the presence or absence of the p38-pathway inhibitor SB203538 (25µM) 
up to seven days; LIPG expression in RNA extracts analyzed by quantitative real time PCR; as 
endogenous control UBC (ubiquitin C protein) was used. The bars represent mean ± SEM (n=3) 
 
MEK1/2-inhibitor PD98059 showed no influence on LIPG gene expression after 24h 
and only a very slight effect after three days incubation of senescent MCF7/NeuT 
cells. Solely at the time point seven days there was a remarkable reduction of LIPG 
expression by two-fold (Fig. 3.14). 
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Fig. 3.14: Blocking the MEK1/2-pathway by adding PD98059 inhibitor to MCF7/NeuT cells 
treated with doxycycline slightly affects the induction of LIPG expression. MCF7/NeuT cells 
were incubated with or without doxycycline in the presence or absence of the MEK1/2-pathway 
inhibitor PD98059 (25µM) up to seven days; LIPG expression in RNA extracts analyzed by 
quantitative real time PCR; as endogenous control UBC (ubiquitin C protein) was used. The bars 
represent mean ± SEM (n=3) 
 
Similar results were obtained when the SAPK/JNK-pathway inhibitor SP600125 was 
applied. LIPG expression in MCF7/NeuT cells treated with dox was not altered by 
blocking SAPK/JNK at the 24h and three day time points, and only slightly reduced at 
day seven (1.6-fold decreased LIPG level) (Fig. 3.15). 
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Fig. 3.15: Blocking SAPK/JNK-pathway by adding SP600125 inhibitor to MCF7/NeuT cells ± 
doxycycline only slightly affects the induction of LIPG expression. MCF7/NeuT cells were 
incubated with or without doxycycline in presence or absence of the SAPK/JNK-pathway inhibitor 
SP600125 (25µM) up to seven days; LIPG expression in RNA extracts analyzed by quantitative real 
time PCR; as endogenous control UBC (ubiquitin C protein) was used. The results represent mean ± 
SEM (n=3) 
 
In summary, these results showed that p38 MAPK and AKT/PI3K but not MEK1/2- 
and JNK are underlying signaling pathways involved in NeuT-triggered stimulation of 
LIPG expression. 
 
3.1.7 LIPG gene expression in additional HER2-overexpressing MCF7 cells 
NeuT is an oncogenic variant of ErbB2 that contains a valine to glutamine amino acid 
exchange in the transmembrane domain at position 664 (Schechter et al. 1984, 
Bargmann et al. 1986). This mutation has been shown to constitutively stimulate 
NeuT tyrosine kinase activity (Weiner et al. 1989). LIPG induction by wildtype HER2 
(ErbB2) or mutated isoforms has not been reported in other studies. Therefore, we 
investigated whether LIPG expression is also elevated in MCF7 breast cancer cells 
stably transfected with the HER2 oncogene. In addition to wildtype HER2, we 
examined a different HER2 mutant containing an YVMA insertion at codon 776 
(YVMA: insertion of four amino acids; Y=tyrosine, V=valine, M=methionine and 
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A=alanine). This YVMA insertion results in a higher constitutive auto-phosphorylation 
of HER2 resulting in enhanced tyrosine kinase activity (Greulich et al. 2012, Wang et 
al. 2006). Real time qRT-PCR analysis was performed to investigate LIPG 
expression in the MCF7/HER2wt and in the MCF7/HER2-YVMA cells. However no 
significant higher levels of LIPG mRNA could be observed in these two cell lines 
compared to the parental MCF7 cells (not shown). This shows that HER2 
overexpression is not necessary associated with upregulation of LIPG. 
 
 
3.2 LIPG overexpression in MCF7 breast cancer cells 
In order to investigate whether LIPG influences the lipid content in breast cancer cells 
we first overexpressed LIPG in MCF7 cells. The transfection was done with a non- 
liposomal reagent (Roche). Figure 3.16a illustrates the dramatic increase in the 
mRNA expression level of LIPG in transfected cells, with 15.000-fold increase 
compared to empty vector control cells. Representative bright field and confocal 
microscopic images of full media (FM, untreated), empty vector (EV, control) and 
LIPG-overexpressing cells (LIPG-OE) were shown in Figure 3.16b/c. No phenotypical 
changes were recognizable between control and LIPG-OE cells. 
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Fig. 3.16: LIPG overexpression (OE) in MCF7 cells. (A) LIPG mRNA levels are increased 48 hours 
after transfection with 1500ng of a FLAG-tagged LIPG-OE vector with the X-tremeGENE HP DNA 
transfection reagent (Roche); LIPG expression in RNA extracts was analyzed by quantitative real time 
PCR; as endogenous control UBC (ubiquitin C protein) was used. The bars represent mean ± SEM 
(n=3) (B) Representative bright field microscopic images of full media (FM, untreated), EV (empty 
vector control) and LIPG-OE (overexpressing) cells; scale bar 100µm; (C) Confocal microscopic 
images of fixed MCF7 cells labelled with fluorescent LIPG (anti-FLAG, red), nuclei (DAPI, blue) and 
lipid droplets (Bodipy 493/503; green); scale bar 20µm, representative images are shown 
 
To control the efficiency of LIPG overexpression on protein level also immunoblotting 
was done. The protein LIPG is intracellularly synthetized with a size of 55kDa. After 
glycosylation and transport to the cell membrane it acquires a size of 68kDa. 
Furthermore, LIPG becomes secreted into the media and becomes cleaved and thus 
inactivated by pro-protein convertases into the fragments of 40kDa and 28kDa.  
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To demonstrate proper localization of the overexpressed LIPG, whole cell protein 
lysates, as well as membrane-bound protein and extracellular fractions were 
prepared.  
As described by Gauster et al. 2005 we could confirm that LIPG-overexpressing 
MCF7 breast cancer cells produced intracellular LIPG which can be found also on 
cell surface and released into the supernatant. In the whole cell lysates a small 
55kDa protein band was detectable (corresponding to the immature LIPG), 
accompanied by a strong 68kDa glycosylated LIPG protein together with the cleaved 
40kDa product were detected. In the fraction corresponding to the cell-surface 
attached LIPG (prepared by heparine release) only a strong 68kDa band was 
observed. The cell supernatant contained the 68kDa released LIPG protein together 
with the 40kDa cleaved product (Fig. 3.17). 
 
Fig. 3.17: LIPG overexpression (OE) in MCF7 cells results in increased LIPG protein levels in all 
three subcellular fractions (intracellular, membrane-bound and extracellular). The comparison of 
full media (FM, untreated) and empty vector (EV, control) with LIPG-overexpressing (LIPG-OE) cells 
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illustrates a strong 68kDa protein band in all three compartments. A representative immunoblot is 
shown (n=3) 
 
3.2.1 Induction of LIPG in MCF7 breast cancer cells is accompanied by 
increased triacylglyceride levels  
The literature has reported a high phospholipase A1 and low triglyceride lipase 
activity of LIPG (Strauss et al. 2002). Accordingly, the addition of high-density 
lipoprotein (HDL) as the main substrate of LIPG to LIPG-overexpressing cells is 
expected to result in the release of fatty acids from the phosphatidylcholine contained 
in HDL particles and subsequent cellular uptake and incorporation into cellular lipid 
stores, such as triacylglycerides (TAG). Because we were restricted by the great 
variability of HDL quality that is commercially available we also explored the ability of 
exogenously added phosphatidylcholine (PC) to serve as a LIPG substrate in cell 
culture. For this purpose we added vesicles of PC esterified with oleic acid (1,2-
dioleoyl-sn-glycero-3-phosphocholine; DOPC; PC-OA, Avanti). After overexpression 
of LIPG for 48h cells were serum-starved and incubated with HDL or PC-OA for 
further 48h. Subsequently, lipids were extracted for quantification of the accumulated 
TAG amount by using the Triglyceride Quantification Kit (abcam). 
 
Serum-starved LIPG-overexpressing cells that were incubated for 48h with 800µg 
HDL accumulated 2.5-fold more TAG than control cells (Fig. 3.18a). Lipid droplets 
staining by oil red O and immunofluorescence (Bodipy) confirmed the TAG 
quantification results (Fig. 3.18b/c). Only LIPG-overexpressing cells were able to 
incorporate HDL-derived fatty acids leading to lipid accumulation. 
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Fig. 3.18: LIPG-overexpressing MCF7 cells incubated with HDL show increased lipid 
accumulation. After 48 hours transfection with 1500ng LIPG-FLAG expression vector and X-
tremeGENE HP DNA transfection reagent (Roche) cells were incubated with serum-free media 
supplemented with 800µg high density lipoprotein (HDL) for further 48h. (A) Quantification of cellular 
triacylglycerol (TAG) levels after lipid extraction by using Triglyceride Quantification Kit (ab65336) from 
abcam. The results represent mean ± SEM (n=3); (B) Confocal microscopic images of fixed MCF7 
cells after transfection and culture with HDL as described above labelled with fluorescent LIPG (anti-
FLAG, red), nuclei (DAPI, blue), actin cytoskeleton (Rhodamine Phalloidin, grey) and lipid droplets 
(Bodipy 493/503, green); scale bars are 20µm; representative images are shown; (C) Representative 
bright field microscopic images of empty vector (EV, control) and LIPG-OE (overexpressing) cells 
stained with triglyceride dye oil red O. Only LIPG-overexpressing cells are able to incorporate HDL 
and show increased cellular triglycerides; scale bar 20µm 
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LIPG-overexpressing cells fed with PC-OA had a twelve-fold increased TAG 
accumulation compared to empty vector (EV) cells (Fig. 3.19). Staining of lipid 
droplets with oil red O and immunofluorescence (Bodipy) also confirmed the results 
of the TAG quantification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19: LIPG-overexpressing MCF7 cells incubated with PC-OA (DOPC, 1,2-dioleoyl-sn-
glycero-3-phosphocholine, Avanti) show increased cellular triglyceride levels. After 48 hours 
transfection with 1500ng LIPG-FLAG expression vector and X-tremeGENE HP DNA transfection 
reagent (Roche) cells were incubated with serum-free media supplemented with 800µg PC-OA for 
further 48h. (A) Quantification of triacylglycerol (TAG) amount by using Triglyceride Quantification Kit 
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(ab65336) from abcam. The results represent mean ± SEM (n=3); (B) Representative bright field 
microscopic images of empty vector (EV, control) and LIPG-OE (overexpressing) cells stained with 
triglyceride dye oil red O. Only LIPG- overexpressing cells are able to incorporate oleic acid released 
from PC-OA into TAG; scale bar 100µm; representative images are shown; (C) Confocal microscopic 
images of fixed MCF7 cells labelled with fluorescent LIPG (anti-FLAG, red), nuclei (DAPI, blue), 
cytoskeleton actin (Rhodamine Phalloidin, grey) and lipid droplets (Bodipy 493/503, green); scale bars 
are 50µm; representative images are shown 
 
In addition to PC-OA also feeding of LIPG-overexpressing cells with 
phosphatidylcholine containing other fatty acid species, such as stearic acid in 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC; PC-SA) and palmitic acid in 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; PC-PA), was tested. As illustrated 
in Figure 3.20 adding these PC species does not result in accumulation of 
intracellular in lipid droplets. 
 
 
 
 
 
 
 
Fig. 3.20: LIPG-overexpressing MCF7 cells incubated with PC-SA (DSPC, 1,2-distearoyl-sn-
glycero-3-phosphocholine, Avanti) and PC-PA (DPPC, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, Avanti) show no increased TAG levels. After 48 hours transfection with 1500ng 
LIPG-FLAG expression vector and X-tremeGENE HP DNA transfection reagent (Roche) cells were 
incubated with serum-free medium supplemented with 800µg (A) PC-SA or (B) PC-PA for further 48h. 
Quantification of triacylglycerol (TAG) amount by using Triglyceride Quantification Kit (ab65336) from 
abcam. The numbers represent mean of biological replicates ± SEM (n=1) 
 
To make sure that the increased TAG amount is dependent on addition of LIPG 
substrates cells were transfected with EV or LIPG-OE and incubated in serum-free 
media without any additional substrates. Quantification of TAGs demonstrated the 
need of a LIPG-specific substrate like HDL or PC-OA to accumulate intracellular 
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lipids (Fig. 3.21) since LIPG overexpression alone (without HDL or PC-OA) does not 
lead to increased TAG levels. 
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Fig. 3.21: LIPG-overexpressing MCF7 cells did not show lipid accumulation under serum-free 
conditions without substrate. After 48 hours transfection with 1500ng LIPG-FLAG expression vector 
and X-tremeGENE HP DNA transfection reagent (Roche) cells were serum-starved for further 48h. 
Quantification of triacylglycerol (TAG) levels was performed by the Triglyceride Quantification Kit 
(ab65336) from abcam. The numbers represent (n=1) 
 
 
3.2.2 Induction of LIPG is accompanied by expression of the lipid droplet-
coating protein PLIN2 and of LCN2  
TAG quantification demonstrates increased lipid accumulation in LIPG- 
overexpressing cells fed with LIPG main substrates. These results could be 
confirmed by measuring the RNA level of the lipid droplet coating protein PLIN2 (Fig. 
3.22). Under both conditions, fed with HDL or PC-OA, LIPG-overexpressing cells 
always display an increased PLIN2 expression (two-fold fed with HDL and three-fold 
with PC-OA). 
 
 
 
 
Results 
 
 
84 
 
 
 
 
 
 
 
 
Fig. 3.22: LIPG-overexpressing MCF7 cells incubated with either (A) HDL or (B) PC-OA show 
increased Perilipin2 (PLIN2) expression, a marker for lipid droplets. After 48 hours LIPG-OE with 
1500ng vector-DNA and X-tremeGENE HP DNA transfection reagent (Roche) cells were incubated 
with serum starved media supplemented with 800µg high density lipoprotein (HDL) or 800µg PC-OA 
(DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti) for further 48h. (A; B) PLIN2 expression in 
RNA extracts analyzed by quantitative real time PCR; as endogenous control UBC (ubiquitin C 
protein) was used. The numbers represent mean ± SEM (n=3) 
 
Because Lipocalin2 (LCN2) has been shown to regulate lipid droplet formation in liver 
(Asimakopoulou et al. 2014) we also tested LCN2 gene expression in HDL and PC-
OA treated LIPG-overexpressing cells. We observed a 1.8-fold increase in LCN2 
expression in cells fed with 800µg HDL and two-fold elevation in the PC-OA-fed ones 
compared to controls (Fig. 3.23). 
 
 
 
 
 
 
 
Fig. 3.23: LIPG-overexpressing MCF7 cells incubated with either (A) HDL or (B) PC-OA show 
enhanced Lipocalin2 (LCN2) expression. After 48 hours transfection with 1500ng LIPG-FLAG 
expression vector and X-tremeGENE HP DNA transfection reagent (Roche) cells were incubated with 
serum-free medium supplemented with 800µg high density lipoprotein (HDL) or 800µg PC-OA (DOPC, 
1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti) for further 48h. (A; B) LCN2 expression in RNA 
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extracts was analyzed by quantitative real time PCR; as endogenous control UBC (ubiquitin C protein) 
was used. The results represent mean ± SEM (n=3) 
 
The overexpression of LIPG without any substrates was not sufficient to enhance 
LCN2 mRNA expression, as shown in Figure 3.24. 
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Fig. 3.24: LIPG-overexpressing MCF7 cells did not show elevated LCN2 expression in absence 
of LIPG substrate. After 48 hours transfection with 1500ng LIPG-FLAG expression vector and X-
tremeGENE HP DNA transfection reagent (Roche) cells were serum-starved for further 48h. LCN2 
expression in RNA extracts analyzed by quantitative real time PCR; as endogenous control UBC 
(ubiquitin C protein) was used. The numbers represent mean of technical duplicates ± SEM (n=1) 
 
Rodvold et al. (2012) described that LCN2 induces epithelial to mesenchymal 
transition (EMT) in MCF7 cells. Several EMT markers exist like twist (increases 
EMT), snai1 (Zinc finger protein; no expression change under EMT), Nedd9 (neural 
precursor cell expressed, developmentally down-regulated; up-regulated by EMT), 
vim (vimentin; up-regulated by EMT) and CDH1 (E-cadherin; down-regulated by 
EMT). Therefore, we studied whether LCN2 induction in LIPG-transfected cells 
promotes EMT. For this purpose we analyzed expression of the aforementioned EMT 
markers. QRT-PCR measurements of LIPG-overexpressing cells fed with 800µg HDL 
show no detectable expression changes of these five mentioned genes (Fig. 3.25). 
These results suggest no correlation between LIPG overexpression-mediated lipid 
accumulation and EMT. 
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Fig. 3.25: LIPG-overexpressing MCF7 cells incubated with 800µg HDL did not show expression 
alterations of genes involved in epithelial to mesenchymal transition (EMT). After 48 hours 
transfection with 1500ng LIPG-FLAG expression vector with the X-tremeGENE HP DNA transfection 
reagent (Roche) cells were incubated with serum-free media supplemented with 800µg high density 
lipoprotein (HDL) for further 48h. Expression of genes involved in EMT was analyzed by quantitative 
real time PCR; as endogenous control UBC (ubiquitin C protein) was used. The results represent 
mean ± SEM (n=3) 
 
 
3.2.3 Incubation of MCF7 cells with oleic acid results in intracellular lipid 
droplet accumulation 
Blood serum contains 33% oleic acid as a free fatty acid (Patil and Magar 1959) 
source. As a control experiment parental MCF7 cells were incubated over 48h with 
oleic acid previously complexed with its carrier bovine serum albumin (OA/BSA) or 
BSA alone to confirm their capability to take up fatty acids independently of LIPG 
expression. This resulted in a 100-fold increase in cellular TAG in OA/BSA-treated 
cells compared to control BSA-alone treated cells (Fig. 3.26a). Lipid droplet staining 
with oil red O and Bodipy confirmed the dramatic lipid accumulation quantified by the 
TAG kit (Fig. 3.26b/c). 
 
 
 
  Results 
 
 
 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.26: Increased cellular triglyceride accumulation in MCF7 cells treated with oleic acid (OA) 
complexed to bovine serum albumin (BSA) compared to BSA-only treated cells. (A) Serum 
starved MCF7 cells incubated for 48h with 800µg oleic acid bound on BSA exhibit huge increased 
triacylglycerol (TAG) level compared with BSA-treated control cells. Quantification of triacylglycerol 
levels was done by using Triglyceride Quantification Kit (ab65336) from abcam. The results represent 
mean ± SEM (n=3); (B) Representative bright field microscopic images of serum starved MCF7 cells 
incubated for 48h with 800µg oleic acid bound on BSA or BSA alone stained with triglyceride dye oil 
red O. MCF7 cells are able to incorporate oleic acid and show lipid accumulation; scale bar 100µm; 
representative images are shown; (C) Confocal microscopic images of fixed MCF7 cells labeled for 
nuclei (DAPI, blue), cytoskeleton actin (Rhodamine Phalloidin, grey), lipid droplets (Bodipy 493/503, 
green) and PLIN2 (ADFP 647nm, red); scale bars are 200µm; representative images are shown 
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Furthermore, LIPG-overexpressing and empty vector-transfected MCF7 cells were 
also incubated with OA/BSA or BSA alone to study whether LIPG expression 
increases fatty acid uptake and thus result in higher cellular lipid accumulation levels. 
Treatment with OA/BSA but not with BSA, resulted in an equally increased TAG 
accumulation in LIPG-overexpressing and in empty vector transfected cells (Fig. 
3.27). This shows that MCF7 breast cancer cells are able to incorporate exogenous 
fatty acids into TAG when added to the cells irrespectively of LIPG, but as seen in 
previous experiments, only LIPG expression renders them capable of using HDL and 
PC-OA as a fatty acid source. 
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Fig. 3.27: The ability to incorporate oleic acid bound on BSA into TAG is independent of LIPG. 
LIPG-overexpressing and empty vector transfected MCF7 cells were incubated for 48h with 800µg 
oleic acid bound on BSA or BSA alone as control. Cellular TAG amounts were quantified with the 
Triglyceride Quantification Kit (ab65336) from abcam. The results represent n=1 
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QRT-PCR analysis of PLIN2 expression confirmed the TAG quantification and lipid 
droplets visualization shown in Figure 3.27. Incubation of MCF7 cells with OA/BSA or 
BSA alone led to a five-fold increase in PLIN2 expression (Fig. 3.28a). Also LCN2 
displayed a four-fold upregulation after OA/BSA treatment compared to BSA control 
cells (Fig. 3.28b). 
 
 
 
 
 
 
 
 
 
Fig. 3.28: MCF7 cells incubated with oleic acid (OA)/bovine serum albumin (BSA) for 48h 
exhibit an increased PLIN2- (A) and LCN2- (B) expression level compared to BSA-treated 
control cells. Gene expressions in RNA extracts were analyzed by quantitative real time PCR; as 
endogenous control UBC (ubiquitin C protein) was used. The results represent mean ± SEM (n=3) 
 
 
3.2.4 MCF7 cells with increased lipid accumulation display survival advantages 
under starvation conditions 
Proliferation assays were performed under harsh starvation conditions to elucidate 
advantages of elevated intracellular lipid content. MCF7 cells were fed with OA or 
solvent (DMSO) for 48h, followed by incubation in medium without glucose and 
serum (starvation period). The number of living cells was recorded by a CASY cell 
counter.  
MCF7 cells incubated with 200µg OA/DMSO showed in all three experiments over 
ten days of harsh starvation conditions an increased number of living cells, indicating 
a survival advantage of lipid droplet-rich cells compared to the control cells (Fig. 
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3.29). The living cell number was measured at the beginning of the starvation period 
(=0h start) and after 10d of starvation. 73.4% of the OA-treated cells survived the 
starvation period, whereas only 20% of the control cells were viable. 
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Fig. 3.29: Intracellular lipid accumulation after oleic acid (OA)/DMSO incubation confers MCF7 
cells survival advantage under starvation conditions. MCF7 cells were incubated with 200µg 
OA/DMSO or 200µg DMSO alone with serum starved media to enables intracellular lipid 
accumulation. After 48h media was removed, washed and incubated with serum starved media 
without glucose (0g/L starv). The experiment shows the living cell number after 48h of OA/DMSO or 
DMSO incubation (0h start) and after 10d of harsh starvation; The numbers represent mean ± SEM 
(n=3) 
 
In order to test the survival behavior of LIPG-transfected cells we performed a 
proliferation assay with LIPG-overexpressing cells fed with 800µg or 400µg PC-OA. 
LIPG-overexpressing cells did not show any alterations in proliferation behavior 
compared to empty vector control (Fig. 3.30). TAG quantification measurements 
confirmed increased lipid accumulation (ten-fold, data not shown) in LIPG- 
overexpressing cells but it seemed not to be sufficient to implicate survival 
advantages under starvation conditions.  
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Fig. 3.30: Intracellular lipid accumulation after LIPG overexpression and PC-OA exposure in 
MCF7 cells did not confer survival advantage under starvation conditions. MCF7 cells were 
transfected under following conditions: EV (empty vector, control) and LIPG-OE (overexpression) for 
48h. Cells were washed and incubated with serum starved media (A,C) + 800µg or (B) 400µg PC-OA. 
After 48h media was removed, washed and incubated with serum starved media without glucose (0g/L 
starv). (A,B) experiments show the living cell number in total over the mentioned time points; each 
experiment contains the mean of biological duplicates ± SEM. (C) shows the cell viability measured by 
CellTiter-Blue®Cell Viability assay (Promega) over the mentioned time points; The numbers represent 
mean ± SEM (n=3) 
 
3.3 Effect of intracellular lipid accumulation on immunosurveillance 
As reported before, LIPG overexpression triggers intracellular lipid accumulation. 
Moreover, we could show that lipid droplets confer a survival advantage upon nutrient 
shortage. In a next step we aimed to explore the possibility that intracellular lipid 
accumulation in cancer cells confers resistance to killing by immune cells. 
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For this purpose we tested the ability of natural killer (NK) cells to kill target cells 
which carry increased intracellular lipid content compared to control cells. The 
51Chromium-release killing assay with leukemia cells line K-562 as target cells is well 
established at the Immunology group (Prof. Dr. C. Watzl) at IfADo and was chosen 
for the experimental set-up. K-562 cells were incubated with OA/BSA to achieve 
intracellular lipid accumulation or with BSA alone (control). Natural killer cells (NK 
cells) were isolated from whole blood samples of healthy donors and co-cultured with 
51Cr-labeled K-562 target cells (OA/BSA and BSA-treated) to perform the killing 
assay.  
Figure 3.31a displays the killing efficiencies of OA/BSA-treated and control K-562 
cells in the 51Chromium (Cr) release assay (killing assay). The y-axis shows the 
specific lysis [%] and the x-axis the effector (NK cells) to target (K-562 cells) ratio 
(e:t). The release of 51Chromium from K-562 cells cultured in media alone (without 
co-culturing with NK cells) is referred as spontaneous value and set to 0%. The 
release of 51Chromium from target cells treated with Triton X-100 was the maximal 
value and set to 100%. These controls underlie the calculation of the specific lysis 
[%]. K-562 cells previously incubated for 48h with OA/BSA to induced intracellular 
lipid accumulation showed less killing compared to BSA control. Figure 3.31b shows 
the results of the TAG quantification in OA/BSA and BSA-treated K-562 cells. All 
OA/BSA incubated cells revealed a high lipid accumulation compared to BSA alone 
treated control cell. 
These results indicate that fat accumulation in cancer cells may partially inhibit 
natural killer cell-mediated cytotoxicity and thus contribute to tumor escape from the 
immune system. 
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Fig. 3.31: K-562 cells incubated for 48h with oleic acid (OA)/bovine serum albumin (BSA) are 
less killed compared to BSA-treated control cells. Leukemia suspension K-562 cells incubated for 
48h with 800µg oleic acid bound on BSA or only with BSA as control. (A) 51Chromium (Cr) release 
assay (killing assay) with natural killer cells indicates less killing of OA/BSA-treated cells compared to 
BSA control cells. Shown are three independent experiments each performed as biological triplicates; 
(B) Quantification of TAG amount by using Triglyceride Quantification Kit (ab65336) from abcam to 
control lipid accumulation 
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3.4 LIPG is induced after blockage of intracellular fatty acid synthesis 
The previous results could show that increased LIPG expression enhances 
intracellular lipid accumulation via lipolysis and uptake of exogenous lipid sources. 
Because cancer cells are usually capable of synthetizing fatty acids de novo (Zaidi et 
al. 2013), we tested the hypothesis that LIPG may be induced if fatty acid synthesis 
(FAS) is impaired. 
5-(tetradecyloxy)-2-furoic acid (TOFA) is an inhibitor of the acetyl-CoA carboxylase 
(ACACA) resulting in blocking the de novo fatty acid synthesis. MCF7 cells were 
incubated for 24h or 48h with 6µM TOFA and LIPG expression was analyzed by 
qRT-PCR. Figure 3.32 illustrates a significant increase in LIPG expression in TOFA-
treated cells compared to control cells. This result suggests that LIPG may be 
induced to compensate a decreased capacity of fatty acid synthesis. 
 
 
 
 
 
 
 
 
 
Fig. 3.32: Blocking the de novo fatty acid synthesis in MCF7 cells by TOFA results in increased 
LIPG expression. MCF7 cells were incubated over 24h (A) or 48h (B) with 6µM 5-(tetradecyloxy)-2- 
furoic acid (TOFA) to inhibit acetyl-CoA carboxylase (ACACA) and prevent de novo fatty acid 
synthesis. LIPG gene expression in RNA extracts was analyzed by quantitative real time PCR; as 
endogenous control UBC (ubiquitin C protein) was used. The numbers represent mean ± SEM (n=3) 
 
Due to the fact that LIPG is upregulated in case of a blocked endogenous fatty acid 
synthesis we tested whether LIPG overexpression and its function as a fatty acid 
“supplier” could confer a survival advantage under these conditions. For this purpose 
LIPG-overexpressing and empty-vector transfected cells fed with 800µg PC-OA for 
48h were incubated with 6µM TOFA in serum starved media for further 48h. We 
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checked the mitochondrial membrane potential by using tetramethylrhodamine ethyl 
ester perchlorate (TMRE). Mitochondrial membrane potential driven accumulation of 
TMRE within inner membrane region indicates healthy functioning mitochondria. In 
case of depolarization (changes in membrane potential towards more positive 
potential) or inactive mitochondria results in decreased membrane potential and fail 
to sequester TMRE (loss of dye at latest less fluorescence). Figure 3.33 illustrates 
that LIPG-overexpressing cells treated with PC-OA incorporated significantly 
(p=0.001) more (1.6-fold) TMRE compared to MCF7 cells transfected with empty 
vector and incubated with PC-OA. That implies that LIPG-mediated lipid supply 
promotes mitochondrial survival in case of intracellular fatty acid depletion. 
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Fig. 3.33: Blocking the de novo fatty acid synthesis by TOFA in LIPG- overexpressing MCF7 
cells fed with PC-OA resulted in increased TMRE amount. MCF7 cells were incubated over 48h 
with 6µM 5-(tetradecyloxy)-2-furoic acid (TOFA) to inhibit acetyl-CoA carboxylase (ACACA) and 
prevent de novo fatty acid synthesis in serum starved media after transfection with either LIPG- or 
empty vector control-DNA both fed with 800µg PC-OA for 48h. LIPG overexpression enables lipid 
accumulation by incubation with PC-OA and maintains the mitochondrial function in case of 
intracellular fatty acid depletion. The numbers represent mean ± SEM (n=3) 
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3.5 Increased LIPG expression in MCF7 cells incubated with cobalt chloride 
(CoCl2) 
Cobalt chloride (CoCl2) has hypoxia-mimicking effect under normoxic conditions and 
induces generation of reactive oxygen species (ROS) in different cell types (Oh et al. 
2014). Recently, it has been reported that lipid droplets protect against ROS and 
support survival in hypoxia-reoxygenation (Bensaad et al. 2014). Moreover, it could 
be shown that lipid droplet formation under these conditions was due to fatty acid 
uptake while de novo lipid synthesis is repressed (Bensaad et al. 2014). Therefore 
we explored the possibility that LIPG plays a role in lipid uptake under oxidative 
stress conditions. For this purpose, MCF7 cells were incubated with different 
concentrations of CoCl2 for 24h to induce oxidative stress. Expression of LIPG as 
well as of PLIN2, as a lipid droplet marker, was analyzed by real time qRT-PCR. In 
this thesis we had the opportunity to obtain already isolated RNA from CoCl2 treated-
MCF7 cells, kindly provided by Rosemarie Marchan, Joanna Stewart and Michaela 
Lesjak. Interestingly, both genes LIPG and PLIN2 showed a CoCl2-concentration 
dependent increase on mRNA levels (Fig. 3.34a/b). LIPG revealed a ten-fold 
enhanced expression accompanied by 2.5-fold PLIN2 expression increase. This 
suggested that CoCl2 induces formation of lipid droplets and that LIPG may be 
involved in this process by promoting lipolysis of extracellular lipoproteins and 
subsequent uptake of fatty acids. Oxidative stress upon CoCl2 exposure was 
measured by analyzing expression of antioxidant proteins (Fig. 3.34c/d). Thioredoxiin 
reductase (TXNRD1) is required for reducing thioredoxin (TXN), which in turn is 
necessary for repair of oxidized proteins. Interestingly, at the highest concentrations 
of CoCl2 the TXN-inhibitor thioredoxin interacting protein (TXNIP) was 
downregulated. Upregulation of TXNRD1 and downregulation of TXNIP have been 
shown to occur in our model of MCF7/NeuT induced senescence (Cadenas et al. 
2010), which is also accompanied by high levels of ROS (Cadenas et al. 2010). This 
concomitant upregulation of the thioredoxin activator and downregulation of its 
inhibitor is meant increased availability of active, reduced thioredoxin in the cell. 
Moreover, these gene expression alterations in MCF7/NeuT cells are also associated 
to upregulation of LIPG and PLIN2 as well as by accumulation of intracellular lipid 
droplets. This shows that LIPG is induced upon conditions of acute oxidative stress 
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associated with uptake of extracellular lipids, both in a model of oncogene-induced 
senescence and toxicity by chemical hypoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.34: Hypoxic-mimicking effect of CoCl2 induces huge LIPG- and weak PLIN2 expression in 
MCF7 cells. MCF7 cells were incubated with different cobalt chloride (CoCl2) concentrations over 24h. 
LIPG (A), PLIN2 (B), TXNRD1 (C) and TXNIP (D) gene expression in RNA extracts was analyzed by 
quantitative real time PCR; as endogenous control UBC (ubiquitin C protein) was used. The numbers 
represent mean ± SEM (n=3) 
 
 
3.6 Endogenous LIPG expression in different cancer cell lines  
In addition to breast cancer cells we investigated LIPG expression in cell lines 
derived from other tumors, including endometrial, liver and ovarian cancer. For this 
purpose real time qRT-PCR analysis of endogenous LIPG expression in available 
cDNA samples was performed.  
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LIPG expression in the different cell lines was normalized to LIPG expression level in 
MCF7/NeuT cells. Figure 3.35 shows that the highest endogenous LIPG expression 
was detected in the MDA-MB-468 breast cancer cell line, in the AN3-CA endometrial 
cancer cell line, in the SFL004 liver cancer cell line and in the OVCAR-3 ovarian 
cancer cells. This observation suggested in general higher expression of LIPG in 
more aggressive, metastazing cells lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.35: LIPG expression is higher in more aggressive cancer cell lines. RNA extracts were 
analyzed by quantitative real time PCR to compare LIPG expression in different cancer cell lines; As 
an endogenous control UBC (ubiquitin C protein) was used and LIPG expression level in MCF7/NeuT 
cells was taken as a reference. (A) Among the breast cancer cell lines MCF7, MDA-MB-231 and MDA-
MB-468, MDA-MB-468 cells showed the highest endogenous LIPG expression compared to the other 
cell lines. The numbers represent mean ± SEM (n=3) (B) Among the endometrial cell lines MFE296 
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and AN3-CA, AN-3CA exhibited a 125-fold higher LIPG expression level compared to the other cell 
lines. The numbers represent mean ± SEM (n=3) (C) Liver cancer HepG2 and SFL004 cell lines, 
whereas SFL004 showed a 14-fold elevated endogenous LIPG expression. The numbers represent 
one biological experiment (D) Ovarial cancer OVCAR-3, OVCAR-5 and OVCAR-8 cell lines. OVCAR-3 
cells indicated the highest LIPG expression level compared to the other cell lines. The numbers 
represent one biological experiment 
 
 
3.7 Transient reduction of LIPG gene expression by siRNA in vitro 
Small interfering RNAs (siRNA) enable the transient reduction of expression of genes 
of interest. In order to explore the consequences of LIPG downregulation LIPG knock 
down experiments were performed. Cells were incubated for 72h with either a 
specific LIPG-siRNA or a control-siRNA (negative control; NC), which is non-specific. 
Different siRNA concentrations and transfection conditions were tested in order to 
generate a robust maximal LIPG knock down efficiency. Knock down efficiencies 
were controlled by quantitative real time PCR and immunoblotting. We aimed to 
achieve a knock down efficiency of at least 80%. MDA-MB-468 cells were chosen for 
the experiment, since, as shown in Figure 3.35, they exhibit a high endogenous LIPG 
expression level compared to other tested breast cancer cell lines.  
In this thesis ten different LIPG-siRNAs were tested combined with five chemical 
transfection reagents as well as electroporation. Figure 3.36 illustrates a 
representative knock down result. Mostly knock down experiments showed on RNA 
level a tolerable efficiency between 50%-80% reduction. Checking the protein 
amount of LIPG by immunoblotting no knock down success could be registered. 
Conditioned by the inefficient transient LIPG reduction no knock down experiments 
could be performed.  
During the knock down experiments different problems were encountered. On one 
hand liposome-based transfection reagents were shown to influence LIPG 
expression. Therefore, five different transfection reagents as well as electroporation 
were tested. On the other hand a satisfactory knock down efficiency could not be 
achieved. Ten different LIPG-siRNA oligos were tested that resulted in a reduction of 
LIPG mRNA levels of 50-80%. However, reduction of LIPG protein levels was not 
observed with any of the siRNA oligos.  
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Fig. 3.36: LIPG-knock down using siRNAs in MDA-MB-468 cells did not lead to LIPG protein 
reduction. MDA-MB-468 cells were transfected with siRNA against LIPG and non-specific siRNA 
(NC) as negative control. (A) LIPG expression was analyzed by quantitative real time PCR to control 
knock down efficiency at different time points: directly after transfection, 24h- and 48h- post-
transfection; as endogenous control UBC (ubiquitin C protein) was used. The numbers represent 
mean of one representative knock down (performed in duplicates); (B) Immunoblotting of LIPG 
expression in MDA-MB-468 cells to detect knock down efficiency on protein level; protein collection of 
whole cell lysate; β-actin used as loading control. A representative immunoblot is shown; (C) 
Representative bright field microscopy images of cells after LIPG knock down by siRNA 
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3.8 The role of LIPG in human breast carcinoma 
In order to investigate LIPG expression in human breast tumors and its possible 
contribution to tumor progression we investigated first a collection of homogenous 
lymph node-negative untreated (no chemotherapy) breast cancer patients. The main 
study cohort (Mainz GSE11121) comprises 200 node-negative breast cancer 
patients. Additional investigated node-negative untreated cohorts included Rotterdam 
(GSE2034, n=286), Transbig (GSE6532, n=84 & GSE7390, n=196) and Yu 
(GSE5327, n=58).  
Histograms of LIPG expression in the four cohorts showed a bimodal distribution of 
LIPG mRNA. The majority of tumors displayed low LIPG levels and a limited subset 
of tumors appeared to express high levels of LIPG mRNA (Fig. 3.37), suggesting that 
LIPG in breast cancer represents a rare event.  
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Fig. 3.37: Histograms of LIPG expression in four different cohorts. All cohorts show a bimodal 
distribution of LIPG expression with only a small population displaying high LIPG mRNA levels 
 
Mainz Transbig 
Rotterdam Yu 
combined cohort 
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LIPG mRNA expression in breast tumors was validated by quantitative real time PCR 
(qRT-PCR). Ten samples of the Mainz cohort (two samples with high, four samples 
with moderate and four samples with low LIPG expression) were available for the 
analysis. The qRT-PCR results could confirm the Affymetrix gene array data (Fig. 
3.38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.38: LIPG expression in ten breast cancer patients of Mainz cohort. (A) Affymetrix gene 
array data of LIPG expression of two breast cancer patients with increased LIPG level, four with 
moderate level and four patients with lower LIPG expression level; numbers represent n=1; (B) 
Validation of Affymetrix gene array data by quantitative real time PCR from RNA extracts of selected 
breast cancer patients; normalized on LIPG level in MCF7 cells; as endogenous control UBC (ubiquitin 
C protein) was used; numbers represent n=1 
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3.8.1 Uni- and multivariate Cox model for LIPG in untreated, node-negative 
cohorts  
As shown in Figure 3.37 all studied cohorts of untreated patients exhibited a similar 
distribution of LIPG expression with only a few outliers showing high expression of 
LIPG. Due to the limited number of LIPG-expressing tumors it was not possible to 
use LIPG mRNA expression as a continuous variable to investigate survival 
associations in Cox models. A 98% quantile cut-point (CP=6.451), quantile plus 
interquartile range, discriminated n=4 outliers with strong LIPG expression in the 
Mainz cohort, n=8 in the Rotterdam cohort, n=2 in the Transbig cohort and n=3 in the 
Yu cohort.  
Based on this dichotomization we performed an univariate Cox-analysis to 
investigate the correlation between LIPG expression and survival. A significant 
association of LIPG-high expression with worse prognosis (HR>1; p value <0.05) was 
observed in the Mainz (HR=6.42, p=0.002), the Transbig (HR=22.52, p=0.003) and 
the combined cohort (HR=2.49, p=0.011) (Tab. 3.1). These results are illustrated in 
the Kaplan-Meier curves (Fig. 3.39). 
To investigate the relationship between LIPG expression and metastasis-free survival 
considering the impact of other clinical parameters (age, histological grade, pTstage, 
HER2 and ER-status) we performed a multivariate Cox-analysis (calculation of 
independence) (Tab. 3.1-3.6). In the combined cohort increased LIPG expression 
was associated with worse prognosis independently of the clinico-pathological 
factors. 
                        Tab. 3.1: Univariate Cox-analysis 
univariate Cox-analysis (LIPG >6.451) 
cohorts hazard ratio 
 
p-value 
 
Mainz 6.42 0.002 
Rotterdam 1.11 0.853 
Transbig 22.52 0.003 
Yu 2.55 0.373 
combined 2.49 0.011 
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                       Tab. 3.2: Multivariate Cox-analysis for Mainz cohort 
multivariate Cox-analysis (LIPG >6.451) in  
Mainz cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
LIPG 3.53 0.064 
age > 50years 0.93 0.816 
stage II + III 0.91 0.759 
grade III 4.66       <0.001  
ER + 1.64 0.201 
HER2 + 1.5 0.248 
 
                        Tab. 3.3: Multivariate Cox-analysis for Rotterdam cohort 
multivariate Cox-analysis (LIPG >6.451) in  
Rotterdam cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
LIPG 1.13 0.847 
ER + 1.01 0.966 
HER2 + 1.02 0.953 
 
                        Tab. 3.4: Multivariate Cox-analysis for Transbig cohort 
multivariate Cox-analysis (LIPG >6.451) in  
Transbig cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
LIPG 20.59 0.007 
age > 50years 1.10 0.691 
stage II + III 1.65 0.042 
grade III 0.94 0.814 
ER + 0.66 0.149 
HER2 + 0.91 0.803 
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                        Tab. 3.5: Multivariate Cox-analysis for Yu cohort 
multivariate Cox-analysis (LIPG >6.451) in  
Yu cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
LIPG 2.25 0.441 
HER2 + 0.43 0.429 
  
                        Tab. 3.6: Multivariate Cox-analysis for combined cohort 
multivariate Cox-analysis (LIPG >6.451) in  
combined cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
LIPG 4.53 0.005 
age > 50years 1.03 0.892 
stage II + III 1.18 0.374 
grade III 1.72 0.012 
ER + 0.93 0.752 
HER2 + 1.17 0.527 
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Fig. 3.39: Association of LIPG and metastatic-free survival (MFS) visualized by Kaplan-Meier 
plots. Increased LIPG expression is significantly associated with worse prognosis (shorter metastatic 
free survival) in Mainz (p<0.001), Transbig (p<0.001) and in the combined cohort (p=0.007) 
combined cohort 
Mainz 
Rotterdam 
Transbig 
Yu 
Kaplan-Meier plots for LIPG 
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3.8.2 Increased LIPG-expression is associated with negative estrogen receptor 
status and grade III  
For studying the association of LIPG with clinical parameters (age, histological grade, 
pTstage, HER2 and ER-status) contingency tables for each clinical parameter after 
dichotomization of LIPG expression (low 98% and high 2% LIPG; CP=6.451) for 
available cohort data were generated (Tab. 3.7-3.11). In the Mainz, the Rotterdam 
and in the combined cohort a significant association of LIPG expression 
(LIPG>6.451) with negative estrogen receptor (ER) status was shown. In the Mainz 
cohort and in the combined cohort LIPG-high tumors also displayed predominantly 
grade III. No associations were found with a positive HER2 status, pT stage or age.  
Tab. 3.7: Correlation of LIPG expression with clinical parameters in Mainz cohort 
Mainz (GSE11121, n=200) 
clinical parameter LIPG ≤6.451 LIPG >6.451 
 
p-value 
 
histological 
grade 
grade I + II 151 0 0.0033 grade III 45 4 
pT stage stage I 97 1 0.6215 
stage II + III 99 3 
age age ≤ 50 years 47 2 0.2522 
age > 50 years 149 2 
ER status ER - 34 4 0.0011 ER + 162 0 
HER2 status HER2 - 167 2 0.1143 HER2 + 29 2 
 
Tab. 3.8: Correlation of LIPG expression with clinical parameters in Rotterdam                           
       cohort 
Rotterdam (GSE2034, n=286) 
clinical parameter LIPG ≤6.451 LIPG >6.451 
 
p-value 
 
ER status ER - 70 7 0.0005 ER + 208 1 
HER2 status HER2 - 229 8 0.3588 HER2 + 49 0 
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Tab. 3.9: Correlation of LIPG expression with clinical parameters in Transbig cohort 
Transbig (GSE6532, n=84 & GSE7390, n=196) 
clinical parameter LIPG ≤6.451 LIPG >6.451 
 
p-value 
 
histological 
grade 
grade I + II 164 1 1 grade III 99 1 
pT stage stage I 148 1 1 
stage II + III 130 1 
age age ≤ 50 years 157 1 1 
age > 50 years 121 1 
ER status ER - 77 2 0.0848 ER + 191 0 
HER2 status HER2 - 244 1 0.2348 HER2 + 34 1 
 
Tab. 3.10: Correlation of LIPG expression with clinical parameters in Yu cohort 
Yu (GSE5327, n=58) 
clinical parameter LIPG ≤6.451 LIPG >6.451 
 
p-value 
 
HER2 status HER2 - 44 3 1 HER2 + 11 0 
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Tab. 3.11: Correlation of LIPG expression with clinical parameters in the combined  
       cohort 
combined cohort 
clinical parameter LIPG ≤6.451 LIPG >6.451 
 
p-value 
 
histological 
grade 
grade I + II 315 1 0.0143 grade III 144 5 
pT stage stage I 245 2 0.4379 
stage II + III 229 4 
age age ≤ 50 years 204 3 1 
age > 50 years 270 3 
ER status ER - 181 13     <0.0001 ER + 616 4 
HER2 status HER2 - 684 14 0.7344 HER2 + 123 3 
 
Due to the fact that increased LIPG expression in tumors was predominantly 
associated with negative ER status and high grade we explored association of LIPG 
expression with prognosis in these breast cancer subgroups in the combined cohort 
separately, as illustrated by Kaplan-Meier plots (Fig. 3.40). 
 
 
 
 
 
 
 
 
 
Fig. 3.40: Association of LIPG and metastatic-free survival (MFS) visualized by Kaplan-Meier 
plots in ER-/HER2- and grade III subgroups in combined cohort. Grade III tumors with high LIPG 
expression showed a shorter metastatic-free survival (MFS) than grade III tumors with low/ no LIPG 
Kaplan-Meier plots for LIPG in subgroups in the  
combined cohort 
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significant in the combined cohort. ER-/Her2- tumors with high LIPG expression showed no 
association with MFS 
 
 
3.9 Perilipin2 (PLIN2) expression in human breast carcinoma and its correlation 
with LIPG-expression 
Previous in vitro experiments revealed increased PLIN2 expression as a result of 
LIPG overexpression in MCF7 breast cancer cells fed with HDL or PC-OA, 
accompanying intracellular TAG accumulation. Therefore, we investigated a possible 
co-expression of PLIN2 with LIPG in the aforementioned breast cancer cohorts 
(Affymetrix gene array data (U133A_2.0, probe set 209122_at). 
Scatter plots illustrating the relationship between LIPG- and PLIN2 expression (Fig. 
3.41) and showed no linear correlation between LIPG and PLIN2; however, the 
majority of LIPG-high breast tumors also seemed to have increased PLIN2 
expression. 
To further explore the hypothesis that LIPG-high tumors are also PLIN2-high we 
generated contingency tables (Tab. 3.12).  An 80%-quantile cut-point (CP=10.203) 
was chosen to select tumors with high PLIN2 expression (in Mainz cohort n=34, 
Transbig n=54, Rotterdam n=55 and Yu n=22). In the Mainz and in the combined 
cohort a significant correlation between high PLIN2 (>10.203) and high LIPG 
(>6.451) was found. 
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Fig. 3.41: Relationship between LIPG- and PLIN2 expression in breast tumors by scatterplots. 
Scatterplots did not illustrate a linear correlation between LIPG and PLIN2. Majority of tumors with 
high LIPG expression also express high PLIN2    
Mainz Transbig 
Rotterdam Yu 
combined cohort 
Relationship of LIPG and PLIN2 expression 
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Tab. 3.12: Contingency tables showing a possible correlation between LIPG- and  
                 PLIN2 expression 
Contingency tables for LIPG and PLIN2 
cohorts PLIN2  
≤10.203 
PLIN2  
>10.203 
 
p-value 
 
Mainz LIPG ≤6.451 165 31 0.0161 LIPG >6.451 1 3 
Rotterdam LIPG ≤6.451 226 52 0.1839 LIPG >6.451 5 3 
Transbig LIPG ≤6.451 224 54 0.1000 LIPG >6.451 2 0 
Yu LIPG ≤6.451 35 20 0.3194 LIPG >6.451 1 2 
combined LIPG ≤6.451 650 157 0.0102 LIPG >6.451 9 8 
 
LIPG and PLIN2 mRNA expression in ten breast tumors was validated by qRT-PCR 
in the Mainz cohort. As shown in Fig. 3.42 not all LIPG-high tumors exhibited also 
increased PLIN2 expression. 
 
 
 
 
 
 
 
 
 
Fig. 3.42: Comparison of RNA analysis extracts for LIPG- (A) and PLIN2- (B) expression by 
qRT-PCR in some breast cancer patients from Mainz cohort, normalized on LIPG- (A) respectively 
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PLIN2- (B) level in MCF7 cells. Not all LIPG-high tumors showed also increased PLIN2 expression. As 
endogenous control UBC (ubiquitin C protein) was used; numbers represent n= 1 (see Fig.3.38) 
 
Partial co-expression of PLIN2 and LIPG in breast cancer tumors suggests that - as 
observed in vitro - high levels of LIPG may induce expression of PLIN2 via enhanced 
lipid droplet synthesis. Since LIPG is associated with shorter MFS it was investigated 
whether PLIN2 also associates with MFS itself. Histograms in the four cohorts 
showed a normal distribution of PLIN2 expression (Fig. 3.43). Therefore, we could 
use PLIN2 mRNA expression as a continuous variable for studying its association 
with metastasis-free survival with the uni- and multivariate Cox model.  
A significant association of PLIN2-high expression with worse prognosis (HR>1; 
p<0.05) was observed in the Mainz (HR=3.15, p<0.001), the Rotterdam (HR=1.7, 
p=0.019) and the combined cohort (HR=1.67, p<0.001) (Tab. 3.13).  
The multivariate Cox-analysis showed no association of PLIN2 with survival 
independently of the clinico-pathological variables age, grade, stage, ER status and 
HER2 status (Tab. 3.14-3.18). 
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Fig. 3.43: Histograms of PLIN2 expression in four different cohorts. Mainz and Rotterdam cohorts 
show a normal modal distribution of PLIN2 expression whereas Transbig and Yu cohorts exhibit a 
weak bimodal distribution 
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                       Tab. 3.13: Univariate Cox-analysis for PLIN2 
univariate Cox-analysis for PLIN2 
cohorts hazard ratio 
 
p-value 
 
Mainz 3.15      < 0.001 
Rotterdam 1.70 0.019 
Transbig 1 0.994 
Yu 3.34 0.054 
combined 1.67      < 0.001 
 
                       Tab. 3.14: Multivariate Cox-analysis for Mainz cohort 
multivariate Cox-analysis in  
Mainz cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
PLIN2 1.92 0.057 
age > 50years 0.88 0.713 
stage II + III 0.95 0.882 
grade III 3.93       <0.001 
ER + 1.54 0.236 
HER2 + 1.64 0.157 
 
                       Tab. 3.15: Multivariate Cox-analysis for Rotterdam cohort 
multivariate Cox-analysis in  
Rotterdam cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
PLIN2 1.81 0.013 
ER + 1.19 0.459 
HER2 + 1.08 0.771 
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                       Tab. 3.16: Multivariate Cox-analysis for Transbig cohort 
multivariate Cox-analysis in  
Transbig cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
PLIN2 0.67 0.224 
age > 50years 1.14 0.594 
stage II + III 1.63 0.043 
grade III 0.96 0.881 
ER + 0.57 0.050 
HER2 + 0.96 0.908 
 
                       Tab. 3.17: Multivariate Cox-analysis for Yu cohort 
multivariate Cox-analysis in  
Yu cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
PLIN2 3.07 0.083 
HER2 + 0.63 0.666 
 
                       Tab. 3.18: Multivariate Cox-analysis for combined cohort 
multivariate Cox-analysis in  
combined cohort 
clinical 
parameter  hazard ratio 
 
p-value 
 
PLIN2 1.15 0.546 
age > 50years 1.08 0.698 
stage II + III 1.21 0.318 
grade III 1.71 0.014 
ER + 0.91 0.672 
HER2 + 1.20 0.455 
 
Kaplan-Meier curves of dichotomized PLIN2 mRNA expression levels (low 80% and 
high 20% PLIN2; CP=10.203) (Fig. 3.44) showed that tumors with high PLIN2 
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expression were significant associated with worse prognosis (shorter MFS) in Mainz 
(p<0.001), Rotterdam (p=0.018), Yu (p=0.041) and in the combined cohort (p<0.001). 
 
    
 
                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.44: Association of PLIN2 with metastasis-free survival (MFS) visualized by Kaplan-Meier 
plots. Increased PLIN2 expression (>80%) is significantly associated with worse prognosis (shorter 
metastasis free survival) in Mainz (p<0.001), Rotterdam (p=0.018), Yu (p=0.041) and in the combined 
cohort (p<0.001) 
Kaplan-Meier plots for PLIN2 
≤ 10.203 
> 10.203 
Mainz Transbig 
Rotterdam Yu 
combined cohort 
  Results 
 
 
 
119 
 
As done for LIPG, the association of PLIN2 with clinical parameters (age, histological 
grade, pTstage, HER2 and ER-status) (Tab. 3.19-3.23) was studied. In the Mainz 
cohort a significant association of higher PLIN2 expression with grade III and 
negative ER status was shown, in Rotterdam PLIN2 associated significantly with 
negative ER status, in the Transbig with grade III, stage II + III and with negative ER 
status, and in the Yu cohort with negative HER2 status. In the combined cohort 
PLIN2 significantly associated with grade III, stage II + III and with negative ER 
status. 
Tab. 3.19: Correlation of PLIN2 expression with clinical parameters in the Mainz  
       cohort 
Mainz (GSE11121, n=200) 
clinical parameter PLIN2  
≤10.203 
PLIN2  
>10.203 
 
p-value 
 
histological 
grade 
grade I + II 140 11 
    <0.0001 grade III 26 23 
pT stage stage I 84 14 0.3507 
stage II + III 82 20 
age age ≤ 50 years 40 9 0.8273 
age > 50 years 126 25 
ER status ER - 23 15 0.0002 ER + 143 19 
HER2 status HER2 - 143 26 0.1914 HER2 + 23 8 
  
Tab. 3.20: Correlation of PLIN2 expression with clinical parameters in the Rotterdam                              
                 cohort 
Rotterdam (GSE2034, n=286) 
clinical parameter PLIN2  
≤10.203 
PLIN2  
>10.203 
 
p-value 
 
ER status ER - 46 31     <0.0001 ER + 185 24 
HER2 status HER2 - 190 47 0.6920 HER2 + 41 8 
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Tab. 3.21: Correlation of PLIN2 expression with clinical parameters in the Transbig  
       cohort 
Transbig (GSE6532, n=84 & GSE7390, n=196) 
clinical parameter PLIN2 
 ≤10.203 
PLIN2  
>10.203 
 
p-value 
 
histological 
grade 
grade I + II 147 18 
    <0.0001 grade III 65 35 
pT stage stage I 129 20 0.0097 
stage II + III 97 34 
age age ≤ 50 years 124 34 0.2904 
age > 50 years 102 20 
ER status ER - 46 33     <0.0001 ER + 172 19 
HER2 status HER2 - 199 46 0.6465 HER2 + 27 8 
 
Tab. 3.22: Correlation of PLIN2 expression with clinical parameters in the Yu cohort 
Yu (GSE5327, n=58) 
clinical parameter PLIN2 
 ≤10.203 
PLIN2  
>10.203 
 
p-value 
 
HER2 status HER2 - 26 21 0.0387 HER2 + 10 1 
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Tab. 3.23: Correlation of PLIN2 expression with clinical parameters in the combined  
       cohort 
combined cohort 
clinical parameter PLIN2  
≤10.203 
PLIN2  
>10.203 
 
p-value 
 
histological 
grade 
grade I + II 287 29 
    <0.0001 grade III 91 58 
pT stage stage I 213 34 0.0093 
stage II + III 179 54 
age age ≤ 50 years 164 43 0.2360 
age > 50 years 228 45 
ER status ER - 115 79     <0.0001 ER + 536 84 
HER2 status HER2 - 558 140 1 HER2 + 101 25 
 
As done for LIPG, we investigated the association of PLIN2 with metastasis-free 
survival in the negative ER-negative status and grade III subgroups. As shown in the 
Kaplan-Meier plots (Fig. 3.45), high expression of PLIN2 (CP=10.203) was not 
significantly associated with shorter MFS in these subtypes. 
 
 
 
 
 
 
 
 
 
Fig. 3.45: Association of PLIN2 with metastasis-free survival (MFS) visualized by Kaplan-Meier 
plots in ER-negative and grade III subgroups. High PLIN2 expression did not associate 
significantly with MFS in these subtypes 
Kaplan- Meier plots for PLIN2 in subgroups 
in the combined cohort 
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3.10 Correlation of LIPG expression and different metabolic genes in the Mainz 
cohort 
The previous results show that the majority of the LIPG-expressing tumors are high 
grade tumors, have an ER-negative status, and express PLIN2 to a certain degree. In 
order to get an insight into some metabolic properties shared by LIPG-high tumors 
scatter plots were generated to visualize co-expression (as determined by Affymetrix 
gene arrays) of LIPG and other genes involved in different metabolic processes in 
Mainz patients (Fig. 3.46a-f). Based on the results obtained in the experimental part 
of the work: 1) Expression of LIPG in a context of oncogene-induced senescence, 
characterized by oxidative stress; 2) Expression of LIPG in CoCl2-induced chemical 
hypoxia, also characterized by oxidative stress and by an hypoxia-related expression 
signature, 3) Expression of LIPG upon conditions of reduced fatty acid synthesis 
capacity, we searched for surrogates of oxidative stress, hypoxia, fatty acid and lipid 
droplet metabolism. The following graphs show on the x-axis LIPG expression level. 
The red vertical line marks the 98% cut-point (CP=6.451) discriminating the four 
outliers in the Mainz cohort with LIPG expression >6.451. The y-axis displays 
expression of different selected metabolic genes with the corresponding median 
shown as a blue horizontal line. Each point displays one breast cancer patient from 
the Mainz cohort (n=200).  
In order to investigate if LIPG is highly expressed in tumors that have a lower 
capacity to synthetize fatty acids the correlation of LIPG expression with genes 
involved in de novo fatty acid synthesis was investigated (Fig. 3.46a). The enzyme 
fatty acid synthase (FASN) catalyzes the formation of fatty acids from malonyl-CoA 
(Mullen and Yet 2015). Three out of four patients with LIPG >6.451 also express 
higher levels of FASN. Acetyl-coenzyme A carboxylase (ACACA) catalyzes ATP- 
dependent carboxylation of acetyl-CoA to form malonyl-CoA (Wang et al. 2010). High 
expression of ACACA in LIPG-high tumors is only partial and Affymetrix gene array 
probe set-dependent. These results do not seem to support the hypothesis, that 
LIPG becomes induced when the endogenous fatty acid synthesis is compromised. 
On the other hand it is known that fatty acid synthesis is regulated by post-
translational modifications (phosphorylation) of acetyl-CoA carboxylase rather than 
on the level of transcription. 
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To study whether LIPG-high tumors display oxidative stress, as shown in our 
experimental work, the correlation of LIPG expression with genes involved in the anti-
oxidant response, such as TXNRD1, TXN and TXNIP was studied. Interestingly, 
LIPG-high tumors showed high levels of TXNRD1 and TXN mRNA but low levels of 
TXNIP mRNA. This suggests that LIPG expression in vivo may be relevant in a 
context of oxidative stress (Fig. 3.46b). 
Because oxidative stress is known to occur under prolonged hypoxia (LeGrand and 
Aw 1996), the correlation of LIPG expression with genes involved in hypoxic 
processes was investigated. Figure 3.46c shows correlation of LIPG expression with 
markers of hypoxia. Hypoxia inducible factor 1 alpha (HIF-1α) triggers the 
transcription of hypoxia-inducible genes and is involved in several biological 
processes (Enns and Ladiges 2012). All four LIPG >6.451 patients correlate with 
increased HIF-1α expression. Pyruvate dehydrogenase kinase 1 (PDK1) 
phosphorylates and inactivates pyruvate dehydrogenase (PDH) therefore limiting the 
generation of acetyl-CoA from pyruvate, which becomes converted to lactate by 
lactate dehydrogenase A (LDHA). Three out of four tumors with increased LIPG 
expression show elevated PDK1 expression. Vascular endothelial growth factor a 
(VEGFa) is an angiogenic factor induced by HIF-1α (Bensaad et al. 2014). All four 
tumors with elevated LIPG-expression display VEGFa expression higher than the 
median. These results suggest that LIPG-high tumors have characteristics of 
hypoxia-driven tumors with a high glycolytic and angiogenic capacity. 
Since we could show experimentally that LIPG promotes lipid droplet formation, the 
relationship between LIPG and genes involved in TAG formation in Mainz patients 
was also studied, and shown in Figure 3.46d. Acylglycerophosphate acyltransferases 
(AGPAT) participate in the synthesis of phosphatidic acid (Yamashita et al. 2014). 
Most LIPG >6.451 patients also express increased AGPAT levels. The enzyme 
Lipin1 (LPIN1) encodes for a magnesium-ion-dependent phosphatidic acid 
phosphohydrolase which catalyzes dephosphorylation of phosphatidic acid to yield 
diacylglycerol (Jiang et al. 2015). All four patients with LIPG expression about the 
chosen cut-point show LPIN1 levels higher than the median. Diacylglycerol 
acyltransferase (DGAT) triggers the final step in the sn-glycerol-3-phosphate pathway 
resulting in TAG formation (Liu et al. 2012). Three out of four with high LIPG exhibit 
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also high DGAT expression. Lipocalin 2 (LCN2), a member of the innate immune 
system associated with inflammation processes as a pro-inflammatory molecule, has 
lately been shown to be involved in control of intracellular lipid droplet formation 
(Asimakopoulou et al. 2014). LIPG-high tumors also showed enhanced LCN2 mRNA 
levels. All together, these findings suggest that LIPG-high tumors are characterized 
by enhanced triglyceride synthesis, probably from fatty acids derived from LIPG-
mediated extracellular lipolysis. The low-density lipoprotein receptor (LDLR) enables 
the uptake of cholesterol-carrying lipoproteins by endocytosis (Jeon and Blacklow 
2005). Fatty acid binding protein 7 (FABP7) is essential for fatty acid uptake and their 
intracellular transport (Bensaad et al. 2014). Increased LIPG expression correlates 
with enhanced LDLR- and FABP7 expression.  
Monoacylglycerol lipase (MAGL or MGLL) regulates free fatty acid levels and builds a 
diverse lipid network enriched in pro-tumorigenic signaling molecules which facilitates 
cell migration, survival, and cancer cell growth (Nomura et al. 2010). Three out of four 
LIPG >6.451 patients also show increased MGLL expression (Fig. 3.46e) 
A further interesting finding was that LIPG-expressing tumors displayed quite low 
levels of the pro-protein convertase PCSK5 (Fig. 3.46f). As previously mentioned, 
secreted active 68kDa LIPG protein is cleaved and inactivated by pro-protein 
convertases (pPC) into fragments of 40kDa and 28kDa size and PCSK5 (PC6) has 
been shown to specifically inactivate LIPG (Gauster et al. 2005). The finding that 
tumors with high LIPG expression in the Mainz cohort exhibit low PCSK5 expression 
is interesting because it suggests that LIPG-high/ PCSK5-low tumors may have not 
only increased levels of LIPG mRNA but also higher levels of active LIPG protein. 
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Fig. 3.46: Relationship of LIPG expression and genes involved in (A) de novo fatty acid 
synthesis, (B) involved in anti-oxidant response, (C) involved in hypoxic processes, (D) 
involved in TAG formation, (E) monoacylglycerol lipase (MAGL or MGLL) gene expression, (F) 
pro-protein convertase PCSK5 in Mainz patients. (A) Three out of four patients with LIPG >6.451 
express higher level of fatty acid synthase (FASN) in two tested Affymetrix gene array probe sets. 
Similar results are observed with Acetyl-coenzyme A carboxylase (ACACA) in the two used probe 
sets. (B) LIPG-high tumors showed high levels of TXNRD1 and TXN but low levels of TXNIP. (C) All 
four LIPG >6.451 patients correlate with increased HIF-1α expression. Three out of four patients with 
increased LIPG expression show elevated PDK1 expression. All four patients with elevated LIPG 
expression represent increased VEGFa expression. (D) Most LIPG >6.451 patients also express 
increased AGPAT levels. All four patients with LIPG-high expression show enhanced Lipin1 amount. 
Three out of four with high LIPG exhibit also high DGAT expression. Increased LIPG expression 
correlates with enhanced LCN2-, LDLR- and FABP7 expression. (E) Three out of four LIPG >6.451 
patients also show increased MGLL expression. (F) Patients with increased LIPG expression exhibit 
decreased PCSK5 expression in Mainz cohort. Red vertical line illustrates LIPG cut-point of 6.451; 
blue horizontal line marks the mean value of gene expression of tested metabolic genes 
 
In summary, expression of LIPG in breast cancer in vivo is restricted to a very limited 
number of tumors. These are characterized by high grade and loss of ER expression, 
metastatic capacity and expression of oxidative stress and hypoxia markers, as well 
as high expression of genes involved in metabolism of triacylglycerides. Interestingly, 
oxidative stress was also observed in the in vitro models showing upregulation of 
LIPG. This strongly suggests that oxidative stress represents the biological context in 
which LIPG becomes induced to promote survival. 
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4. Discussion                
                  
The association of endothelial lipase LIPG and atherosclerosis is widely accepted 
(Hirata et al. 1999, Dalan et al. 2013), but there is only little known and published 
about LIPG in the context of human cancer. LIPG is a cell surface-associated protein 
that displays a strong phospholipase A1 and little triacylglycerol lipase activity 
towards high-density lipoproteins (HDL). This enzymatic function enables LIPG to 
cleave HDL into fatty acids and lysophosphatidylcholine (LPC), which can be 
followed by cellular fatty acid intake. An additional, non-enzymatic LIPG activity binds 
HDL and facilitates holoparticle or selective HDL-cholesterol ester uptake (Strauss et 
al 2002). Several diseases, including cancer, are accompanied by changes in lipid 
metabolism and in the lipid composition of cellular membranes. Santos and Schulze 
(2012) reported how lipids support several aspects of cancer development, including 
proliferation, resistance to oxidative stress and survival under energy stress. 
Furthermore, fatty acids are able to alter the immune cell behavior (Calder et al. 
2011), which is bond to influence immunosurveillance. Therefore, our initial finding 
that LIPG is induced by oncogene overexpression in breast cancer cells (Cadenas et 
al. 2012) prompted us to explore the role of LIPG-mediated lipid supply in breast 
cancer and its possible contribution to tumor progression in vivo.  
This work has revealed LIPG expression in breast cancer. However, LIPG- 
expression did not display a broad pattern but rather appeared in a very limited 
subset of dedifferentiated tumors in vivo and was induced only under particular 
circumstances in vitro. Interestingly, regardless of its limited expression, LIPG mRNA 
levels were significantly associated with poor outcome (short metastasis-free 
survival) and could discriminate a subset of particularly aggressive tumors within a 
group of grade III tumors, which is aggressive per se. Therefore, induction of LIPG in 
human breast cancer cells is a rare but relevant event during tumor progression. 
Integrating our experimental data and our statistical analysis of LIPG-expressing 
tumors has enabled us to propose a hypothesis on how LIPG may contribute to 
tumor progression and in what biological context LIPG is required.  
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We hypothesize that LIPG becomes induced in cancer cells under conditions of high 
oxidative stress to enable uptake of fatty acids derived from HDL-lipoproteins, when 
the fatty acid requirement exceeds the cellular capacity to synthesize fatty acids de 
novo, or when it is repressed. A repression of fatty acid synthesis may take place 
under conditions of oxidative stress to avoid consumption of NADPH (Jeon et al. 
2012), which should be instead redirected towards ROS detoxification and protein 
repair. LIPG-mediated lipid supply is NADPH-independent and therefore 
compensates the lack of lipid synthesis and helps maintain NADPH levels. 
The following findings, reported in this thesis, support the aforementioned hypothesis 
and underline the importance of LIPG expression in cancer: 
1) Only LIPG-expressing tumor cells can utilize serum HDL-lipoproteins as fatty 
acid sources to promote intracellular lipid accumulation. Therefore, LIPG 
induction confers a new ability to utilize additional exogenous lipid sources. 
2) Intracellular lipid droplet accumulation confers a survival advantage upon 
nutrient shortage and - to a lesser extent - resistance to NK cell-mediated 
cytotoxicity. Moreover, LIPG-promoted lipid droplet accumulation is able to 
sustain mitochondrial integrity upon blockage of de novo fatty acid synthesis. 
Lipid droplet formation, triggered by addition of free fatty acids or by 
overexpression of LIPG in presence of its substrate, induced expression 
changes in genes known to support mitochondria, including PLIN2 and LCN2.  
3) Oxidative stress appears to be the biological context in which LIPG  
expression is induced and may be required. This condition is shared by both 
cell culture models in which we observed LIPG induction and by the breast 
tumors displaying high levels of LIPG mRNA.  In all three cases LIPG 
expression was accompanied by increased levels of the NADPH-consuming 
anti-oxidant enzyme thioredoxin reductase (TXNRD1). Under this condition 
fatty acid synthesis is often downregulated (Jeon et al. 2012, Bensaad et al. 
2014). 
These aspects are discussed in detail in what follows. 
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4.1 LIPG induction confers the ability to utilize HDL as alternative exogenous 
lipid sources 
The in vitro experiments performed in MCF7 cells with oleic acid addition could show 
that breast cancer cells can take up extracellular fatty acids and incorporate them into 
lipid droplets, regardless of LIPG expression. However, only LIPG-expressing cells 
are capable of using HDL as an extracellular source of fatty acids. Circulating high-
density lipoproteins are not reported so far to serve as lipid sources to cancer cells; 
thus, this represents a novelty. The function of HDL is to collect excess of cholesterol 
from peripheral tissues and to transport it to the liver. Thus, tumor-specific LIPG-
mediated modification of HDL particles may impact cholesterol homeostasis as well. 
However, this remains unexplored. 
 
4.2 LIPG-mediated intracellular lipid accumulation confers survival advantages  
 
LIPG-overexpressing MCF7 breast cancer cells fed with PC-OA or HDL showed a 
strong intracellular lipid accumulation, that could be quantitatively confirmed by the 
triglyceride quantification assay, visualized by lipid droplets (LD) staining and verified 
by increased expression of the LD-coating protein PLIN2. These read outs could be 
mimicked by oleic acid incubation. 
MCF7 breast cancer cells exposed to oleic acid (OA) showed survival advantages 
under harsh starvation conditions (no glucose and without serum) compared to 
control cells. This shows that upon nutrient shortage accumulated lipid droplets 
support cell metabolism and growth. Unfortunately, LIPG-overexpressing cells 
previously fed with PC-OA as a substrate failed to display this survival advantage 
under starvation. A plausible explanation could be a limited transfection efficiency or 
insufficient lipid accumulation, which is much lower than the triglyceride accumulation 
resulting from direct exposure to oleic acid. A further possible explanation is that the 
advantage of LIPG may only come up if the endogenous lipid synthesis is 
compromised. This is supported by the fact that LIPG-overexpressing MCF7 cell 
cultures displayed healthier mitochondria in presence of a fatty acid synthesis 
inhibitor.  
How lipid droplet accumulation and turnover may support mitochondrial function? 
Aon et al. (2014) described a physical and metabolic interaction between lipid 
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droplets and mitochondria based on channeled lipid utilization. Perilipin 5 (PLIN5) 
regulates LD degradation by recruitment of mitochondria to LD surface and enables  
the flux of lipolysis-derived fatty acids to mitochondria for energy production. 
Mitochondrial fractions isolated from fasted rat hearts showed PLIN5 enriched 
mitochondria as well as PLIN5-coated LD (Aon et al. 2014, Wang et al. 2011). Beside 
increased PLIN2 expression LIPG-overexpressing cells fed with lipoprotein substrate 
also displayed increased LCN2 expression. Interestingly, Asimakopoulou et al. 
(2014) described LCN2 as a key modulator controlling intracellular LD formation via 
regulation of PLIN5 expression. Our findings showing increased lipid droplet 
formation and increased LCN2 levels upon LIPG overexpression argues for LIPG 
expression as a mechanism that promotes cell survival by preserving mitochondrial 
integrity under conditions of impaired fatty acid synthesis.  
 
 
4.3 TAG-accumulation in K-562 cells facilitates survival advantage in killing 
assay  
 
In our studies human leukemia K-562 cells incubated for 48h with oleic acid (OA) 
were less killed by natural killer (NK) cells compared to control cells, as measured by 
the 51Chromium release assay (killing assay). NK cells are the major component of 
antitumor immune response. Their activity is inhibited by receptors that recognize 
MHC-I molecules which healthy cells carry on cell surface. Activated NK cells attack 
target cells by developing an immunological synapse (contact site between immune 
cells and target cells), creating pores in plasma membrane by released cytolytic 
proteins, including perforin and apoptosis-inducing proteases like granzymes 
(Mamessier et al. 2011). Several possible explanations exist why lipid-accumulated 
cells could be less killed: A) altered apoptosis pathways of target cells, B) less 
efficient uptake of perforin or granzymes by target cells. 
NK cells ensure apoptosis of target cells by different means. Cytotoxic granula 
proteins like granzyme A, granzyme B, FAS-ligand (tumor necrosis factor 
superfamily) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) 
have different targets (Rink et al. 2012, Spektrum Verlag). Granzyme A damages 
mitochondria whereas granzyme B cleaves and activates Caspase-3. Both appertain 
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to the intrinsic or mitochondrial apoptosis pathway. FAS-ligand, which binds to its 
FAS-receptor (CD95), and TRAIL, which recognizes the tumor-necrosis receptor 
(Murray et al. 2015), belong to the extrinsic pathway. Which of these pathways may 
be affected by lipid accumulation is not clear. On the other hand, it is known that the 
cellular membrane composition affects cell function. Phospholipids are the main 
building block of cellular membranes which can influence physiochemical 
characteristics of membranes and are essential for their proper functioning. The 
number of carbon atoms and saturation degree of membrane lipid acyl chains 
influence its fluidity, which decreases by less double bounds and longer carbon chain 
length (Cadenas et al. 2012). Also cholesterol accumulation in a higher ratio to 
phospholipids results in a fluidity decrease (Baritaki et al. 2007). We could speculate 
that lipid accumulation results in changes in membrane composition, which in turn 
affect membrane fluidity/rigidity. As a consequence receptor presentation and binding 
to ligands, or perforin binding on target cell could be compromised.  
In order to elucidate the mechanism underlying the observed resistance to NK-
mediated cytotoxicity in lipid-loaded cells further experiments should be performed. A 
loss of function of NK cells can for instance be investigated by FACS analysis. This 
technique enables the detection of lysosomal markers (LAMP-1 or CD107a) of active 
NK cells during granulation and development of immunological synapse (Claus and 
Watzl 2010).  
 
 
4.4 Induction of LIPG expression upon oxidative stress may be a compensatory 
mechanism for reduced fatty acid synthesis 
 
Induction of NeuT expression (oncogenic variant of HER2) leads to premature 
senescence in MCF7/NeuT breast cancer cells. LIPG mRNA became immediately 
induced upon NeuT overexpression and further increased as cells entered the 
senescence state (Cadenas et al. 2012). Upon NeuT overexpression in MCF7/NeuT 
cells upregulation of LIPG mRNA was reduced by the small molecule inhibitors of 
p38 MAPK (SB203580) and PI3K (LY294002). MEK1/2- (PD98059 inhibitor) and 
SAPK/JNK- (SP600125 inhibitor) pathway did not reveal any influence on LIPG 
expression. These results showed that p38 MAPK and PI3K are underlying signaling 
pathways involved in NeuT-triggered stimulation of LIPG expression. Both pathways 
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play a central role in the regulation of inflammatory processes and stress response 
(Cuenda and Rousseau 2007). Interestingly, these two pathways are known to lead 
to nuclear factor-kB (NF-kB) activation, which in turn is known to bind LIPG promotor 
(containing five functional NF-kB binding sites) to activate its transcription (Kempe et 
al. 2005, Kivelä et al. 2010). 
 
In addition to NeuT, we studied LIPG expression upon overexpression of wildtype 
HER2 as well as of a HER2 mutant with YVMA insertion of four amino acids at codon 
776 that results in enhanced tyrosine kinase activity (Greulich et al. 2012, Wang et al. 
2006). Neither HER2-wildtype nor HER2 insYVMA-transfected cells exhibited altered 
LIPG expression levels (data not shown). Statistical analysis also failed to detect a 
correlation between LIPG expression and HER2-status in breast tumors. The ability 
to induce LIPG was therefore unique to the oncogenic variant NeuT and is not 
determined by HER2 overexpression/amplification. Since only NeuT overexpression 
in MCF7 cells results in oncogene-induced senescence (OIS), whereas HER2 
wildtype and HER2 insYVMA-transfected cells still proliferate, this may indicate that 
LIPG induction by NeuT may be part of a senescence-associated metabolic 
reprogramming.  
 
Previous work at IfADo has shown that NeuT-mediated senescence in MCF7 cells is 
accompanied by a strong increase in levels of reactive oxygen species (ROS) and 
induction of oxidative stress markers, including TXNRD1 (Cadenas et al. 2010). 
Importantly ROS generation is known to be a critical mediator of oncogene-induced 
senescence (Weyemi et al. 2012). This prompted us to investigate whether LIPG can 
be induced by other stimuli that generate high levels of ROS. We explored LIPG 
induction upon exposure to different concentrations of CoCl2 and found parallel 
induction of LIPG and activation of the TXNRD1-TRX system, in a similar way as 
found in oncogene-induced senescence. Also the breast tumors displaying high 
levels of LIPG are characterized by expressing high levels of TXNRD1 and TXN and 
lower levels of TXNIP mRNA. Importantly, combined upregulation of TXNRD1 and 
downregulation of TXNIP help maintain levels of reduced thioredoxin that are 
necessary to combat oxidative stress.  
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Recently, a role of lipid droplets in protection against ROS has been reported 
(Bensaad et al. 2014). Moreover, it could be shown that lipid droplet formation under 
hypoxia-induced oxidative stress was due to fatty acid uptake while de novo lipid 
synthesis is repressed (Bensaad et al. 2014). Interestingly, Ras oncogene-induced 
senescent cells have also been reported to show reduced de novo synthesis of fatty 
acids (Quijano et al. 2012). This has prompted us to speculate that LIPG induction 
may compensate the reduced de novo synthesis of fatty acids occurring under 
oxidative stress. 
 
Regularly, fatty acid synthesis consumes nicotinamide adenine dinucleotide 
phosphate (NADPH), which becomes oxidized to NADP+. In addition to fatty acid 
synthesis, consumption of NADPH takes place for maintenance of proteins in their 
reduced native state via the thioredoxin system and for detoxification of H2O2 via 
peroxiredoxin, thioredoxin and glutathione peroxidase. Because redox homeostasis 
is critical for cell survival we speculated that under oxidative stress a reduction of the 
de novo synthesis of fatty acids takes place to allow the availability of NADPH for 
protection against the toxicity of ROS (Jeon et al. 2012). Under these conditions fatty 
acid supply may be overtaken by LIPG. 
 
Induction of the NADPH-dependent TXNRD1 in both senescent MCF7/NeuT and 
CoCl2-treated cells provided evidence for an increased demand of NADPH in our two 
cell models. Whether the de novo fatty acid synthesis is inhibited, is currently under 
investigation. An inhibition of the acetyl-CoA carboxylases ACC1 and ACC2 (the first 
step in fatty acid synthesis) by AMPK has been reported to maintain NADPH levels 
by decreasing NADPH consumption in fatty acid synthesis under metabolic stress 
conditions (Jeon et al. 2013). Therefore, to strengthen our hypothesis 
phosphorylation of ACC by AMPK in our cell models should be verified. 
 
4.5 LIPG versus other extracellular lipases 
 
In addition to LIPG, other phospholipases have been shown to promote intracellular 
lipid accumulation in breast cancer. Pucer et al. (2013) reported that the human 
group X secreted phospholipase A2 (hGX PLA2) induces lipid droplet formation by 
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releasing fatty acids from the cell membrane and from lipoproteins in invasive breast 
cancer cells to stimulate proliferation and survival in periods of serum starvation. In 
addition, hGX PLA2 mediates upregulation of PLIN2 and fatty acid oxidation 
enzymes, and activation of protein kinase B/ Akt and AMPK in MDA-MB-231 breast 
cancer cells. These phospholipase A2-based effects are also mimicked by oleic acid.  
Kuemmerle et al. (2011) reported widespread expression of lipoprotein lipase (LPL) 
in solid breast tumors, which enables cells to acquire exogenous fatty acids from the 
circulation via lipolysis of lipoproteins. LPL has higher triglyceride lipase and less 
phospholipase activity than LIPG and preferentially hydrolyzes very low density 
lipoproteins (VLDL). Moreover, expression of LPL in breast tumors was independent 
of their HER2/ER status. LPL-mediated fatty acid uptake led to prevention of 
cytotoxic effect of FA synthesis inhibition by therapeutic drugs in cancer cells. This 
shows that fatty acid uptake derived from lipolysis of extracellular lipoproteins seems 
to occur frequently in breast cancer. However, there are important differences in the 
type of lipase that operates, its distribution, its association with clinico-pathological 
parameters, its substrate preference and specificity. According to our results, high 
expression of LIPG in breast tumors is very rare and it is remarkable that the majority 
of these tumors display low LPL expression. This fits to the finding that LIPG 
expression in cardiac tissue was markedly elevated in the early phase of cardiac 
hypertrophy in mice, whereas lipoprotein lipase expression was significantly reduced 
(Nakajima et al. 2013). A possible explanation is that upregulation of LIPG only takes 
place in a context of insufficient LPL action upon tissue injury (Nakajima et al. 2013). 
Nomura et al. (2010) described the function of intracellular increased 
monoacylglycerol lipase- (MAGL/ MGLL) expression in aggressive human cancer 
cells. MGLL converts monacylglycerols into free fatty acids and glycerol and 
promotes tumorigenic malignancy by supporting tumor cells with fatty acids.  
Thus, in addition to LIPG other lipases have been reported to contribute to tumor-
specific lipid metabolism; however their expression patterns may differ temporarily or 
may be context-dependent. 
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4.6 Implication of lipid metabolism in breast cancer treatment 
 
Cancer cells require high amounts of lipids based on the high proliferation rate 
whereby lipids support various aspects in development of cancer (Santos and 
Schulze 2012). Therapeutic targeting of lipid metabolism for cancer treatment was 
shown by several research groups in vitro and in vivo xenograft animal models. 
Several cancer types, including breast cancer, express high levels of fatty acid 
synthase (FAS) and display an elevated fatty acid synthesis capacity. This is 
associated with clinically aggressive tumor behavior and offers a target for 
therapeutic treatment as a strategy for early intervention (Kuhajda 2000, Milgraum et 
al. 1997). Pharmacological inhibition of FAS with cerulenin or of ACACA with TOFA 
in MCF7 breast cancer cells and human breast cancer xenografts induced apoptosis 
in cancer cells. This anti-tumor effect was accompanied by lack of toxicity to 
proliferating normal tissues (Thupari et al. 2001). Combined application of TOFA 
(inhibitor of ACACA in fatty acid synthesis) and etomoxir (inhibitor of fatty acid 
oxidation) was cytotoxic for MCF7 cells (Pizer et al. 2000, Thupari et al. 2001). 
Despite these promising results fatty acid synthesis has not been used as target of 
anticancer therapies in human breast cancer patient trials in vivo so far. In this thesis 
we could show that LIPG is induced (approximately three-fold) when the de novo 
fatty acid synthesis is blocked by pharmacological inhibition of ACACA by TOFA. 
Moreover, LIPG overexpression in presence of TOFA promoted cell survival by 
preserving mitochondrial integrity. Our results suggest that tumors treated with TOFA 
may be able to avoid cytotoxic effects of fatty acid inhibition by upregulation of 
alternative mechanisms of lipid supply (such as LIPG) that promote cell survival. It is 
also tempting to speculate that upregulation of LIPG may causes resistance towards 
therapies aimed to block endogenous lipogenesis.  
 
In this context it is important to note that in contrast to TOFA- (an ACACA inhibitor), 
cerulenin- (a FAS inhibitor) treated MCF7 cells did not result in LIPG induction (data 
not shown). An important difference is that these inhibitors lead to accumulation of 
different intermediates (acetyl-CoA/malonyl-CoA). Thus, LIPG may not be induced by 
simply blocking de novo fatty acid synthesis but accumulation or shortage of key 
metabolites may play an important role as well. This deserves additional research. 
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5. Summary                                                         
 
The endothelial lipase LIPG is a cell surface-associated member of the triglyceride 
lipase family, discovered in 1999 in endothelial cells. LIPG displays phospholipase 
A1 activity towards high-density lipoproteins (HDL) as main substrate and releases 
fatty acids and lysophosphatidylcholine which can be taken up by cells. Besides its 
role in HDL metabolism, a function of LIPG in the development of atherosclerosis has 
been reported. However, a role for LIPG in cancer remains unexplored up to date. 
The aim of the study was to investigate the expression and importance of LIPG in 
human breast cancer. For this purpose we studied 1) the consequences and possible 
advantages of LIPG overexpression in tumor cells in vitro, 2) the context in which 
LIPG becomes induced and 3) its expression and association with adverse outcome 
in a large collection of node-negative, untreated breast cancer tumors. 
Overexpression of LIPG in MCF7 cells in presence of HDL or phosphatidylcholine 
(PC) leads to intracellular accumulation of lipid droplets and was accompanied by 
induction of perilipin 2 (PLIN2) and lipocalin 2 (LCN2). Remarkably, LIPG-mediated 
lipid supply was shown to support mitochondrial functionality after blocking de novo 
fatty acid synthesis by TOFA (an inhibitor of ACACA). We observed that LIPG 
expression becomes induced under cellular stress conditions including oncogene-
induced senescence (OIS), and chemical hypoxia (cobalt chloride), both 
characterized by excessive accumulation of reactive oxygen species. LIPG induction 
could also be observed by pharmacological inhibition of the de novo fatty acid 
synthesis by TOFA, contributing to the assumption that LIPG becomes induced to 
compensate the reduced capacity to synthesize fatty acids upon metabolic stress.  
Affymetrix gene array data analysis of breast tumors revealed that LIPG is only 
expressed in a very limited number of tumor samples and thus represents a rare 
event in breast cancer. In these samples LIPG correlates with grade III, negative 
estrogen receptor status and a shorter metastasis-free survival. Moreover, LIPG-
expressing tumors were characterized by high expression of oxidative stress and 
angiogenesis markers. 
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In summary, based on the results presented in this thesis, LIPG supports tumor cells 
with fatty acids derived from exogenous lipid sources, and thus helps maintain 
mitochondrial functionality. This represents a survival advantage when de novo fatty 
acid synthesis capacity is compromised, a condition that arises under oxidative 
stress. The limited LIPG expression in 1) breast cancer in vivo - only confined to a 
few highly dedifferentiated aggressive tumors - and 2) under particular circumstances 
in vitro - OIS and high concentrations of the hypoxia mimicking agent cobalt chloride -
explains the lack of data concerning LIPG in the context of breast cancer. It can be 
concluded that LIPG-mediated lipid supply occurs only under very adverse conditions 
and contributes to tumor progression by enabling survival of tumor cells.  
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6. Zusammenfassung 
 
Die 1999 erstmalig beschriebene endotheliale Lipase LIPG gehört zu der Familie der 
Zelloberflächen-assoziierten Proteine. LIPG hydrolysiert, bedingt durch dessen 
Phospholipase A1 Aktivität, als Hauptsubstrat Lipoproteine mit hoher Dichte (HDL). 
HDL wird in Lysophosphatidylcholin und Fettsäuren gespalten, welche wiederum von 
Zellen aufgenommen werden können. Neben der Rolle im HDL-Metabolismus, ist 
LIPG mit Arteriosklerose assoziiert. Bis heute ist eine mögliche Funktion von LIPG in 
Krebs unklar.  
Ziel dieser Arbeit war die Expression und Beteiligung von LIPG im humanen 
Brustkrebs zu erforschen. Zu diesem Zweck haben wir 1) die Konsequenz und 
möglichen Vorteile einer LIPG Überexpression in Tumorzellen in vitro, 2) den Kontext 
in welchem LIPG induziert wird und 3) die Expression und Assoziation mit dem 
ungünstigen Krankheitsverlauf in einer großen Kohorte von unbehandelten 
Brustkrebspatientinnen ohne Lymphknotenbefall untersucht.  
Die LIPG Überexpression in MCF7 Zellen führt in der Präsenz von HDL oder 
Phosphatidylcholin (PC) zu einer intrazellulären Akkumulation von Lipidtröpfchen, 
begleitet von der Induktion von Perilipin2 (PLIN2) und Lipocalin2 (LCN2). 
Bemerkenswerterweise zeigte die LIPG-vermittelte Versorgung eine 
Aufrechterhaltung der mitochondrialen Funktionalität, sobald die de novo 
Fettsäuresynthese durch TOFA (Inhibitor von ACACA) blockiert wurde. Wir konnten 
feststellen, dass die LIPG Expression durch zelluläre Stressbedingungen wie 
Onkogen-induzierte Seneszenz (OIS) und chemische Hypoxie (Kobalt(II)-chlorid), 
beides charakterisiert durch exzessive Akkumulation von reaktiven 
Sauerstoffspezies, induziert wird. Eine erhöhte LIPG Expression durch die 
pharmakologische Blockade der de novo Fettsäuresynthese durch TOFA, trägt zu 
der Annahme bei, dass LIPG induziert wird, um die reduzierte Kapazität Fettsäuren 
zu synthetisieren unter metabolischem Stress zu kompensieren.  
Affymetrix gene array Datenanalysen von Brusttumoren zeigen, dass LIPG lediglich 
in einer geringen Anzahl von Tumorproben exprimiert wird und daher ein seltenes 
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Ereignis im Brustkrebs darstellt. In den entsprechenden Proben korreliert das 
gesteigerte LIPG-Level mit Krebsstadium III, negativen Östrogenrezeptorstatus und 
einer kürzeren Metastasen-freien Überlebenszeit. Darüber hinaus konnte in LIPG-
exprimierenden Tumoren eine erhöhte Expression von oxidativem Stress- und 
Angiogenese-Markern gemessen werden.  
Basierend auf den in dieser Dissertation vorliegenden Ergebnissen, kann 
zusammengefasst werden, dass LIPG Tumorzellen mit Fettsäuren aus exogenen 
Lipidquellen versorgt und damit die mitochondriale Funktionalität aufrecht hält. Dies 
repräsentiert einen Überlebensvorteil sobald die de novo Fettsäuresynthese-
Kapazität gefährdet ist, wie es unter oxidativem Stress der Fall ist. Die limitierte LIPG 
Expression in 1) Brustkrebs in vivo - begrenzt in wenigen stark-dedifferenzierten 
aggressiven Tumoren - und 2) unter bestimmten Umständen in vitro - Onkogen-
induzierte Seneszenz und hohe Konzentrationen der Hypoxie-imitierenden Substanz 
Kobalt(II)-chlorid - erklären das fehlende Wissen über die Verbindung von LIPG und 
Brustkrebs. Zusammenfassend konnte gezeigt werden, dass die LIPG-vermittelte 
Versorgung mit Fettsäuren nur unter zellschädigenden Umständen stattfindet, 
dadurch ein Überleben von Tumorzellen ermöglicht und letztlich zu einer 
Tumorprogression beiträgt. 
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8. Supplement     
 
8.1 Abbreviation                                      
ACACA acetyl-coenzyme A carboxylase 
ACSL3 acyl-CoA synthase long chain 
AMPK adenosine monophosphate activated protein kinase 
ATP adenosine triphosphate 
BMI body mass index  
BSA bovine serum albumin 
cDNA complementary deoxyribonucleic acid 
CDP cytidine diphosphate 
CHPT1 choline phosphotransferase 1 
CMP cytidine monophosphate 
CMV cytomegalovirus promoter  
CP cut-point 
CPT-1 carnitine palmitoyltransferase-1  
Cr chromium 
DAG diacylglycerol 
DGAT diacylglycerol acyltransferase  
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dox doxycyclin 
DTT dithiothreitol  
EDTA ethylendiamintetraessigsäure 
e:t effector to target ratio 
eGFP enhanced green fluorescent protein 
EGFR epidermal growth factor receptor  
EMT epithelial-to-mesenchymal transition  
ER estrogen receptor 
EV empty vector 
FABP7 fatty acid binding protein 7 
FASN /FAS fatty acid synthase 
FFA free fatty acids  
Fig. figure 
FM full media 
h hours 
HDL high density lipoproteins 
HDL-PC high density lipoproteins phosphatidylcholine 
HER2 human epidermal growth factor receptor 2 
hGX PLA2 human group X secreted phospholipase A2  
HIF-1α hypoxia-inducible factor-1 alpha 
HL/ LIPC hepatic lipase 
HR hazard ratio 
HSPG heparan sulfate proteoglycans 
IDL intermediate-density lipoprotein  
IL-1β interleukin 1 beta 
IL-6 interleukin-6 
IL-8 interleukin-8 
ILCNC International Lipid Classification and Nomenclature Committee  
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kd knock down 
kDa kilo dalton 
kg/ g/ mg kilogram/ gram/ milligram 
L/ mL/ µL litre/ milliliter/ microlitre 
LCN2 lipocalin2 
LD lipid droplets 
LDL low density lipoproteins  
LDLR low-density lipoprotein receptor 
LDHA lactate dehydrogenase A 
LIPG/ EL/ EDL lipoprotein lipase G; endothelial lipase 
LPC lyso-phosphatidylcholine 
LPE lysophosphatidylethanolamine  
LPIN1 lipin1 
LPL/ LIPD lipoprotein lipase  
LPS lipopolysaccharide  
lyso-PC lysophosphatidylcholine  
M/ mM/ µM/ nM mole/ millimole/ micromole/ nanomole 
mA milliampere 
MAG monoacylglycerol 
MAGL/ MGLL monoacylglycerol lipase 
MCP-1 monocyte chemoattractant protein-1 
MFS metastatic free survival  
MHC-I major histocompatibility complex-I  
min minute 
NADPH nicotinamide adenine dinucleotide phosphate 
NC negative control 
NF-kB Nuclear factor-kB 
NK cells natural killer cells 
NPC1 niemann-Pick C1 
OA oleic acid  
OE overexpression 
OIS oncogene-induced senescence  
PA phosphatidic acid 
PC phosphocholine 
PC-OA/ DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
PC-PA/ DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
PC-SA/ DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine 
PDK1 3-Phosphoinositide dependent protein kinase-1 
PLD1 phospholipase D1 
PLIN2 perilipin2 
PLIN5 perilipin 5  
PMSF phenylmethylsulfonylfluorid 
pPC proprotein convertases 
PR progesterone receptor 
qRT-PCR quantitative realtime polymerase chain reaction 
RNA ribonucleic acid 
ROS reactive oxygen species  
siRNA small interfering RNA 
SDS sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Tab. table 
TAG triacylglycerol 
TBARS thiobarbituric acid reactive substances 
TEMED N,N,N',N'-Tetramethylethylendiamin  
TLR4 toll-like receptor4 
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TMRE tetramethylrhodamine ethyl ester perchlorate 
TNF-α tumor necrosis factor alpha 
TOFA 5-(tetradecyloxy)-2- furoic acid 
TRAIL tumor necrosis factor- related apoptosis-inducing ligand 
Tris Tris(hydroxymethyl)-aminomethan 
TXN thioredoxin 
TXNIP thioredoxin-interacting protein 
TXNRD thioredoxin reductase 
UBC ubiquitin C 
VEGF vascular endothelial growth factor 
VLDL very low density lipoproteins  
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